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Abstract 
 
The clinically important alkaloids (+)-vinblastine (1) and (+)-vincristine (2) both exhibit 
extraordinary potency as anti-mitotic agents and act by destabilising polymerised 
tubulin. While the development of a structure-activity-relationship (SAR) profile around 
these natural products should allow for the identification of the relevant pharmacophore, 
this task is especially daunting because of the structural complexity of these 
compounds. Indeed, most analogues of the Vinca alkaloids are obtained through 
modifications of the natural products rather than being generated de novo by “total 
synthesis”.  
 
In principle, a useful starting point in generating small molecule analogues of the title 
alkaloids that may well retain useful biological properties would be to prepare a series 
of compounds mimicking the indole-indoline core of (+)-vinblastine (1) and involving a 
range of different pairings of aryl groups as surrogates for these heterocyclic units. This 
approach, which would lead to compounds such as 175, requires establishing methods 
for the generation and appropriate linking of these units.  
 
The methodology ultimately established for obtaining the abovementioned (+)-
vinblastine analogues is detailed in Chapter Two and involved Pinhey-type arylation of 
α-carbomethoxylated cycloalkenones such as 75 with the relevant plumbated arenes, 
e.g. 99. The resulting α-arylated cycloalkenone, e.g. 106, was submitted to a Banwell-
type indole synthesis involving α′-iodinaton of such compounds under conditions 
defined by Johnson and then subjecting the product of this process, e.g. 155, to a 
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palladium[0]-catalysed Ullmann cross-coupling reaction with o-iodonitrobenzene 
(137). The resulting product, e.g. 169, was then subjected to reductive cyclisation 
using dihydrogen in the presence of palladium on carbon, and so affording the target 
mimetics, e.g. 175, of the indole-indoline core of alkaloids 1 and 2 
 
Attempts, as described in Chapter Three, were then made to extend such chemistry to 
the preparation of the bis-indole 44 containing a tetracyclic structure resembling the 
carbomethoxyvelbamine portion of (+)-vinblastine (1). 
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vi 
The following Chapter (Four) details attempts to extend the methodology introduced in 
Chapter Two to the enantioselective preparation of vinblastine analogues such as 175. 
In particular, the carbomethoxy group associated with the α-
carbomethoxycycloalkenone precursors, e.g. 75, to such compounds were replaced by 
carboalkoxy groups incorporating chiral alcohol residues such as menthol, (1-methyl-1-
phenylethyl)cyclohexanol, 8-β-naphthylmenthol and [N-benzenesulfonyl-N-(3,5-
diphenyl)-amino]-2-bornanol and then seeking to effect the diastereoselective Pinhey 
arylation of these compounds. Some diastereoselection was achieved in this regard 
when the chiral auxiliary 244 was employed. 
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Glossary 
 
The following abbreviations and symbols have been used throughout this thesis: 
 
AcOH acetic acid 
Ac acetyl 
Ac2O acetic anhydride 
Ar                          Aryl 
aq. aqueous  
atm. atmosphere 
BINAP 2,2-bis(diphenylphosphino)-1-1' binaphthyl 
Bn benzyl 
bipy 2,2′-bipyridyl 
Boc tert-butoxycarbonyl 
(Boc)2O di-tert-butyldicarbonate 
b.p. boiling point (°C) 
Bu butyl 
n-BuLi n-butyllithium 
t-Bu tertiary-butyl 
t-BuLi tertiary-butyllithium  
c concentration (g/100 mL) 
ca. circa (approximately) 
conc. concentrated 
COSY homonuclear (1H/1H) correlation spectroscopy 
d doublet 
δ chemical shift (parts per million) 
   
 
x 
DCM dichloromethane 
DBU 1,8-diazabicyclo[5.4.0]undec-7-ene 
DEPT distortionless enhancement of polarisation transfer 
DNA deoxyribonucleic acid 
dm demimetre 
DMAP 4-(N,N-dimethylamino)pyridine 
DMF N,N-dimethylformamide 
DMSO dimethyl sulfoxide 
dppp 1,4-bis(diphenylphosphino)propane 
d.r. diastereomeric ratio 
e.g. exemplia gratia 
e.e. enantiomeric excess 
E entgegen (opposite) 
EI electron impact 
ether diethyl ether 
equiv. or eq. equivalents 
ESI electrospray ionisation 
Et ethyl 
Et3N triethylamine 
eV electron volt 
FTIR fourier transform infrared 
g gram 
h hour(s) 
Hg(OTf)2 mercuric (II) triflate  
HMPA hexamethylphosphoramide 
HRMS high resolution mass spectrum 
Hz Hertz 
  
 
xi 
 
 
Im. imidazole 
IR infrared 
J coupling constant (Hz) 
Jones’ reagent Chromic and sulfuric acid in acetone 
t-BuOK potassium tert-butoxide 
KHMDS potassium hexamethyldisilazide 
L length (dm) 
LDA lithium diisopropylamide 
lit. literature 
LiHMDS lithium hexamethyldisilazide 
M Molar (molL-1) 
m multiplet 
M+ molecular ion 
Mander’s reagent methyl cyanoformate  
Me methyl 
MeCN acetonitrile 
MeOH methanol 
min. minute(s) 
mg milligram 
mL millilitre 
mm millimetre 
mol mole 
mmol millimole 
m.p. melting point (ºC) 
MS mass spectrum 
MsCl methanesulfonyl chloride 
   
 
xii
m/z mass-to-charge ratio 
nm nanometre 
NaHMDS sodium hexamethyldisilazide 
NMP N-methylpyrrolidinone 
NMR nuclear magnetic resonance 
NOE nuclear Overhauser enhancement 
t-BuONa sodium tert-butoxide 
Ns 2-nitrobenzenesulfonyl 
OMe methoxy 
vmax infrared absorption maxima (cm-1) 
p pentet 
p-BQ para-benzoquinone 
Pd(PPh3)4 tetrakis(triphenylphosphine)palladium[0] 
Pd2(dba)3 tris(dibenzylideneacetone)dipalladium[0] 
Ph phenyl
 
 
Piv pivaloyl 
i-Pr isopropyl 
i-Pr2NH diisopropylamine 
py. pyridine 
q quartet 
R rectus   
RCM ring closing metathesis 
Rf  retardation factor 
r.t. room temperature (assumed to be ~18°C) 
S sinister 
s singlet 
SAR structure-activity-relationship 
  
 
xiii 
 
 
sat. saturated 
sept septet 
sex sextet 
(Bu)3SnSn(Bu)3 hexabutyl ditin 
(Bu)3SnCl tri-n-tributylstannyl chloride 
t triplet
 
 
TBS tert-butyldimethylsilyl 
TBDMS tert-butyldimethylsilyl 
TIPS triisopropylsilyl 
Tf trifluoromethanesulfonyl 
TfOH trifluoromethanesulfonic acid 
TFA trifluoroacetyl 
(TfO)2 trifluoromethanesulfonic anhydride 
THF tetrahydrofuran 
TiCl3•THF titanium trichloride tetrahydrofuran complex 
TLC thin layer chromatography 
TMS trimethylsilyl 
TMSCl trimethylsilyl chloride 
UV ultraviolet 
v/v volume ratio 
Z zusammen (together) 
< less than 
> greater than 
°C  degrees Celsius 
% percentage 
∆ heating 
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C h a p t e r  O n e  
The Biological Activity of (+)-
Vinblastine and Motives for the 
Synthesis of Small Molecule 
Analogues  
 
1.1 Introduction 
Malignant tumours represent one of the most common human diseases worldwide, and 
the subset of such cancers that are amenable to curative treatment is rather small. 
Although there has been tremendous progress in understanding the molecular events 
that lead to malignancy, the development of clinically innovative drugs remains slow. 
The recent and dramatic success of the natural product Taxol in treating breast and 
ovarian cancers has refocussed attention on compounds that act as tubulin binding 
agents or spindle toxins and that can, therefore, stop the division of cancerous cells. 
 
1.1.1 Tubulin and Microtubules 
 
Every nucleated cell contains two similar spherical proteins, α- and β-tubulin. Through 
a series of events that are not yet fully understood, these two proteins couple to form 
heterodimers that can, in turn, combine in a head-to-tail arrangement to give a long 
protein fibre composed of alternating α-and β-tubulin subunits known as a 
protofilament. The protofilament then curls along a single axis to form a pipe-like 
assembly called a microtubule (Figure 1.1). 
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Figure 1.1: The structure of the microtubule and its component parts1 
 
Once formed, these assemblies are not static. Rather, they exist in equilibrium, with the 
constituent heterodimers constantly adding to one end and leaving at the other. The 
resulting control of the length of the microtubules is vital for a number of their 
functions in the cell. Arguably, the most important role of microtubules is their 
formation into a bundle that grows towards the newly forming chromosomes. This 
bundle is known as the mitotic spindle, a structure that is intimately involved in cell 
replication.  
 
Microtubules and Mitosis 
 
During division the cell duplicates its internal components, including ordering its DNA 
into two identical sets of chromosomes that separate towards the opposite ends of the 
cell and are, thereby, ready to form the nuclei of the two new progenitor cells.  Once 
fully separated, the cell splits forming two identical daughter cells. The events 
associated with the ordering and relocation of genetic material is known as mitosis. 
Four distinct phases are involved and these are illustrated in Figure 1.2. 
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Figure 1.2: The four stages of cellular mitosis 
 
During the initial or prophase, DNA is replicated and organised into two sets of genetic 
material. Towards the end of this event, the microtubules begin to form and 
conglomerate towards the newly formed chromosomes. This event created the mitotic 
spindles.  
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The next stage, the metaphase, is where the chromosomes arrange vertically along the 
axis of microtubule bundles known as centrioles. Once this has occurred, the cell 
abruptly enters anaphase, where the daughter chromosomes begin to separate and the 
microtubules decay, thus drawing the daughter chromosomes apart and towards the 
opposite ends of the dividing cell.  
 
During the final phase, the telophase, new nuclear envelopes form around the daughter 
chromosomes. This ends the cell division process, with microtubules having played a 
pivotal role by maintaining a structural scaffold that allows replication to occur. 
Accordingly, agents that interfere with the dynamics of tubulin/microtubule equilibrium 
may also act as inhibitors of mitosis. Thus, if microtubules in a tumour cell can be 
selectively prevented from forming, the chromosomes cannot separate, the cell cannot 
reproduce and, therefore, the tumour cannot grow.  
 
The Vinca Alkaloid Binding Site on Tubulin 
 
The alkaloids (+)-vinblastine (1) and (+)-vincristine (2) each destabilise polymerised 
tubulin by binding to a site on β-tubulin.2 Both compounds have a high affinity for this 
protein3 and so exhibit an extraordinary potency as anti-mitotic agents. It has been 
suggested that this destabilising effect arises from the prevention of polymerisation 
through the forming of a wedge between two tubulin molecules.4  
 
Recently, the structural basis for the regulation of tubulin by (+)-vinblastine (1) has 
been explored. The X-ray structure of crystals of compound 1 attached to the Vinca 
alkaloid binding site of tubulin has been resolved to 4 Å.5 This structure reveals that the 
Vinca alkaloid binding site of tubulin is comprised of residues that form a hydrophobic 
pocket. (+)-Vinblastine (1) is orientated so that its “upper” and “lower” hemispheres 
N
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CO2Me
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N
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MeO2C
HN
R
1, R = Me, (+)-vinblastine     
2, R = CHO, (+)-vincristine
UPPER HEMISPHERE
LOWER HEMISPHERE
20'
17
16'
10
C-16' to C-10 bond linking two hemispheres
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each interact with both tubulin heterodimers to a similar extent. Key interactions of the 
binding site with (+)-vinblastine (1) probably include those between the tertiary alcohol 
attached to C-20′ of the alkaloid and the carboxyl carbonyl of the β222 proline residue. 
This alcohol functionality may also hydrogen bond with the β224 tyrosine residue. 
Another possible point of contact may be between the backbone amide of β329 
asparagine and the carbonyl of the acetate attached to C-17. These interactions are 
illustrated in Figure 1.3.  
Figure 1.3: Possible key interactions between (+)-vinblastine (1) (cyan) 
and proline β222 (green), tyrosine β224 (purple) and asparagine α329 
(yellow) within the Vinca alkaloid binding site on tubulin5 
 
As the microtubule is a dynamic structure, constantly polymerising and depolymerising, 
Vinca alkaloid poisoned tubulin dimers could easily be incorporated into the 
microtubule polymer and so prevent further growth. Most studies of analogues of the 
Vinca alkaloids have been confined to ones involving modifications of the natural 
products. Accordingly, an approach involving synthetically-derived small molecule 
analogues of the Vinca alkaloids could provide important insights into the exact mode 
of action of this class of compounds because of the capacity it offers for the 
identification of precisely which functionalities within these natural products are pivotal 
for interaction with tubulin. While the drugs that interact with tubulin seem to differ 
greatly in structure,6 analysis of a number of the compounds that inhibit polymerisation 
β224
α329
β222
20’
17
 6 
of this protein, including (+)-vinblastine (1), reveals that they contain a “bridging 
region” between an “upper” and a “lower” hemisphere as shown in Figure 1.4. 
 
Figure 1.4: “Bridging regions” (highlighted in red) present in known 
inhibitors of tubulin polymerisation 
 
In principle, a series of compounds containing this “bridging region”, and incorporating 
a range of different pairings of aryl groups, representing the “upper” and “lower” 
hemispheres of the natural product, might be able to be used to identify those 
functionalities that are responsible for the biological activity of (+)-vinblastine (1). 
Accordingly, the major focus of the work described in the body of this thesis was the 
development of chemistry that would allow for the assembly of such (+)-vinblastine 
analogues. However, before any discussion of such work, it is appropriate to highlight 
some key aspects of the chemistry that has been developed in connection with the total 
synthesis of (+)-vinblastine (1), as well as providing some indications of the 
structure-activity-relationship (SAR) work that has been carried out around this natural 
product. This is done in the following sections.  
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1.2 (+)-Vinblastine 
In the late 1950’s cellular extracts from the Madagascan periwinkle, Catharanthus 
roseus (L.) G. Don,7 were found to dramatically suppress the growth of murine 
leukaemias. Fractionation of these extracts led to the isolation of a number of 
structurally novel binary alkaloids, including (+)-vinblastine (1) and (+)-vincristine (2) 
and from which the observed oncolytic activity was derived.8  
 
Since their original isolation and structural elucidation, these particular binary alkaloids, 
which represent “exotic” members of the aspidosperma family, have risen to 
prominence as components of combinatorial therapies for the treatment of a range of 
cancers. These include Hodgkin’s and non-Hodgkin’s lymphoma, testicular cancer, 
bladder cancer and acute childhood leukaemia.9 Although some SAR studies have been 
undertaken on these alkaloids,10 thus far, essentially no structurally simpler analogues 
with clinical utility have been uncovered.  
 
Biosynthetically speaking, the binary aspidosperma alkaloids are derived from a 
late-stage coupling of catharanthine (6) and (-)-vindoline (7). This pivotal coupling is 
followed by a series of functionalisation steps, not yet fully understood, that delivers the 
natural product 1 (Scheme 1.1).7, 11-14  
 
Scheme 1.1: The late stages of the biosynthesis of (+)-vinblastine (1) 
 
The biosynthetic relationship between the binary alkaloids and their monomeric 
precursors has been exploited by many research groups investigating the total synthesis 
of (+)-vinblastine (1) and related compounds.15-22 In the most recent example of such an 
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approach, Fukuyama prepared (+)-vinblastine (1) by coupling (-)-vindoline (7) with a 
macrocyclic catharanthine precursor so as to provide a conjugate that was then readily 
elaborated to the natural product.23 This approach was later extended to the preparation 
of (+)-vincristine (2).24  
 
It is interesting to note that neither of the in vivo precursors to compounds 1 and 2, 
namely catharanthine (6) and (-)-vindoline (7), exhibit cytotoxicity.25 It is only when 
these subunits are coupled through a C-16′ to C-10 linkage, to form various binary 
indole-indoline alkaloids, that oncolytic activity is observed. Clearly, then, this 
dimerisation leads to the biological activity associated with these alkaloids. As part of 
an ongoing program within these laboratories that is directed towards developing an 
expeditious preparation of (+)-vinblastine (1) and various analogues, a synthetic 
protocol was sought for the assembly of the C-16′ to C-10 linkage between the “upper” 
and “lower” hemispheres of compounds related to the precursors of the alkaloids 1 and 
2. If identified, such a protocol could be used to prepare models of the “bridging 
region” within compounds 1 and 2 and these would be subject to biological evaluation 
in order to develop a SAR around a range of (+)-vinblastine substructures. The body of 
this thesis, therefore, details the development of protocols aimed at identifying an 
efficient and flexible method for establishing this pivotal linkage and for the preparation 
of analogues incorporating a biaryl core that might be used to help “pinpoint” the key 
functionalities responsible for the chemotherapeutic properties of (+)-vinblastine (1). 
 
1.3 Studies on the C-16′ to C-10 Linkage of (+)-Vinblastine 
Before discussing protocols that have been developed within these laboratories for the 
installation of the C-16′ to C-10 linkage, it is appropriate to survey the existing methods 
available for constructing this bond within (+)-vinblastine (1). Certainly, it has become 
well recognised that one of the major difficulties associated with the synthesis of such 
binary alkaloids is the need to control the absolute stereochemistry at C-16′, which must 
be S.26 Significantly, analogues of compound 1 incorporating the R-configuration at this 
centre lack the therapeutically valuable cytotoxicity observed in the natural products.27, 
28
 Only five total syntheses of (+)-vinblastine (1)19-23 have been reported to date. In the 
key step, the formation of the C-16′ to C-10 linkage, the three different approaches 
reported all involve coupling of (-)-vindoline (7) to a precursor of the “upper” 
hemisphere of the target structure 1.  
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A comprehensive review of each total and formal total synthesis of (+)-vinblastine (1) 
reported thus far is beyond the scope of this introduction, but summaries of such work 
are provided in Appendix A. However, a detailed commentary on each type of coupling 
strategy that has been used to link the two hemispheres of this natural product is 
presented in the following sections. 
 
1.3.1 The Hydroxyindole Approach 
 
The earliest reported coupling reaction relevant to present discussion was based on the 
rapid self-condensation observed for 1-hydroxy-1,2,3,4-tetrahydrocarbazole in the 
presence of dilute acids.29 This was extended to the ring opening of the pentacyclic N-
acyl ammonium intermediate 8 and so forming iminium ion 9 (Scheme 1.2).30 Trapping 
of the latter by an acetate ion, cleavage of the acetate group so introduced with base, 
followed by hydride reduction of the lactam function gave the coupling precursor 10 as 
a mixture of diastereoisomers. Treatment of alcohol 10 with 1.5% methanolic HCl in 
the presence of (-)-vindoline (7) then afforded the binary system 11, lacking a C-16′ 
carbomethoxy moiety and obtained as an unspecified mixture of diasteroisomers. 
Surprisingly, the possibility of directly trapping the postulated iminium ions 8/9 with   
(-)-vindoline (7) was not investigated. 
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Scheme 1.2: Key elements associated with the hydroxyindole approach to 
the binary indole-indoline alkaloids  
 
1.3.2 The Chloroindolenine Approach 
 
In a strategy related to that outlined above, and developed almost simultaneously by 
Neuss31 and Kutney32 then extended by Atta-ur-Rahman,33 the chloroindolenine 
approach (Scheme 1.3) involves the conversion of a mixture of the epimeric 
carbomethoxycleavamines 12 into the chloroindolenine 13 that readily rearranges to the 
azafulvene-type cation 14. This last species then reacts with (-)-vindoline (7) at 70°C to 
afford 16′-epi-anhydrovinblastine (15), possessing the opposite stereochemistry to that 
required at C-16′. As a result, a total synthesis of (+)-vinblastine (1) could not be 
realised by such means. Nevertheless, these early studies of this coupling reaction 
provided important information about the mechanism of the process.  
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Scheme 1.3: The chloroindoline approach to 16′-epi-anhydrovinblastine 
(15) 
 
This undesired outcome is attributed to the steric hindrance exerted by the C-3′ 
methylene group, which retards the approach to the lower face of the nine-membered 
ring as would be required to establish the correct stereochemistry at C-16′ (Scheme 1.4). 
 
Scheme 1.4: Preferred trajectory for the reaction of (-)-vindoline (7) with 
azafulvenium cation 14  
 
As explained in the following section, such problems associated with the 
chloroindolenine route were eventually solved and thus allowed Kuehne to establish a 
total synthesis of (+)-vinblastine (1).  
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1.3.3 The Biomimetic Approach 
 
The breakthrough in studies directed towards the total synthesis of (+)-vinblastine (1) 
came with the work of Potier,16, 34, 35 Kutney18, 36, 37 and Atta-ur-Rahman.33 Their basic 
premise involved the notion that, as noted earlier, binary alkaloids are formed in plants 
through the coupling of (-)-vindoline (7) and catharanthine (6) and one could use, 
therefore, a surrogate for compound 13 associated with the chloroindolenine approach. 
Utilising this concept, Potier17 and Kutney38 found a solution to the stereochemical 
problem by exploiting the Polonovski reaction.35, 39, 40 Thus, catharanthine N-oxide (16) 
(Scheme 1.5) was treated with trifluoroacetic anhydride to give N-trifluoroacetoxy 
cathranthine (17) which underwent spontaneous fragmentation to form the bis-iminium 
ions 18/19 that were then trapped by (-)-vindoline (7) to furnish, after hydride 
reduction, either anhydrovinblastine (20) or 16′-epi-anhydrovinblastine (15). The 
stereochemical outcome at C-16′ was observed to be dependent upon reaction 
temperature. At –50°C, the natural or S-isomer is formed, while at 0°C, the R-isomer 
predominated. 
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Scheme 1.5: Exploitation of the Polonovski rearrangement in generating 
vinblastine-like coupling products with defined stereochemistry at C-16′ 
 
This temperature dependence on stereochemical outcome can be rationalised by 
invoking an alteration in the conformations of the intermediate iminium ions. At –50°C, 
ion 18 is generated from catharanthine N-oxide (16) and the conformation of this 
species resembles that associated with precursor 16 and so forces the electrophilic 
substitution reaction with (-)-vindoline (7) to take place from the less hindered α-face 
and thus producing the coupling product possessing the (correct) S stereochemistry at 
C-16′. At higher temperatures equilibration of ion 18 with congener 19 (closely related 
to the electrophile involved in the chloroindolenine route) becomes more rapid and 
results in (-)-vindoline (7) now attacking the latter intermediate and thus leading to the 
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formation of compound 15 incorporating the unnatural C-16′ stereochemistry. On the 
basis of these results, Keuhne was able to modify the chloroindolenine approach so as 
to generate (+)-vinblastine (1) in a stereoselective fashion. The following section details 
Kuehne’s effort in this regard.  
 
Total Synthesis of (+)-Vinblastine by Kuehne 
 
Kuehne’s enantioselective synthesis of (+)-vinblastine (1)21 involved the coupling of the 
chlorinated vincadifformine intermediate 21 with (-)-vindoline (7) as shown in Scheme 
1.6. The coupling was achieved by treating chloroindolenine 21 with silver 
tetrafluoroborate so as to generate the intermediate iminium salt 22.  This intermediate 
was then trapped with (-)-vindoline (7), resulting in the tetracyclic indolenine 24 
possessing the correct stereochemistry at C-16′.  
 
As suggested in the preceding section, the stereochemistry established at C-16′ is 
strongly dependent on temperature, with the yield of undesired stereoisomer 25 
increasing as the reaction mixture is warmed up. While steric considerations can be 
used to explain the stereochemical outcome observed in the coupling of (-)-vindoline 
(7) with chloroindolenines (Scheme 1.4), stereoelectronic reasons explain why the 
correct stereochemistry is obtained when the appropriate chlorinated vincadifformine 
intermediates are used.  
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Scheme 1.6: Kuehnes’s use of the chloroindolenine approach in 
establishing a total synthesis of (+)-vinblastine (1) 
 
Thus, the success of the coupling is based on the ready cleavage of the C-7′ to C-3′ 
bond in intermediate 21 which is facilitated by the trans-periplanar orientation of this 
bond and the Nb lone pair and all while maintaining the desired C-3′ to C-14′ trans-
substitution. This allows the ring to flip to a less strained conformation that then leads to 
establishment of the correct stereochemistry in compound 24. At the point of formation 
of the pivotal bond from C-16′ of iminium ion 22 to C-10 of (-)-vindoline (7), the one-
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sided interaction of the extended polyene, including at the reaction site C-16′, differs 
between the potentially interconverting iminium ions 22 and 23. This is due to the 
reversible cleavage of the C-7′ to C-3′ bond in precursor 21 during the reaction, with the 
relative amount of the correct stereoisomer 24 arising from the maintenance of some 
semblance of the initial confirmation of this precursor in the product iminium ion. With 
increasing temperature, the yield of the correct stereoisomer 24 decreases because of the 
diminished stereoelectronic control exerted by the abovementioned factors. 
 
Total Synthesis of (+)-Vinblastine by Fukuyama 
 
Fukuyama23 has completed the most recently reported stereocontrolled total synthesis of 
(+)-vinblastine (1) by exploiting the coupling protocols established in Kuehne’s 
synthesis.21 The final stages in this total synthesis of  (+)-vinblastine (1) are illustrated 
in Scheme 1.7. Thus, treatment of chloroindolenine 26 with (-)-vindoline (7) in the 
presence of trifluoroacetic acid, furnished, via in situ formation of cation 27, the desired 
compound 28 as the sole reaction product and in 97% yield. After deprotection of the 
tertiary alcohol, the Ns group was then removed, under mild conditions, to liberate the 
corresponding secondary amine, which spontaneously formed a piperidine ring via 
transannular alkylation of nitrogen by the pendant tosyloxymethyl group. In this way 
the total synthesis of (+)-vinblastine (1) was completed. 
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Scheme 1.7: The late stages of Fukuyama’s stereocontrolled total synthesis of (+)-
vinblastine (1) involving chloroindolenine 26 as a precursor to the coupling species 27 
 
Total Synthesis of (+)-Vinblastine by Magnus 
 
Magnus’s group22 was the first to exploit a new, nonoxidative coupling methodology in 
the preparation of (+)-vinblastine (1) and a novel solvent effect was used to attain the 
correct stereochemistry at the crucial C-16′ stereocentre. The key to this approach was 
the assumption that intermediate iminium ions such as 9, 14, 18/19 all contain a 
substituent at C-14′ that will exert some control on the stereochemistry at C-16′ in their 
coupling products with (-)-vindoline (7). Therefore, in preliminary work Magnus 
studied the reactions of a nine-membered ring iminium ion lacking such a substituent. 
To this end, tetracyclic amine (+)-29 was synthesised. This compound was then treated 
with p-nitrobenzyl chloroformate to afford the intermediate 30 that underwent non-
oxidative cleavage to generate the iminium ion which, in the presence of (-)-vindoline 
(7), was trapped at C-16′ to give a 1:1 mixture of the diastereomeric coupling products 
32 and 33 (Scheme 1.8). 
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Scheme 1.8: Magnus’s model study on the non-oxidative coupling of 
tetracyclic amine (+)-29 with (-)-vindoline (7) 
 
A major reason for obtaining a 1:1 mixture of epimers is that, remarkably, the 
electrophilic aromatic substitution reaction of the iminium ion 31 is reversible. Hence, 
when this process is slow, as is the case when (-)-vindoline (7) is the nucleophile, the 
iminium ion 31 undergoes equilibration with iminium ion 30 and so allowing for the 
formation of the observed diastereoisomeric forms of the final coupling product. 
However, this did not prove a problem, as the equivalent amine to (+)-29 that would 
need to be used in the total synthesis study (Scheme 1.9) must have a sidechain at C-14′ 
that eventually becomes part of the piperidine ring. Fortuitously, this moiety slows the 
conformational inversion of the nine-membered ring and allows coupling with (-)-
vindoline (7) to proceed with establishment of the required configuration at C-16′. 
Thus, treatment of amine (-)-34 with p-nitrobenzyl chloroformate followed by (-)-
vindoline (7) at –20°C in nitrobenzene and using 2,6-di-tert-butyl-4-methylpyridine as 
catalyst gave a 2:1 mixture of the 16′S-stereoisomer 37 and its epimer 38 (Scheme 1.9). 
The Magnus total synthesis (+)-vinblastine (1) was then completed through a series of 
relatively straightforward functionalisation steps and so affording (+)-vinblastine (1). 
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Scheme 1.9: Late stages of Magnus’s total synthesis of (+)-vinblastine (1) 
 
Initially, dichloromethane was used as the solvent in a coupling reaction that was 
conducted at room temperature. However, this led to the incorrect stereochemistry at C-
16′. Magnus explained this outcome by invoking the establishment of an equilibrium 
between cations 35 and 36. Under these reaction conditions the equilibration is faster 
than the coupling reaction. Nevertheless, the rate of the coupling reaction relative to the 
conformational equilibration could be increased by either decreasing the reaction 
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correct stereochemistry at C-16' was observed as the major product of the reaction. 
Magnus attributed the stereochemical consequences of replacing dichloromethane with 
nitromethane to a preferential solvation of the “closed” iminium ion 35 over the more 
delocalised and “open” iminium ion 36. The localised charge in the “closed” ion should 
be lowered by solvation with nitromethane compared with that in the delocalised 
“open” ion. The “closed” ion is of a shape that allows electrophilic attack by (-)-
vindoline (7) from the less hindered α-face and so leading to the desired 
stereochemistry in the coupling product.   
 
To summarise, then, although there have been five total syntheses of (+)-vinblastine (1) 
reported, only three distinct approaches to the title alkaloid have been developed and 
these all involve the direct coupling of (-)-vindoline (7) with catharanthine (6) or an 
equivalent thereof. (-)-Vindoline (7) invariably acts as the nucleophile in such coupling 
processes. 
 
The remainder of this introduction details a new synthetic strategy for the preparation of 
(+)-vinblastine analogues that mimic the “bridging region” between the “upper” indole 
and “lower” indoline hemispheres of the natural product. 
  
1.4 Towards a Synthesis of “Bridging Region” Analogues of (+)-
Vinblastine 
Traditionally, (+)-vinblastine (1) has been constructed by coupling (-)-vindoline (7), 
which acts as a nucleophile, to a suitable carbomethoxyvelbamine precursor that acts as 
an electrophile. Such an approach is required because coupling of 
carbomethoxyvelbamine (39) itself to (-)-vindoline (7) gives the incorrect 
stereochemistry at C-16′ in the reaction product.20  
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The coupling strategy developed as part of the work described below involved a 
nucleophilic synthetic equivalent for carbomethoxyvelbamine (39) and an electrophilic 
equivalent for (-)-vindoline (7). This approach represents a reversal of the polarity 
associated with biomimetic coupling of those units that has been used in all approaches 
to (+)-vinblastine (1) reported to date. Nevertheless, it provided a capacity to gain ready 
access to a series of small molecule analogues mimicking the indole-indoline core or 
“bridging region” of (+)-vinblastine (1). These analogues should allow for the probing 
of the key functionalities responsible for the biological activity of the title natural 
product. In principle, this approach could also be employed to explore key aspects of a 
potentially new strategy for the synthesis of (+)-vinblastine (1). As matters turned out, 
at no stage during the work reported in this thesis were efforts made to prepare (+)-
vinblastine (1) itself. However, through such work the possibility of successfully 
tackling such a formidable problem has been greatly enhanced.  
 
1.5 Aims of the Research Described in this Thesis 
The three key areas studied, and reported upon in the body of this thesis, are introduced 
below. These involve, (i) the preparation of “bridging region” or indole-indoline 
analogues of (+)-vinblastine (1), (ii) attempts to develop a synthesis of the 
carbomethoxyvelbamine framework representing the “upper” hemisphere of (+)-
vinblastine (1) and (iii) the use of chiral auxiliaries to develop a diastereoselective 
arylation reaction pivotal for the construction of the aforementioned analogues. 
 
1.5.1 Preparation of “Bridging Region” Analogues of (+)-Vinblastine  
 
The primary aim of this project was the development of a methodology for forming a 
series of “bridging region” or indole-indoline analogues of (+)-vinblastine (1). The 
approach required the initial preparation of an α-arylated β-ketoester 41, perhaps via an 
enantioselective and Pd[0]-catalysed arylation reaction41-46 of the corresponding non-
arylated precursor 40 (Scheme 1.10).  
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Scheme 1.10: Key Pd-catalysed arylation reaction associated with the 
initial stages of proposed approach to “bridging region” analogues of (+)-
vinblastine 
 
The motivation for seeking an enone like 41 was the development, within these 
laboratories,47 of protocols for converting such compounds into their α′-(o-nitrophenyl) 
derivatives (e.g. 42) that can undergo reductive cyclisation to give the corresponding 
indoles, (e.g. 43) (Scheme 1.11). Provided that the original aryl group (Ar) was an 
appropriate one, these last compounds could be regarded as representing the desired 
(+)-vinblastine analogues. Studies aimed at the implementation of such ideas are 
described in Chapter Two. 
 
Scheme 1.11: Key indole-forming reaction associated with the final stage of 
a proposed approach to “bridging region” analogues of (+)-vinblastine  
 
1.5.2 Development of Carbomethoxyvelbamine Framework 
 
The second aim of the work detailed in this thesis was to develop a method for 
constructing the carbomethoxyvelbamine framework of (+)-vinblastine (1). A model 
study involving attempts to prepare bis-indole 44 that contains a tetracyclic structure 
similar to that of the “upper” hemisphere of (+)-vinblastine (1) represented the initial 
objective in this area. The results of studies on this topic are detailed in Chapter Three.  
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1.5.3 Controlling the Stereochemistry of C-16′ to C-10 Linkage in the 
Targetted (+)-Vinblastine Analogues 
 
In contemplating the preparation of a series of “ bridging region” analogues of (+)-
vinblastine, it is clear that the correct stereochemistry at the equivalent to C-16´ in such 
compounds would need to be established through a stereoselective arylation reaction. 
Accordingly, the third aim of this project was to develop a method, utilising chiral 
auxiliaries, for controlling the stereoselectivity of this key bond forming process. 
Relevant work directed towards this end is described in Chapter Four. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 24 
1.5 References 
 
1. http://vbaulin.front.ru/research/f_microtub.html. 
2. Rai, S. S.; Wolff, J., J. Biol. Chem. 1996, 271, p. 14707. 
3. Rahmani, R.; Zhou, X. J., Cancer Surveys 1993, 17, p. 269. 
4. Torio, T.; Uzawa, S.; Jung, M. K.; Oakley, B. R.; Tanaka, K.; Yanagida, M., J. 
Cell. Sci. 1991, 99, p. 693. 
5. Gigant, B.; Wang, C.; Ravelli, R. B. G.; Roussi, F.; Steinmetz, M. O.; Curmi, P. 
A.; Sobel, A.; M., K., Nature 2005, 435, p. 519. 
6. Van Angerer, E., Curr. Opin. Drug. Discov. Devel. 2000, 3, p. 575. 
7. Blasko, G.; Cordell, G. A., In The Alkaloids, Brossi, A., Suffness, M., Academic 
Press Inc: San Diego, 1990; Vol. 37, p. 1. 
8. McCormack, J. J., In The Alkaloids, Brossi, A., Suffness, M., Academic Press 
Inc: San Diego, 1990; Vol. 37, p. 205. 
9. Neuss, N.; Neuss, M., In The Alkaloids, Brossi, A., Suffness, M., Academic 
Press Inc: San Diego, 1990; Vol. 37, p. 229. 
10. Kuehne, M. E.; Bornmann, W. G.; Marko, I.; Qin, Y.; LeBoullec, K. L.; Frasier, 
D. A.; Xu, F.; Mulamba, T.; Ensinger, C. L.; Borman, L. S.; Huot, A. E.; Exon, 
C.; Bizzarro, F. T.; Cheung, J. B.; Bane, S. L., Org. Biomol. Chem. 2002, 1, p. 
2120. 
11. Scott, A. I.; Gueritte, F. L., J. Am. Chem. Soc. 1978, 100, p. 6253. 
12. Stuart, K. L.; Kutney, J. P.; Honda, T.; Worth, B. R., Heterocycles 1978, 9, p. 
1419. 
13. Stuart, K. L.; Kutney, J. P.; Worth, B. R., Heterocycles 1978, 9, p. 1015. 
14. Kutney, J. P.; Aweyn, B.; Choi, L. S. L.; Honda, T.; Kolodziejczyk, P.; Lewis, 
N. G.; Sato, T.; Sleigh, S. K.; Stuart, K. L.; Worth, B. R., Tetrahedron 1983, 39, 
p. 3871. 
15. Kuehne, M. E.; Marko, I., In The Alkaloids, Brossi, A., Suffness, M., Academic 
Press Inc: San Diego, 1990; Vol. 37, p. 77. 
16. Potier, P.; Langlois, Y.; Langlois, N.; Gueritte, F., J. Chem. Soc. Comm. 1975, p. 
670. 
17. Langlois, N.; Langlois, Y.; Gueritte, F.; Potier, P., J. Am. Chem. Soc 1976, 98, p. 
7017. 
18. Kutney, J. P.; Ratcliffe, A. H.; Treasurywals, A. M.; Wunderly, S., Heterocycles 
1975, 3, p. 639. 
 25
19. Mangeney, P.; Andriamialisoa, R. Z.; Langlois, N.; Langlois, Y.; Potier, P., J. 
Am. Chem. Soc 1979, 101, p. 2243. 
20. Kutney, J. P.; Choi, L. S. L.; Nakana, J.; Tsukamato, H.; McHugh, M.; Boulet, 
C. A., Heterocycles 1988, 27, p. 1845. 
21. Kuehne, M. E.; Matson, P. A.; Bornmann, W. G., J. Org. Chem 1991, 56, p. 
513. 
22. Magnus, P.; Mendoza, J. S.; Stamford, A.; Ladlow, M.; Willis, P., J. Am. Chem. 
Soc. 1992, 114, p. 10232. 
23. Yokoshima, S.; Ueda, T.; Kobayashi, S.; Sato, A.; Kuboyama, T.; Tokuyama, 
H.; Fukuyama, T., J. Am. Chem. Soc. 2002, 124, p. 2137. 
24. Kuboyama, T.; Yokoshima, S.; Tokuyama, H.; Fukuyama, T., Proc. Natl. Acad. 
Sci. U.S.A. 2004, 101, p. 11966. 
25. Farnsworth, N. R.; Blomster, R. N.; Buckley, J. P., J. Pharm. Sci. 1967, 56, p. 
23. 
26. Cary, F. A.; Kuehne, M. E., J. Org. Chem 1982, 47, p. 3811. 
27. Kuehne, M. E.; Zeobovitz, T. C.; Bornmann, W. G.; Marko, I., J. Org. Chem 
1987, 52, p. 4320. 
28. Borman, L. S.; Kuehne, M. E.; Matson, P. A.; Marko, I., J. Biol. Chem. 1988, 
263, p. 6945. 
29. Plant, S. G. P.; Robinson, R.; Tomilnson, M., Nature 1950, 165, p. 928. 
30. Harley-Mason, J.; Atta-ur-Rahman, J. Chem. Soc., Chem Commun. 1967, p. 
1048. 
31. Neuss, N.; Gorman, M.; Cone, N. J.; Huckstep, L. L., Tetrahedron Lett. 1968, p. 
783. 
32. Kutney, J. P.; Beck, J.; Bylsma, F.; Cretney, W. J., J. Am. Chem. Soc 1968, 90, 
p. 4505. 
33. Atta-ur-Rahman, Pak. J. Sci. Ind. Res. 1971, 14, p. 487. 
34. Potier, P., J. Nat. Prod. 1980, 43, p. 72. 
35. Potier, P., Rev. Latinoam. Quim. 1978, 9, p. 47. 
36. Kutney, J. P.; Hibino, T.; Jahngen, E.; Okutani, T.; Ratcliffe, A. H.; 
Treasurywals, A. M.; Wunderly, S., Helv. Chem. Acta. 1976, 59, p. 2858. 
37. Kutney, J. P., Lloydia 1977, 40, p. 107. 
38. Vucovic, J.; Goodbody, A. E.; Kutney, J. P.; Misawa, M., Tetrahedron 1988, 44, 
p. 325. 
39. Lounasmaa, M.; Koskinem, A., Heterocycles 1984, 22, p. 159. 
40. Cave, A.; Kan-Fan, C.; Potier, P.; Le Men, J., Tetrahedron 1967, 23, p. 4681. 
 26 
41. Hamada, T.; Chieffi, A.; Ahman, J.; Buchwald, S. L., J. Am. Chem. Soc. 2002, 
124, p. 1261. 
42. Fox, J. M.; Huang, X.; Chieffi, A.; Buchwald, S. L., J. Am. Chem. Soc. 2000, 
122, p. 1360. 
43. Ahman, J.; Wolfe, J. P.; Troutman, M. V.; Palucki, M.; Buchwald, S. L., J. Am. 
Chem. Soc. 1998, 120, p. 1918. 
44. Culkin, D. A.; Hartwig, J. F., Acc. Chem. Res. 2002, 36, p. 234. 
45. Beare, N. Å.; Hartwig, J. F., J. Org. Chem. 2002, 67, p. 541. 
46. Kawatsura, M.; Hartwig, J. F., J. Am. Chem. Soc. 1999, 121, p. 1473. 
47. Banwell, M. G.; Kelly, B.; Kokas, O. J.; Lupton, D. W., Org. Lett. 2003, 5, p. 
2497. 
 
 
 
 27
                                                                              Chapter Two 
The Synthesis of Analogues of the 
Indole-Indoline Core of (+)-
Vinblastine 
 
2.1 Introduction 
2.1.1 Overview and Context  
 
In an effort to identify the key functionalities that are responsible for the biological 
activity of (+)-vinblastine (1), a series of analogues corresponding to the indole-indoline 
core of this natural product but incorporating a range of different aryl groups was 
sought. 
 
Initially, attention was directed to constructing the link between the indole and indoline 
units, or their surrogates, and that would, therefore, mimic the C-16′ to C-10 bond 
present in Vinca alkaloid 1. To this end, it was envisaged (Figure 2.1) that a β-ketoester 
such as 45 would first be α-arylated to form a derivative of the general form 46. It was 
hoped this latter compound could then be transformed into the corresponding α′-
iodinated enone, for example 47, and that this would, in turn, engage in a Pd[0]-
catalysed Ullmann cross coupling reaction1 with, for example, o-nitroiodobenzene to 
give a product such as 48. Finally, reductive cyclisation should afford the desired 
vinblastine analogue of the general type 49 that embodies the ABC-ring system of the 
alkaloid together with a “mimic” of the indoline portion of this natural product.  
 
 
 
 
N
N
Me OAc
MeO
CO2Me
OH
N
OH
MeO2C
HN
(1)
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Figure 2.1: Proposed route to the target vinblastine analogues 49 
 
A key feature of this approach is the need to effect the α-arylation of a β-ketoester such 
as 45 and to then use Pd[0]-catalysed Ullmann cross-coupling chemistry to install the 
D-ring of the requisite analogues. The product, e.g. 48, of such a sequence would then 
be elaborated to a target of the general type 49. This Chapter details the development of 
a method to prepare enones of the general form 46, and how such systems were then 
converted into the desired analogues, e.g. 49, of (+)-vinblastine. 
 
2.2 α-Arylation of β-Ketoesters 
2.2.1 Background 
 
Unlike alkyl halides and their equivalents, aryl halides do not normally react with metal 
enolates to give α-arylated carbonyl compounds.2-4 Therefore, finding an efficient and 
reliable way to form a bond between an arene and the α-carbon of an enolisable 
carbonyl unit has been a challenging problem in organic synthesis. Of course, this type 
of conversion represents one of the key steps (see 45 → 46 in Figure 2.1) associated 
with the proposed route to the required (+)-vinblastine (1) analogues. It is appropriate, 
therefore, to review those methods currently available for this purpose.  
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Chelation-controlled Heck Reactions 
 
In an example of a chelation-controlled Heck reaction, Nilsson5 arylated the prolinol 
vinyl ether 50 with a range of aryl halides 51 using catalytic quantities of palladium 
acetate. The initial arylation products engaged in a syn-selective β-elimination reaction 
and so forming compounds of the type 52 that were not isolated. Rather they were 
subjected to acid hydrolysis and by such means gave products of the general form 53 in 
high e.e. (90 – 95%) and in yields in the range of 45 to 78% (Scheme 2.1).  
 
Scheme 2.1: Asymmetric, chelation-controlled Heck arylation of prolinol vinyl ether 50 
with a range of aryl halides 51 
 
The disadvantage associated with this protocol is that the preparation of the prolinol 
vinyl ether 50 involves an acid-catalysed acetalization-elimination sequence that is not 
regioselective and leads to nearly equal quantities of two possible regioisomeric enol 
ethers. This lack of selectivity is clearly undesirable, so another palladium-mediated 
technique was sought for the present purposes.  
 
Buchwald/Hartwig Palladium Mediated α-Arylations 
 
Buchwald6-8 and Hartwig9-11 have independently reported the synthesis of α-aryl 
ketones from ketones and aryl bromides using catalytic amounts of a Pd[0] species that 
is stabilised by bulky dialkylphosphino-binaphthyl ligands. Inorganic bases are utilised 
in these reactions which can proceed enantioselectively, a quality required in the present 
studies in order to establish the correct absolute stereochemistry at the equivalent of C-
16′ in the proposed analogues. The Buchwald chemistry is exemplified in Scheme 2.2. 
Thus, a series of 2-alkylcyclopentanones 54 was treated with a range of aryl bromides 
(55), (S)-BINAP, sodium tert-butoxide and a Pd[0] catalyst so as to generate the 
corresponding series of aryl-2-alkylcyclopentanones 56.  
Me
ONMe
+ R
ONMe
Me
R
O
Me
R
H3O+
X= I or Br R = m-OMe, 68% yield, 93% e.e.
R = p-Me, 50% yield, 94% e.e.
R = Np, 45% yield, 90% e.e.
R = p-COPh, 78% yield, 95% e.e.
(50) (51) (52) (53)
Pd(OAc)2, LiCl,
K2CO3, NaOAc,
(1:1 v/v) DMF/H2O
70 - 100oCX
45 - 78%
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Scheme 2.2: Buchwald/Hartwig α-arylation of cyclic ketone 54 
 
It should be noted, however, that a blocking group was required to prevent arylation 
occurring at what would otherwise be the less substituted α-carbon of the ketone. In 
substrate 54 this blocking group is an aryl-substituted methylene unit. After 3 hours at 
100°C, the products illustrated were formed in yields ranging from 75 to 86% and with 
e.e.’s from 86 – 98%.  
 
On the basis of such reports, an investigation of the α-arylation of the known β-
ketoester 5712 with bromobenzene (58) was undertaken and in the expectation that this 
would generate the corresponding arylated β-ketoester 59. However, even though a 
range of bases, solvents and palladium sources was used (Table 2.1) it was not possible 
to generate the desired product 59. Indeed, despite employing, in certain cases, rather 
forcing reaction conditions, only starting material was recovered in each instance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
O
Ph
Me
+
Pd[0], (S)-BINAP
t-BuONa
toluene, 100oC
O
Me
(54) (55) (56)
R = m-Me, 80% yield, 94% e.e. 
R = m-1,3 dioxolane, 86% yield, 95% e.e.
R = p-t-Bu, 75% yield, 98% e.e.
Ph
R
R
Br
75 - 86%
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Table 2.1: Attempted Buchwald-type α-arylations of β-ketoester 57 
 
entry catalysta ligandb base solvent temp (°C) 
/time (h) 
product 
1 Pd(OAc)2 rac-BINAP t-BuONa toluene 100/3 No reaction 
2 Pd(OAc)2 rac-BINAP t-BuONa toluene 100/12 No reaction 
3 Pd(PPh3)4 rac-BINAP t-BuONa toluene 100/3 No reaction 
4 Pd2(dba)3 rac-BINAP t-BuONa toluene 100/3 No reaction 
5 Pd2(dba)3 rac-BINAP t-BuONa toluene 100/3 No reaction 
6 Pd2(dba)3 rac-BINAP t-BuONa THF 70/12 No reaction 
7 Pd2(dba)3 rac-BINAP NaHMDS THF 70/3 No reaction 
8 Pd2(dba)3 rac-BINAP t-BuOK THF 70/3 No reaction 
 
acatalyst loading: 10 mol%. bPd/ligand ratio 1.25. 
 
Direct Asymmetric α-Arylations Using Diaryl Iodonium Salts 
 
Recently, high-valent iodonium salts have been exploited in a variety of contexts as 
equivalents of aryl iodides.13 Aggarwal and Olofsson14 have, for example, developed a 
method for the direct asymmetric α-arylation of 4-(tert-butyl)cyclohexanone (60) that 
involves the asymmetric enolisation of this substrate using the chiral base 62. Reaction 
of the resulting enolate with the diphenyl iodonium salt 61 then afforded the cis-
configured and α-arylated product 63 in 84% chemical yield, 90% e.e. and 95% d.e. 
(Scheme 2.3).  
 
Scheme 2.3: Asymmetric α-arylation of 4-(tert-butyl)cyclohexanone (60) with diphenyl 
iodonium salt 61 employing chiral base 62 
O
Ph
CO2Me
O
Ph CO2Me
(57) (58) (59)
+
See Table
for Conditions
X
Br
t-Bu
O
O
t-Bu
Ph N
H
Ph
4 eq. n-BuLi, THF, -118oC 
then DMF, -45oC
OTf
(61)
2 eq.
(62)
(60) (63)
84%
90% e.e.
95% d.e.
I+
_
+ +
I
(64)
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However, applications of this protocol are somewhat restricted by the need to employ a 
symmetrical carbonyl-containing compound. 
 
Oh, during studies directed towards the total synthesis of the sesquiterpene laurene,15 
demonstrated that the sodium salt of ethyl 2-oxocyclopentanecarboxylate (65) reacted 
smoothly with the iodonium salt 66 to afford, as shown in Scheme 2.4, the phenylated 
product 67 in 82% yield together with the expected by-product 68.  
 
 
Scheme 2.4: Arylation of β-ketoester 65 with diaryl iodonium salt 66 
 
In order to investigate the utility of such a protocol for the present purposes, 
iodobenzene diacetate (69) was treated with trifluoromethanesulfonic acid then benzene 
so as to form the diphenyl iodonium salt 61 which was obtained in 90% yield (Scheme 
2.5).16 Methyl 2-oxocyclopentanecarboxylate (70) was then treated with this salt under 
conditions defined by Oh15 and product 71 was obtained in 85% yield. Iodobenzene 
(64) was also isolated as the expected by-product of this reaction.  
 
Scheme 2.5: Arylation of methyl 2-oxocyclopentanecarboxylate (70) with diphenyl 
iodonium salt 61 
 
While this procedure is clearly quite effective when structurally simple products are 
being sought, it proved inapplicable in more complex cases because the yields of the 
required bis(heteroaryl) iodonium salts were poor due to their rapid decomposition 
under the acidic conditions required to generate them.17  
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The Pinhey Reaction 
 
Pinhey has shown that aryllead triacetates of the general form 72 react with various soft 
carbon-centred nucleophiles to deliver a range of C-arylation products. 18-22   
Essentially, such aryllead compounds behave as synthetic equivalents to aryl cations in 
reactions that are postulated to involve a ligand-coupling mechanism.21, 23 In order to 
test the utility of aryllead triacetates in the proposed synthesis of the targetted analogues 
of (+)-vinblastine, bromobenzene (58) was treated (Scheme 2.6) with n-butyllithium 
and the resulting aryllithium was then reacted with tributyltin chloride to produce 
stannane 73. Reaction of this last compound with lead tetraacetate in a mercury-
catalysed tin-lead exchange process then gave phenyllead triacetate (74).24 Compound 
74 was, in turn, reacted with methyl 2-oxocyclohex-3-enecarboxylate (75), in the 
presence of three equivalents of pyridine and the α-arylated product methyl 2-oxo-1-
phenylcyclohex-3-enecarboxylate (76) was generated in 79% yield (Scheme 2.6).  
 
Scheme 2.6: Pinhey arylation of methyl 2-oxocyclohex-3-ene carboxylate (75) with 
phenyllead triacetate (74) 
 
Based on these results the Pinhey arylation reaction seemed to offer a useful means of 
effecting the desired arylation reaction. Nevertheless, the scope of such a process 
needed to be investigated. Accordingly, a series of cyclic β-ketoesters of differing ring 
sizes was synthesised with a view to using these as the nucleophilic coupling partners in 
various Pinhey arylation reactions. 
R
Pb(OAc)3
(72)
O
CO2Me
(75)
py., CHCl3, 
r.t. to 40oC
O
(76)
CO2Me
(58)
Pb(OAc)4, Hg(OTf)2,
CHCl3, 40oC
(73)
1. n-BuLi, THF, -78oC
2. (Bu)3SnCl, -78oC to r.t.
(74)
79%
85% 85%
+
Br (Bu)3Sn (AcO)3Pb
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Preparation of Cyclic β-Ketoesters  
 
The substrates sought for use in a study of the scope of the Pinhey arylation process 
were the homologous series of cyclic β-ketoesters 70, 75 and 79.  
 
Compound 70 was commercially available, while higher homologues 75 and 79 were 
generated in 80 and 74% yield, respectively, by trapping the corresponding lithium 
enolates of 2-cyclohexen-1-one (77) and 2-cyclohepten-3-one (78) with methyl 
cyanoformate utilising chemistry developed by Mander and co-workers.25 The saturated 
five-membered carbonyl compound was employed as attempts to generate the 
corresponding enone using the abovementioned chemistry only led to polymerisation 
products. The spectral data derived from compound 75 generated by such means were 
in full accord with those reported in the literature.25 The 1,3-dicarbonyl compound 79 
was new so full spectral characterisation was undertaken. Compound 79 exists as a 
mixture of keto-enol tautomers, with the keto-form predominating. In the 1H NMR 
spectrum of this material a singlet was observed at δ 3.77 and this corresponds to the 
methyl group protons of the methyl ester unit. This assignment was further reinforced 
by the presence, in the 13C NMR spectrum, of signals at δ 170.8 and 167.9 that are 
attributed to the ester carbonyl groups of the enol- and keto-forms, respectively. Signals 
appearing at δ 102.5 and 64.0 and being indicative of the α-carbon of the enol- and 
keto-forms of compound 79 were also observed. The IR spectrum exhibited bands at 
1747 and 1653 cm-1 that are due to carbonyl stretching absorptions of the ester and α,β-
unsaturated enone functionalities, respectively. Finally, the 70 eV electron impact mass 
spectrum showed the expected molecular ion at m/z 168. A fragment ion (30%) 
appearing at m/z 109 and arising from the loss of a carboxymethyl radical was also 
observed. This fragmentation is common for this class of compound. The base peak at 
m/z 81 is attributed to the loss of both carbon monoxide and a carboxymethyl radical 
from the molecular ion. 
 
 
O
CO2Me
O
CO2Me
O CO2Me
(70) (75) (79)
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Preparation of Arylstannanes 
 
The next stage of the proposed arylation study was to prepare the requisite aryllead 
triacetates for the use in the Pinhey arylation reaction. To this end, the precursor 
arylstannanes were required. These were chosen to mimic the “lower” hemisphere of 
(+)-vinblastine (1) and they proved accessible through elaboration of bromoarenes 58, 
80 – 84.  
 
Compounds 58, 80 – 83 were readily obtained from chemical suppliers while congener 
84 was prepared from the commercially available 3-methoxy-4-bromoaniline (85) using 
the Bischler indole synthesis (Scheme 2.7) as reported by Forbes.26  
 
Scheme 2.7: Bischler indole synthesis of indole 84 
 
Thus, compound 85 was first converted, under standard conditions, into 
methanesulfonamide 86. The 1H NMR spectrum of this compound revealed a signal at δ 
3.90 and this corresponds to the three methyl protons of the methanesulfonyl group, 
while the 13C NMR spectrum showed a signal at δ 39.2 arising from the 
methanesulfonamide carbon. Electron impact mass spectral analysis revealed the 
Br
MeO MeO
MeO
OMe
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OMe
OMeMeO
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Boc NBoc
BrBr
MeO
(80) (81) (82)
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Br
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MeO
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MsCl, py., CH2Cl2
0oC to r.t.
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MeO NHMs
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Ms
EtO OEt1. NaH, DMF, 0
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Br
MeO NMs
Br
MeO NH
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(84)
(85) (86)
(87) (88)
(89)
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HO
OEtEtO
TfO
OEtEtO
98% 98%
72% 89%
100%
10% NaOH, EtOH,
reflux
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expected molecular ion at m/z 279. The base peak was observed at m/z 200 and 
corresponds to the loss of the methanesulfonyl radical from the parent ion. The triflate, 
88, derived from commercially available alcohol 87 was treated with the conjugate base 
of sulfonamide 86 to give the expected N-alkylated derivative 89 in 98% yield. The 1H 
NMR spectrum of compound 89 showed various signals corresponding to the protons of 
the diethyloxyethyl group and these appeared as a triplet at δ 4.61 (J = 5.4 Hz), 
multiplets at δ 3.74 and 3.52 and a triplet at δ 1.16 (J = 7.0 Hz). In the 13C NMR 
spectrum signals corresponding to the diethyloxyethyl carbons were observed at δ 
110.9, 62.7, 53.3 and 15.3. In addition, the 70 eV electron impact mass spectrum 
showed the expected molecular ion at m/z 395, with a base peak appearing at m/z 103 
and that is attributed to the loss of a diethyloxyethyl radical from the molecular ion. 
Compound 89 underwent the pivotal cyclisation reaction on exposure to titanium 
tetrachloride. Under such conditions the indole 90 was formed as the exclusive product 
of the reaction and obtained in 89% yield. The 1H NMR spectrum of compound 90 
showed a pair of mutually coupled doublets at δ 7.34 and 6.61 (J = 3.7 Hz) and these 
correspond to the H-2 and H-3 protons of the indole group. Furthermore, in the 13C 
NMR spectrum of this indole, signals corresponding to the C-2 and C-3 indole carbons 
appeared at δ 125.6 and 96.7, respectively. The synthesis of the desired indole, 84, was 
completed by alkaline hydrolysis of sulfonamide 90. The 1H NMR spectrum of product 
84 so obtained was fully consistent with the assigned structure. In particular, the 
appearance of a broad signal at δ 7.80 that corresponds to the N-1 indolic proton 
indicated that hydrolysis of precursor 90 had been successful. Furthermore, the IR 
spectrum displayed a diagnostic absorption band at 3402 cm-1 that corresponds to NH 
stretching. An accurate mass measurement on the molecular ion observed at m/z 224 in 
the 70 eV electron impact mass spectrum established that this species had the expected 
composition, viz C9H879BrNO.  
 
With the relevant bromoarene precursors in hand, the preparation of the required 
arylstannanes, 73 and 91 – 95, could now be undertaken.  
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Stannanes 73 and 91 were prepared (Table 2.2.) by previously reported methods24, 27 
and the derived spectral data were in complete accord with the assigned structures. 
Compound 93 was synthesised by similar methods,28 while compound 92 was prepared 
utilising a direct ortho-metallation of 1,2,3-trimethoxybenzene following the procedure 
of Sundburg.29 Finally, indoles 94 and 95 were synthesised using a modification of a 
protocol developed by Konopelski et al during the course of a total synthesis of the 
alkaloid N-methylwelwitindolinone C isothiocyanate.30 The 1H NMR spectrum of each 
of these arylstannanes showed signals that are indicative of the constituent n-butyl 
protons at ca. δ 1.60 – 0.80, while resonances corresponding to the n-butyl carbons 
were always present in the 13C NMR spectrum. In addition, 70 eV electron impact mass 
spectral analysis of these compounds revealed the expected cluster of molecular ions 
that reflects the natural distribution of tin isotopes. The base peak was always observed 
at m/z 57 and this is assigned to a butyl cation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sn(Bu)3 Sn(Bu)3 Sn(Bu)3
MeO MeO
MeO
OMe
MeO
MeO
N
Boc
N
Boc
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(Bu)3Sn(Bu)3Sn
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Table 2.2: Preparation of arylstannanes 73, 91 – 95  
 
entry starting material procedurea product yield (%) 
 
1 
(58) 
 
Method A 
 (73) 
 
85 
 
2 
(80) 
 
Method A 
(91) 
 
78 
 
3 
 (81) 
 
Method A 
(92) 
 
           57 
 
4 
 (82) 
 
Method A 
 (93) 
 
           40 
 
5 
 (83) 
 
Method B 
(94) 
 
69 
 
6 
 (84) 
 
Method C 
 (95) 
 
90 
aMethod A: (i) n-BuLi (1.1 eq.), diethyl ether, –78°C → r.t., 1 h; (ii) (Bu)3SnCl (1.1 eq,), –78°C → reflux, 3 h. 
Method B: (i) KH (1.1 eq.), diethyl ether, 0°C, 0.25 h; (ii) t-BuLi (1.1 eq.), –78°C, 1 h; (iii) (Bu)3SnCl (1.1 eq.), –
78°C → r.t., 1 h; (iii) Boc2O (1.1 eq.), CH2Cl2, r.t., 1 h. Method C: (i) KH (1.1 eq.), THF, 0°C, 0.25 h; (ii) t-BuLi 
(1.1 eq.), –78°C, 1 h; (iii) HMPA, (Bu)3SnCl (1.1 eq.), –78°C → reflux, 3 h; (iv) Boc2O (1.1 eq.), CH2Cl2, r.t., 1 h. 
 
With the required arylstannanes in hand, the next step was to form the corresponding 
aryllead triacetates, 74 and 96 – 100, that were to act as substrates in the Pinhey 
arylation process.  
 
 
 
 
 
Br
Br
MeO
MeO
MeO
OMe
Br
N
HMeO
Br
N
H
OMe
OMeMeO
Br
Sn(Bu)3
Sn(Bu)3
MeO
Sn(Bu)3
MeO
MeO
OMe
OMe
OMeMeO
Sn(Bu)3
N
Boc
(Bu)3Sn
N
Boc
(Bu)3Sn
MeO
 39
 
 
Preparation of Aryllead Triacetates 
 
The abovementioned aryllead triacetates 74 and 96 – 99 were each prepared in good to 
excellent yields from the corresponding arylstannanes via a transmetallation reaction 
utilising lead tetraacetate and with mercuric triflate present as catalyst (Table 2.3). The 
mechanism of this reaction involves electrophilic ipso-substitution of the tin by mercury 
followed by a mercury-lead exchange reaction. Disappointingly, although this 
transmetallation process permitted the conversion of the stannane 95 into the lead 
derivative 100, the latter material decomposed on work-up. Therefore, the crude 
samples of aryllead triacetate 100 so obtained were used directly in the studies of the 
Pinhey arylation reaction. 
 
Compounds 74 and 96 have been described previously24, 27 and the derived spectral data 
matched those reported. Thus, the 1H NMR spectrum of each of these arylleads 
displayed a singlet in the region of δ 2.00 that corresponds to the acetate protons while 
in the 13C NMR spectrum a signal assigned to the acetate carbonyls was always present 
at ca. δ 180.0. In addition, electron impact mass spectral analysis always revealed the 
expected cluster of molecular ions and reflecting the natural distribution of the isotopes 
of lead. 
 
 
 
 
 
 
 
Pb(OAc)3 Pb(OAc)3 Pb(OAc)3
MeO MeO
MeO
OMe
MeO
MeO
N
Boc
N
Boc
OMe
(AcO)3Pb(AcO)3Pb
(74) (96) (97)
(99) (100)
(98)
Pb(OAc)3
OMe
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Table 2.3: Preparation of aryllead triacetates 74, 96 – 100 required for the Pinhey 
arylation reaction 
 
entry starting material producta yield (%) 
 
1 
 (73) (74) 
 
85 
 
2 
 (91) (96) 
 
70 
 
3 
 (92)  (97) 
 
             75 
 
4 
  (93)  (98) 
 
81 
 
5 
 (94) 
 (99) 
 
78 
 
6 
   (95)  (100) 
 
–
b
 
aMethod: Pb(OAc)4 (1.1 eq.), Hg(OTf)2 (10 mol%), CHCl3, 40°C, 12 h. bCompound 100 was not isolated 
immediately and was subjected to the relevant Pinhey arylation reaction (see Experimental Section) 
 
Arylation of β-Ketoesters 
 
Investigations into the scope of the Pinhey arylation of β-ketoesters involved treating 
the β-ketoesters 70, 75 and 79 with the aryllead triacetates 74, 96 – 100 using three 
equivalents of pyridine in chloroform at 40°C. Gratifyingly, under such conditions the 
five-membered ring β-ketoester 70 coupled with the corresponding aryllead triacetates 
to give the expected products in good yields (Table 2.4).  
 
Pb(OAc)3
MeO
Pb(OAc)3
N
Boc
(AcO)3Pb
MeO
N
Boc
(AcO)3Pb
OMe
OMeMeO
Pb(OAc)3
Pb(OAc)3
MeO
MeO
OMe
Sn(Bu)3
Sn(Bu)3
MeO
MeO
MeO
OMe
Sn(Bu)3
OMe
OMeMeO
Sn(Bu)3
(Bu)3Sn
N
Boc
(Bu)3Sn
N
BocMeO
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Table 2.4: Pinhey arylation of 5-membered ring β-ketoester 70 with aryllead triacetates 
74, 96 and 99 
 
entry β-ketoester arylead triacetate product of arylationa yield (%) 
 
1 
 (70) (74)  (71) 
 
82 
 
2 
 
(70) 
(96)  (101) 
 
72 
 
3 
 
(70) 
 (99) 
 (102) 
 
81 
aMethod: (i)  β-ketoester (1.1 eq.), py. (3.0 eq.), CHCl3, 0.5 h; (ii) aryllead triacetate (1.1 eq.), 40°C, 12 h. 
 
Product 71 had been described previously and the derived spectroscopic data compared 
favourably with those reported.31 Hitherto, compounds 101 and 102 had not been 
prepared and these were, therefore, subject to the usual range of characterisation 
protocols. In the 13C NMR spectrum of each of these compounds a signal that 
corresponds to the quaternary α-carbon bearing the carboxymethyl and aryl groups was 
observed at ca. δ 65.0. The 1H and 13C NMR spectra of α-arylated ketone 102 are 
indicative and shown in Figures 2.2 and 2.3, respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pb(OAc)3
Pb(OAc)3
MeO
(AcO)3Pb
N
Boc O
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N
Boc
O
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O
CO2Me
O
CO2Me
MeO
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Figure 2.2: 300 MHz 1H NMR spectrum of α-arylated β-ketoester 102 recorded in 
CDCl3 at 18°C (line broadening attributed to the presence of carbamate rotomers) 
 
 
Figure 2.3: 75 MHz 13C NMR spectrum of α-arylated β-ketoester 102 recorded in 
CDCl3 at 18°C 
 
ppm6.66.87.07.27.47.67.88.08.2
ppm2345678
O
CO2Me
N
Boc
(102)
INDEX    FREQUENCY  PPM      HEIGHT
  1      15992.798  211.961       18.6
  2      12916.420  171.188       20.0
  3      11262.860  149.273        9.0
  4      10118.880  134.111        8.3
  5       9836.607  130.370       17.4
  6       9805.116  129.952       21.8
  7       9517.690  126.143       25.6
  8       9305.842  123.335       34.2
  9       9015.552  119.488       33.3
 10       8676.596  114.995       35.3
 11       8085.139  107.157       31.9
 12       6299.316  83.488       19.0
 13       5841.839  77.425       20.7
 14       5809.775  77.000       21.5
 15       5777.139  76.567       20.7
 16       4870.773  64.555       29.3
 17       3970.132  52.618       38.2
 18       2822.717  37.411       33.8
 19       2631.481  34.876       34.9
 20       2097.280  27.796      130.0
 21       1433.108  18.994       35.3
ppm406080100120140160180200
O
CO2Me
N
Boc
(102)
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The higher homologue of compound 70, namely 2-oxocyclohex-3-ene carboxylate (75), 
also coupled with the corresponding arylead triacetates to give products 76 and 103 – 
107 in good yields (Table 2.5). 
 
 
Table 2.5: Pinhey arylation of 6-membered ring β-ketoester 75 with aryllead triacetates 
74, 96 – 100 
 
entry β-ketoester aryllead triacetate product of arylationa yield (%) 
 
1 
 (75) (74) 
 (76) 
 
79 
 
2 
 
(75) 
(96) 
 (103) 
 
76 
 
3 
 
(75) 
 (97) 
 (104) 
 
75 
 
4 
 
(75) 
(98) 
  (105) 
 
84 
 
5 
 
(75) 
  (99) 
  (106) 
 
71 
 
6 
 
(75) 
(100) 
  (107) 
 
82b 
aMethod: β-ketoester (1.1 eq.), py. (3.0 eq.), CHCl3, 0.5 h; (ii) aryllead triacetate (1.1 eq.), 40°C, 12 h. bYield over 
two steps. 
 
These products had not been prepared previously and were, therefore, fully 
characterised.  
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MeO
(AcO)3Pb
N
Boc O
CO2Me
N
Boc
O
CO2Me
OMe
OMe
OMe
O
CO2Me
O
CO2Me
O
CO2Me
MeO
O
CO2Me
OMe
OMe
MeO
O
CO2Me
MeO NBoc
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The seven-membered ring compound 79 was also investigated as a potential coupling 
partner in the Pinhey arylation reaction in order to determine the applicability of this 
protocol to larger ring sizes as would be required in a synthesis of (+)-vinblastine (1). 
As can be seen from the results presented in Table 2.6, substrate 79 underwent α-
arylation in preparatively useful yields. 
 
 
Table 2.6: Pinhey arylation of 7-membered ring β-ketoester 79 with aryllead triacetates 
74, 96 and 99 
 
entry β-ketoester aryllead triacetate product of arylationa yield (%) 
 
1 
 (79) (74) 
  (108) 
 
63 
 
2 
 
(79) 
(96) 
   (109) 
 
70 
 
 
12 
 
 
(79) 
(99) 
  (110) 
 
 
71 
aMethod: β-ketoester (1.1 eq.), py. (3.0 eq.), CHCl3, 0.5 h; (ii) aryllead triacetate (1.1 eq.), 40°C, 12 h. 
 
Compounds 108 – 110 had not been prepared previously and were, therefore, fully 
characterised. 
 
The successful arylations detailed above clearly demonstrates that a range of aryllead 
triacetates and cyclic β-ketoesters of varying ring sizes can participate in the Pinhey 
arylation reaction to give the desired products. The conversion of these Pinhey arylation 
products into the desired range of analogues of (+)-vinblastine is detailed in the 
following section.   
 
Pb(OAc)3
Pb(OAc)3
MeO
(AcO)3Pb
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Boc O
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O
CO2Me
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O CO2Me O
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2.3 Synthesis of “Bridging Region” or Indole-Indoline Analogues of 
(+)-Vinblastine  
2.3.1 Background 
 
Although there is a wide range of methods available for the preparation of indoles and 
tetrahydrocarbazoles,32-34 only a few of these, as detailed below, utilise cyclic ketones as 
starting materials and are, therefore, compatible with the synthetic strategy outlined in 
Figure 2.1.  
 
Fischer’s Indole Synthesis 
 
In 1883, Emil Fischer developed the first and still most commonly utilised method for 
the synthesis of indoles.35 This involves the reaction of various arylhydrazines 111 with 
an enolisable ketone, e.g. cyclohexanone (112), to generate the corresponding 
arylhydrazones 113, that, under forcing conditions, tautomerise to unstable ene-
hydrazines 114 that then undergo [3,3]-sigmatropic rearrangement to form, through a 
series of proton shifts and the loss of ammonia, tetrahydrocarbazoles of the general 
form 115 (Scheme 2.8).  
 
Scheme 2.8: The Fischer indole synthesis 
 
The reaction usually requires high temperatures (180 – 250°C) and an acid catalyst. The 
likely instability of α-arylated ketones such as 102 to these conditions meant that this 
approach to the target analogues was not considered. 
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O
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The Bischler-Mohlau Indole Synthesis 
 
In 1892, Bischler discovered that indoles and tetrahydrocarbazoles can be formed by 
first reacting an aniline (e.g. 116) with an α-chloroketone (e.g. 117) in the presence of a 
base and thus generating the corresponding 2-phenylaminoketone 118.36 Such a product 
can be cyclized, using either acid or at high temperatures (70 – 160°C), to give, through 
a cyclocondensation process, the desired tetrahydrocarbazole 119  (Scheme 2.9).  
 
Scheme 2.9: The Bischler-Mohlau indole synthesis 
 
Unfortunately, these represent rather forcing conditions and, in addition, the protocol 
would not lead to the mode of indole ring-fusion required in the targetted analogues. 
Accordingly, this approach to such compounds was not considered in the first instance.  
 
Soderberg’s Indole Synthesis 
 
Scott and Soderberg have recently reported that under Stille cross-coupling conditions 
stannane 120 reacts with α-iodocyclohexenone 121 to give product 12237 and, further, 
that this last compound engages in a novel palladium-catalysed reductive N-
heteroannulation to give the 1,2-dihydro-4-(3H)-carbazolone (123) as illustrated in 
Scheme 2.10. 
 
Scheme 2.10: Soderberg’s synthesis of 1,2-dihydro-4-(3H)-carbazolone (123) 
 
In terms of the synthetic strategy outlined in Figure 2.1, this annulation protocol would 
also lead to the wrong mode of indole ring-fusion. However, the first step of this 
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I
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method could, in principle, be applied to the approach being proposed and is 
emphasised in the following sections. 
Indole Annulation in Shibasaki’s Synthesis of (-)-Strychnine 
 
Shibasaki has reported a total synthesis of the alkaloid (-)-strychnine wherein the 
associated indole skeleton was assembled using a two-step process.38 Thus, the α-
iodocycloalkenone 124 was coupled with stannane 125 to afford nitro-arene 126 and 
this last compound was then converted, through a series of steps including a reductive 
cyclisation reaction using zinc and ammonium chloride, into indole 127 (Scheme 2.11).  
 
Scheme 2.11: The indole annulation step associated with Shibasaki’s (-)-strychnine 
synthesis  
 
However, unlike that used in original Soderberg’s work (vide supra), the reductive 
cyclisation method employed by Shibasaki leads to indole ring-fusion in the same sense 
as required for obtaining the targetted analogues of (+)-vinblastine. 
 
Banwell’s Synthesis of Indoles 
 
The Shibasaki chemistry detailed above required the use of stannylated precursors at an 
early stage of the synthetic sequence. This situation was deemed undesirable from both 
an economic and environmental standpoint and so other cross-coupling protocols were 
considered. Recently, Banwell et al have examined the utility of the Pd[0]-catalysed 
Ullmann cross-coupling reaction, wherein a range of α-halocycloalkenones 128 was 
reacted with o-halonitrobenzenes of the general type 129 using five equivalents of  
copper and Pd[0] as a catalyst.1 Gratifyingly, in most cases the reaction went to 
completion generating the desired cross-coupled products 130 in high yield. Small 
quantities of the homo-coupled products of the general form 131 were also obtained but 
analogous homo-coupling of the enone 128 was not observed (Scheme 2.12). 
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Scheme 2.12: Banwell’s synthesis of indoles 
 
In all cases, the α-arylated enones 130 so obtained could be reductively cyclized, using 
palladium on charcoal under an atmosphere of dihydrogen, to give the corresponding 
indoles 132 in excellent yields. 
 
A proposed mechanism for the reductive cyclisation of nitro-arene 122 to indole 119 is 
shown in Scheme 2.13. Thus, the first step is thought to involve the reduction of the 
enone moiety to provide the corresponding ketone 133. The nitro-group is then reduced, 
probably, via an intermediate N-hydroxyamine 134, to the corresponding aniline 135, 
which engages in an intramolecular Schiff-base condensation reaction with the tethered 
ketone to give, after tautomerisation of the resulting imine 136, the observed 
tetrahydrocarbazole 119. 
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Scheme 2.13: Proposed mechanism associated with the reductive cyclisation of nitro-
arene 122 to tetrahydrocarbazole 119 
 
Such results clearly indicate that the Pd[0]-catalysed Ullmann cross-coupling reaction, 
followed by reductive cyclisation of the coupling product, could provide a simple and 
effective route to the required analogues of (+)-vinblastine. 
 
2.4 Application of the Pd[0]-catalysed Ullmann Cross-Coupling 
Reaction in Preparing “Bridging Region” Analogues of (+)-Vinblastine 
In order to determine if the Pd[0]-catalysed Ullmann cross-coupling route to indoles, as 
described above, could be applied to the present study, o-iodonitrobenzene (137) was 
cross-coupled with α-arylated α′-iodinated enone 138 (prepared as described in the 
following section) using conditions defined by Banwell et al (Scheme 2.14). Pleasingly, 
the desired coupling product, 139, was obtained in 58% yield.  
 
 
 
10% Pd/C, 
H2, 1 atm.
EtOH, r.t
(136)
N
NO2
N
H
(122)
(119)
NO2
(133)
NH2
(135)
O
O
O
90%
NHOH
O
(134)
 50 
 
Scheme 2.14: Pd[0]-catalysed  Ullmann cross-coupling of  o-iodonitrobenzene (137) 
with α-arylated enone 138  
 
These conditions were then applied to a range of other potential cross-coupling partners 
in order to test the utility of the title reaction in generating the relevant precursors to the 
targetted indole-indoline analogues of (+)-vinblastine. 
 
2.4.1 Examining the Scope of Pd[0]-catalysed Ullmann Cross-Coupling 
Reaction 
 
The aromatic coupling partner used to investigate the scope of Pd[0]-catalysed Ullmann 
cross-coupling reaction was o-iodonitrobenzene (137), a commercially available 
compound.  
 
The non-aromatic cross-coupling partners investigated in this study were also chosen to 
allow for an examination of the range of “vinblastine relevant” functionalities that could 
survive this pivotal carbon-carbon bond forming step. The cyclic α′-iodinated enones 
138, 149, 150, 152 – 154, 157 and 158 as well as the indole-containing cyclic α′-
iodinated enones 151, 155, 156 and 159 were selected for this purpose.  
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Preparation of α′-Iodinated Cross-Coupling Partners 
 
The title substrates were all prepared by iodination of the corresponding non-iodinated 
systems using the protocols developed by Johnson39 and others.40-42 In the case of the 5-
membered ring series, the ketones 71, 101 and 102 were first transformed into the 
corresponding trimethylsilylenol ethers 143 – 145 and these were then subjected to 
Saegusa-type oxidation43 with palladium acetate. In this manner, the requisite enones 
146 – 148 were obtained in good overall yields (Table 2.7). 
 
Table 2.7: Preparation of the five-membered cyclic α-arylated  enones 146 – 148 
 
entry α-arylated 
cyclic ketone 
trimethylsilylenol 
ethera 
yield (%) α-arylated 
cyclic enoneb 
yield 
(%) 
 
1 
 (71) 
 (143) 
 
72 
 (146) 
 
97 
 
2 
 (101)  (144) 
 
96 
 (147) 
 
61 
 
3 
 (102)  (145) 
 
72 
  (148) 
 
60 
aMethod: i-Pr2NH (3.0 eq.), TMSCl (2.0 eq.), DMF, 110°C, 3 h. bMethod: Pd(OAc)2 (0.5 eq.), p-benzoquinone (0.5 
eq.), MeCN, r.t, 3 h. 
 
All the trimethylsilylenol ethers shown in Table 2.7 were previously unreported 
compounds and, therefore, subject to full spectroscopic characterisation. In the 1H NMR 
spectrum of each of these compounds a triplet associated with the olefinic proton was 
always observed at ca. δ 4.90. Furthermore, in the corresponding 13C NMR spectrum a 
signal that is attributed to the methyl carbons of the trimethylsilyl moiety was invariably 
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observed at ca δ -0.02. The 1H and 13C NMR spectra of compound 145, as shown in 
Figures 2.4 and 2.5 respectively, are typical.  
 
 
Figure 2.4: 300 MHz 1H NMR spectrum of trimethylsilylenol ether 145 recorded in 
CDCl3 at 18°C 
 
Figure 2.5: 75 MHz 13C NMR spectrum of trimethylsilylenol ether 145 recorded in 
CDCl3 at 18°C 
 
INDEX    FREQUENCY  PPM      HEIGHT
  1      13202.128  174.975       12.7
  2      11600.671  153.750       17.7
  3      11298.930  149.751        5.8
  4      10282.632  136.281       23.1
  5      10096.549  133.815        4.9
  6       9834.888  130.347       12.6
  7       9502.229  125.938       22.3
  8       9342.484  123.821       29.1
  9       8997.229  119.245       27.5
 10       8655.409  114.715       34.3
 11       8110.330  107.490       32.7
 12       7909.933  104.835       29.1
 13       6298.742  83.481       15.0
 14       5841.838  77.425       53.0
 15       5809.774  77.000       56.0
 16       5777.711  76.575       52.3
 17       4795.766  63.561       23.0
 18       3935.205  52.155       28.2
 19       2813.555  37.290       34.4
 20       2121.899  28.123      130.0
 21       1952.993  25.884       33.3
 22        -10.896  -0.144       80.1
ppm20406080100120140160
TMSO
CO2Me
N
Boc
(145)
ppm6.66.87.07.27.47.67.88.08.2
ppm12345678
TMSO
CO2Me
N
Boc
(145)
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The cyclic enones shown in Table 2.7 were also new compounds and once again, fully 
characterised. In the 1H NMR spectrum of each of these compounds, a pair of mutually 
coupled doublets of triplets (J = ca. 5.8 and 3.0 Hz) that are associated with the olefinic 
protons was always present in the regions of δ 7.80 and 6.25. Furthermore, in the 13C 
NMR spectrum, a signal arising from the carbonyl moiety of the cyclic enone unit was 
invariably observed in the region of δ 200.0. The IR spectrum of each enone displayed 
intense absorption bands at ca. 1730 and 1705 cm-1 and these arise from stretching of 
the ester and α,β-unsaturated ketone carbonyl units, respectively. The 1H and 13C NMR 
spectra of enone 148, as shown in Figures 2.6 and 2.7, are typical.  
 
 
Figure 2.6: 300 MHz 1H NMR spectrum of enone 148 recorded in CDCl3 at 18°C 
ppm6.26.46.66.87.07.27.47.67.88.08.2
ppm2345678
O
CO2Me
N
Boc
(148)
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Figure 2.7: 75 MHz 13C NMR spectrum of enone 148 recorded in CDCl3 at 18°C 
 
With these five-membered cyclic enones now available, Johnson conditions were then 
applied to them and in order to form the α′-iodinated derivatives 149 – 151 (Table 2.8) 
required as cross-coupling partners in the foreshadowed Pd[0]-catalysed Ullmann cross-
coupling reactions. 
 
 
Table 2.8: Preparation of 5-membered cyclic α′-iodinated α-arylated enones 149 – 151  
 
entry starting material producta yield (%) 
 
1 
  (146)   (149) 
 
60 
 
2 
 (147)  (150) 
 
96 
 
3 
 (148)  (151) 
 
93 O
CO2Me
I
N
Boc
O
CO2Me
N
Boc
O
CO2Me
O
CO2Me
I
O
CO2Me
MeO
O
CO2Me
MeO
I
ppm406080100120140160180200
INDEX    FREQUENCY  PPM      HEIGHT
  1      15364.696  203.636       12.1
  2      12891.799  170.862       12.0
  3      12310.075  163.152       30.7
  4      11285.761  149.576        6.0
  5      10120.597  134.134        4.4
  6      10030.704  132.942       14.9
  7       9964.287  132.062       33.7
  8       9854.928  130.613       10.8
  9       9540.018  126.439       24.6
 10       9324.735  123.586       32.0
 11       9005.245  119.351       29.9
 12       8709.803  115.436       34.6
 13       8104.032  107.407       34.0
 14       6322.217  83.792       14.0
 15       5841.837  77.425       59.3
 16       5809.774  77.000       61.4
 17       5777.710  76.575       61.1
 18       4719.043  62.544       14.9
 19       4018.799  53.263       32.4
 20       3322.563  44.036       32.8
 21       2120.182  28.100      130.0
O
CO2Me
N
Boc
(148)
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aMethod: I2 (4.0 eq.), (1:1 v/v) CCl4/pyridine 
The 1H and 13C NMR spectra of compound 151 as shown in Figures 2.8 and 2.9, 
respectively are, once again, typical of compounds in this series.  
 
Figure 2.8: 300 MHz 1H NMR spectrum of enone 151 recorded in CDCl3 at 18°C  
 
Figure 2.9: 75 MHz 13C NMR spectrum of enone 151 recorded in CDCl3 at 18°C 
INDEX    FREQUENCY  PPM      HEIGHT
  1      15025.739  199.144        6.1
  2      12849.429  170.300       10.5
  3      11854.888  157.119       22.9
  4      11290.342  149.637        5.7
  5      11198.732  148.423        8.4
  6      10706.328  141.897       12.2
  7      10126.895  134.217        5.7
  8      10051.316  133.215       24.1
  9      10011.237  132.684       12.5
 10       9931.651  131.629       23.5
 11       9865.806  130.757       10.0
 12       9781.067  129.634       24.0
 13       9568.646  126.818       11.2
 14       9541.163  126.454       18.8
 15       9418.062  124.823       26.8
 16       9321.872  123.548       23.1
 17       9018.414  119.526       21.7
 18       8716.101  115.519       25.4
 19       8116.055  107.566       24.6
 20       6323.362  83.807       11.0
 21       5841.837  77.425      128.4
 22       5809.774  77.000      130.0
 23       5777.710  76.575      123.7
 24       4799.774  63.614       15.9
 25       4037.693  53.514       21.3
 26       3192.018  42.306       21.7
 27       2123.044  28.138       88.9
ppm406080100120140160180200
O
CO2Me
N
Boc
I
(151)
ppm6.66.87.07.27.47.67.88.0
ppm2345678
O
CO2Me
N
Boc
I
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 56 
With the successful preparation of the five-membered α′-iodinated cross-coupling 
partners, the same approach was extended to the six- and seven-membered ring series 
(see Tables 2.9 and 2.10, respectively). All the compounds shown in these Tables were 
novel and, therefore, fully characterised. In the 1H NMR spectrum of each of these 
compounds the mutually coupled signals associated with the olefinic protons of the 
precursor α,β-unsaturated enones were replaced with a triplet appearing at ca. δ 7.80 
and arising from the β-olefinic proton. In addition, in the 13C NMR spectra the signals 
associated with the olefinic α-carbon of the precursor were supplanted by a resonance 
for the carbon bonded to iodine that appeared in the region δ 100.0. 
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Table 2.9: Preparation of the 6-membered cyclic α′-iodinated α-arylated enones 
138, 152 – 156 
 
entry starting material producta yield (%) 
 
1 
 (76) 
 (138) 
 
60 
 
2 
 (103) 
  (152) 
 
60 
 
3 
 (104)  (153) 
 
75 
 
4 
  (105)   (154) 
 
98 
 
5 
  (106)   (155) 
 
              73 
 
6 
  (107)    (156) 
 
              70 
aMethod: I2 (4.0 eq.), (1:1 v/v) CCl4/pyridine  
 
 
 
 
 
 
 
 
 
 
 
 
 
I
O
CO2Me
OMe
OMe
OMe
O
CO2Me
OMe
OMe
OMe
O
CO2Me
I
O
CO2Me
O
CO2Me
MeO O
CO2Me
MeO
I
O
CO2Me
MeO
OMe
OMe
O
CO2Me
MeO
OMe
OMe
I
O
CO2Me
MeO NBoc
O
CO2Me
N
Boc
O
CO2Me
N
Boc
I
I
O
CO2Me
MeO NBoc
 58 
Table 2.10: Preparation of the 7-membered cyclic α′-iodinated α-arylated enones 
157 – 159 
 
entry starting material producta yield (%) 
 
1 
 (108)   (157) 
 
58 
 
2 
 (109)   (158) 
 
68 
 
 
3 
 (110)   (159) 
 
 
61 
aMethod: I2 (4.0 eq.), (1:1 v/v) CCl4/pyridine  
 
With the requisite cyclic α′-iodinated enone substrates in hand, their capacity to engage 
in the Pd[0]-catalysed Ullmann cross-coupling reaction could be examined. Details of 
the outcomes of relevant studies are provided in the following section. 
 
Cross-Coupling and Reductive Cyclisation  
 
As can be seen in Tables 2.11 – 2.13, all of the abovementioned α′-iodinated cyclic 
enones coupled with o-iodonitrobenzene (137) in good to excellent yields. In each case, 
these previously unreported coupling products were accompanied by similar amounts of 
the chromatographically separable dimeric species 131 (R = H).  
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Table 2.11: Pd[0]-catalysed Ullmann cross-coupling of 5-membered cyclic α′-
iodinated α-arylated enones 149 – 151 with o-iodonitrobenzene (137) and 
subsequent reductive cyclisation of the products 
 
entry coupling 
partnersa 
coupling 
productb 
yieldc (%) indole yield (%) 
 
1 
  (149)   (160) 
 
60 
(163) 
 
97 
 
2 
  (150) 
   (161) 
 
58 
 (164) 
 
98 
 
 
3 
 (151)  (162) 
 
 
86 
(165) 
 
 
87 
aAll enones were coupled with 137, bThe reaction conditions defined by Banwell  and co-workers were employed for 
the Pd[0]-catalysed Ullmann cross-coupling and in all cases dimer  131 (R = H) was isolated in ca. 50% yield based 
on arene 137. cYield calculation based on non-aromatic coupling partner. 
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Table 2.12: Pd[0]-catalysed Ullmann cross-coupling of 6-membered cyclic α′-
iodinated α-arylated enones 138, 152 – 156 with o-iodonitrobenzene (137) and 
subsequent reductive cyclisation of the products 
 
entry coupling 
partnersa 
coupling productb yield 
(%)c 
indole yield 
(%) 
 
1 
 (138)  (139) 
 
58 
(171) 
 
95 
 
5 
 (152)  (166) 
 
66 
(172) 
 
95 
 
6 
 (153)  (167) 
 
56 
(173) 
 
67d,e 
 
7 
  (154) 
 (168) 
 
    56 
  (174) 
 
95 
 
8 
 (155) 
  (169) 
 
62 
 (175) 
 
87 
 
 
9 
  (156) 
 (170) 
 
 
91 
(176) 
 
 
75 
aAll enones were coupled with 137, bThe reaction conditions defined by Banwell  and co-workers were employed for 
the Pd[0]-catalysed Ullmann cross-coupling and in all cases dimer  131 (R = H)  was isolated in ca. 50% yield based 
on arene 137. cYield calculation based on non-aromatic coupling partner. cThe N-hydroxyindole 177 was also 
isolated in 12% yield.eIndole 173 was formed as the exclusive product in 92% yield when reaction time increased to 
24 h. 
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Table 2.13: Pd[0]-catalysed Ullmann cross-coupling of 7-membered cyclic α′-
iodinated  α-arylated enones 157 – 159 with o-iodonitrobenzene (137) and 
subsequent reductive cyclisation of the products 
 
entry coupling 
partnersa 
coupling productb yield (%) indole  yield (%) 
 
   1 
  (157) 
   (178) 
 
68 
 (181) 
 
71d 
 
   2 
   (158) 
    (179) 
 
56 
  (182) 
 
95d 
 
 
3 
(159)  (180) 
 
 
56 
 (183) 
 
 
88d 
 
 
4 
   
 
(158) 
   
 
(179) 
 
 
56 
   (184) 
 
 
68e 
aAll enones were coupled with 137, bThe reaction conditions defined by Banwell  and co-workers were employed for 
the Pd[0]-catalysed Ullmann cross-coupling and in all cases dimer  131 (R = H)  was isolated in ca. 50% yield based 
on arene 136. cYield calculation based on non-aromatic coupling partner. dCompounds 178 – 180 were reductively 
cyclised using 3 atmospheres of H2. eCompound 179 was reductively cyclised using TiCl3•THF.   
 
In the IR spectrum of each of these cross-coupled materials, an absorption band was 
always observed in the region of 1520 cm-1 and this corresponds to a stretching 
vibration of the nitro group. Furthermore, in the 1H NMR spectrum a doublet in the 
region of δ 8.15 was always present and this is attributed to the aromatic proton 
adjacent to the nitro-functionality. The 1H and 13C NMR spectra of nitro-arene 162 
shown in Figures 2.10 and 2.11, respectively, are typical of this series. 
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Figure 2.10: 300 MHz 1H NMR spectrum of nitro-arene 162 recorded in CDCl3 at 
18°C 
 
Figure 2.11: 75 MHz 13C NMR spectrum of nitro-arene 162 recorded in CDCl3 at 18°C 
 
 
 
ppm406080100120140160180200
INDEX    FREQUENCY  PPM      HEIGHT
  1      14943.290  198.051        9.9
  2      12831.680  170.065       12.0
  3      12657.621  167.758       36.7
  4      11282.326  149.531        6.8
  5      10134.338  134.316        4.9
  6       9969.440  132.130       14.8
  7       9859.508  130.673       12.6
  8       9554.905  126.636       25.8
  9       9300.687  123.267       36.8
 10       9000.664  119.291       34.5
 11       8720.109  115.572       39.5
 12       8102.886  107.392       38.1
 13       7493.107  99.310       15.2
 14       6330.806  83.906       15.8
 15       5841.265  77.417       90.2
 16       5809.774  77.000       89.1
 17       5777.710  76.575       89.8
 18       4523.226  59.949       16.9
 19       4038.266  53.521       32.7
 20       3474.292  46.047       33.4
 21       2121.899  28.123      130.0
O
CO2Me
N
BocNO2
(162)
ppm6.66.87.07.27.47.67.88.0
ppm2345678
O
CO2Me
N
BocNO2
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Having prepared the cross-coupled products, their reductive cyclisation, using 
dihydrogen in the presence of palladium on charcoal, was investigated. Pleasingly, 
under these conditions the target indoles 163 – 165 were each obtained in excellent 
yields. In the 1H NMR spectrum of each of these indoles a broad signal was observed at 
ca. δ 8.20 and this is assigned to the hydrogen attached to the indolic nitrogen. 
Furthermore, signals attributed to the aromatic protons within these indoles appeared at 
significantly higher field, relative to those due to the corresponding hydrogens in the 
nitro-arene precursors.  
 
The reductive cyclisation protocol was then extended to the six-membered ring series 
(Table 2.12) and under these conditions the indoles 171 – 176 were obtained in 
excellent yields. The 1H and 13C NMR spectra of indole 175 are presented in Figures 
2.12 and 2.13, respectively, and are typical of this series. Interestingly, the reduction of 
compound 167 was accompanied by quantities of the chromatographically separable N-
hydroxyindole 177 that was isolated in 12% yield.  
 
In the 1H NMR spectrum of this by-product, there was a sharp signal at δ 9.27 and this 
is assigned to the hydroxyl hydrogen attached to nitrogen. Increasing the reaction time 
for the reductive cyclisation of compound 167 resulted in the formation of indole 173 as 
the exclusive product of the reaction and so suggesting the N-hydroxyindole 177 was an 
intermediate in the process leading to target 173. 
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Figure 2.12: 300 MHz 1H NMR spectrum of indole 175 recorded in CDCl3 at 18°C  
 
Figure 2.13: 75 MHz 13C NMR spectrum of indole 175 recorded in CDCl3 at 18°C 
 
 
ppm2345678
ppm6.66.87.07.27.47.67.88.08.28.4
#
# = diethyl ether
N
H
CO2Me
N
Boc(175)
INDEX    FREQUENCY  PPM      HEIGHT
  1      13159.758  174.413       13.3
  2      11292.059  149.660        6.5
  3      10447.530  138.467       22.6
  4      10254.576  135.909       17.7
          9905.885  131.288       18.6
  6       9850.347  130.552       12.0
  7       9734.689  129.019        9.6
  8       9673.998  128.215        7.5
  9       9580.670  126.978       15.6
 11       9262.325  122.758       36.7
 13       9012.116  119.442       35.3
 14       8993.794  119.199       34.0
 15       8948.561  118.600       36.6
 16       8684.037  115.094       38.8
 17       8609.032  114.100       20.6
 18       8375.426  111.004       38.0
 20      
 21       5841.837  77.425       90.0
 22       5809.774  77.000       93.2
 23       5778.283  76.583       88.5
 24       4968.680  65.853        6.7#
 25       4020.516  53.286       23.7
 26       3979.292  52.740       31.6
 27       2794.087  37.032       30.9
 28       2123.044  28.138      130.0
 29       1584.836  21.005       30.3
 30       1486.355  19.699       27.8
ppm406080100120140160
 
5
 
 
 
 10       9543.453  126.978       25.0
 12       9215.948  122.144       38.9
 6325.080  83.830       14.6
 
  
#
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Finally, the reductive cyclisation of the seven-membered ring α′-(o-nitrophenyl) enones 
was investigated and the results of this study are compiled in Table 2.13 (page 61). The 
cross-coupled products were reductively cyclised using palladium on charcoal under 
three atmospheres of dihydrogen. The use of lower pressures led to incomplete reaction. 
 
A titanium trichloride-mediated reductive cyclisation33 of substrate 179 was also 
attempted, but in this case a product, 184, involving the wrong mode of indole ring-
fusion was obtained. The unexpected synthesis of this indolone can be rationalised by a 
reversal in the order of reduction steps when compared to the reductive cyclisation 
employing palladium on charcoal and dihydrogen (Scheme 2.13). Thus, in the titanium 
trichloride-mediated reductive cyclisation process, it is presumed that the nitrophenyl 
unit is first reduced to the corresponding N-hydroxyaniline. Complexation of titanium to 
the carbonyl of the α,β-unsaturated enone then activates the associated double bond and 
allows for a Michael-type addition reaction to take place and so leading to the N-
hydroxyindolone. Elimination of the elements of water from such a species would then 
give the observed product 184. The IR spectrum of this indolone displayed absorption 
bands at 1732 and 1600 cm-1 and these correspond to the stretching vibrations of the 
ester and indolone carbonyl moieties, respectively. Furthermore, the 13C NMR spectrum 
displayed the two carbonyl carbon resonances at δ 196.0 and 173.6. In addition, the 70 
eV high resolution electron impact mass spectrum gave the expected molecular ion at 
m/z 363.1470 with the base peak appearing at m/z 43.  
 
 
2.5 Summary  
As part of investigations into methods to prepare indole-indoline analogues of (+)-
vinblastine (1) a flexible protocol was developed for installing linkages that mimic the 
C-16′ to C-10 bond in the natural product. The important steps in this approach were the 
synthesis of a series of α-arylated β-ketoesters using chemistry developed by Pinhey 
and the subsequent utilisation of the Pd[0]-catalysed Ullmann cross-coupling reaction to 
N
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install all the indole rings of the targetted “bridging region” analogues of (+)-
vinblastine. This route to the desired analogues has proven very robust and flexible with 
a variety of aryl groups and ring sizes being compatible with the reaction conditions 
used. This suggests that such chemistry might be applicable to the development of a 
total synthesis of (+)-vinblastine (1). Some very preliminary steps directed toward such 
ends are detailed in the following Chapter.    
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Chapter Three 
Approaches to the Synthesis of a (+)-
Vinblastine Analogue Incorporating a 
Carbomethoxyvelbamine Framework  
 
3.1 Introduction 
 
3.1.1 Overview and Context 
 
The preceding chapter described the use of a combination of the Pinhey arylation and 
Pd[0]-catalysed Ullmann cross-coupling reactions for the synthesis of α,α′-diarylated 
enones that could then be manipulated so as to generate a series of analogues of the 
indole-indoline core present in (+)-vinblastine (1). This chapter details attempts to 
extend this approach by developing a synthesis of compound 44 incorporating a 
framework resembling the “upper” carbomethoxyvelbamine hemisphere of (+)-
vinblastine (1).  
 
The acquisition and biological testing of such a compound could provide additional 
insights into the structure-activity-relationship (SAR) profile of (+)-vinblastine (1). 
Furthermore, the lessons learnt during the course of preparing a compound such as 44 
could also be highly relevant in terms of ultimately achieving an efficient total synthesis 
of (+)-vinblastine (1).  
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3.2 Synthetic Strategy for the Preparation of a (+)-Vinblastine 
Analogue Incorporating a Carbomethoxyvelbamine Framework 
 
The first approach to the compound 44 (Figure 3.1) centred on acquiring the previously 
unreported cyclic enone 186. This latter compound would be expected to undergo a 
Johnson iodination reaction1 and the product of this process could then be engaged in a 
Pd[0]-catalysed Ullmann cross-coupling reaction2 to form the nitro-arene 185. 
Reductive cyclisation of this last compound should then give the targetted bis-indole 44. 
In principle, compound 186 could be obtained through a ring-closing metathesis (RCM) 
reaction,3, 4 while the precursor, 187, required for such a process could, in turn, be 
derived from the α-alkylated β-ketoester (3S)-188 via a Pinhey arylation reaction5 
(Section 2.2.1) involving the aryllead triacetate 189. It was believed that compound 
(3S)-188 itself could be accessed by C-alkylation at the 2-position of the known 1,3-
dicarbonyl compound 1906 using the easily accessible bromoalkylpiperidine 1917 as an 
electrophile. The β-ketoester 190 should itself be available in two steps through an aldol 
condensation reaction between (E)-crotylaldehyde (192) and commercially available 
methyl acetate (193) followed by Jones’ oxidation of the resulting allylic alcohol.8   
 
Figure 3.1: Retrosynthetic analysis of the bis-indole 44 
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As part of the initial campaign to put such ideas into effect, the bromoindole 199 was 
sought. Efforts directed towards such ends are described in the following section. 
 
3.3 Synthesis of the Indole Fragment 189 
 
3.3.1 Pd[0]-catalysed Ullmann Cross-Coupling Approach 
 
Based on the research described in the preceding chapter, tetrahydrocarbazole 199 
seemed the logical precursor to the plumbated indole 189. The former compound should 
be accessible via the reaction sequence shown in Scheme 3.1 and involving the 
previously described Pd[0]-catalysed Ullmann cross-coupling reaction as the key step. 
 
 
Scheme 3.1: Pd[0]-catalysed Ullmann cross-coupling approach to tetrahydrocarbazole 
199  
 
To such ends, 4-methoxyphenylacetamide (194) was subjected to bromination under the 
conditions described by Lauer.9 Recrystallisation of the crude reaction product from 
ethanol then gave arylbromide 195 in 87% yield. The spectroscopic properties of this 
compound compared favourably with those reported in the literature.10 Electrophilic 
aromatic nitration of compound 195 then afforded arene 196 as the only isolable 
reaction product and in 66% yield.11 The IR spectrum of this compound showed an 
absorption band at 1529 cm-1 that arises from the presence of the nitro moiety. 
Employing chemistry developed by Soderburg and Scott,12 the nitro-acetamide 196 was 
hydrolysed under acidic conditions and the ensuing aniline subjected to a Sandmeyer-
type reaction using potassium iodide and so giving the aryl iodide 197 in 72% yield 
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over the three steps. The 1H NMR spectrum of product 197 lacked a signal at δ 2.23 that 
corresponds to the acetyl methyl protons of the starting material 196. More importantly, 
the accurate mass measurement on the molecular ion appearing as the base beak at m/z 
357 in the 70 eV electron impact mass spectrum of compound 197 showed that this aryl 
iodide had the expected molecular composition, viz. C7H579Br126INO3. Coupling 
compound 197 with iodoenone 121 using the Pd[0]-catalysed Ullmann cross-coupling 
process2 gave the desired α′-arylated enone 198 in 66% yield. The 13C NMR spectrum 
of this product showed all the signals expected of the desired structure including one at 
δ 196.5 that corresponds to the carbonyl of the enone moiety. The IR spectrum 
displayed a strong absorption band at 1525 cm-1 and this is, once again, attributed to the 
presence of the nitro-unit. Taken together, these data clearly indicate that the desired 
cross-coupling reaction had occurred. With compound 198 in hand, its reductive 
cyclisation to tetrahydrocarbazole 199 could be examined. Since, at higher pH, 
palladium on charcoal also has the capacity to catalyse the hydrogenolysis of 
bromoarenes, the reaction was performed in an acidic medium, but the desired product 
was only obtained in 27% yield, the major product still being the debrominated material 
200.  
 
The 1H NMR spectrum of tetrahydrocarbazole 199 featured a singlet at δ 6.84 that is 
attributed to the H-4 proton, which, as expected, had moved up field considerably when 
compared to the chemical shift of the signal of the equivalent proton in the precursor 
nitro-arene. The resonance assigned to the N-1 indolic proton appeared as a broad 
singlet at δ 7.59. The 13C NMR spectrum is fully consistent with the assigned structure 
with resonances observed at δ 135.2 and 125.5 and corresponding to the C-4a and C-1a 
carbons of the tetrahydrocarbazole, respectively, and so indicating that reductive 
cyclisation had indeed taken place. The IR spectrum showed a prominent absorption 
band at 3357 cm-1 that is attributed to NH stretching. 
 
A variety of other conditions was examined13-15 in an attempt to reductively cyclise 
compound 198 in a more efficient manner and these are presented in Table 3.1.  
 
 
 
 
N
HMeO
(200)
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Table 3.1: Reductive cyclisation of nitro-arene 198 to tetrahydrocarbazole 199 
 
entry conditions yield (%)  
1 1 atm. H2, Pd/C, (9:1 v/v) MeOH/AcOH, r.t. 27a 
2 Fe, NH4Cl, (1:1 v/v) MeOH/H2O, reflux 30 
3 Zn, HCl, EtOH, reflux 32 
4 NaBH4, SnCl2, EtOH, 60°C 33 
5 TiCl3•THF, NH4OAc, (3:1 v/v) acetone/H2O, r.t. 37 
adebrominated material 200 also isolated  
 
Unfortunately, all proved unsatisfactory since although nitro-arene 198 could be 
reduced to the tetrahydrocarbazole 199 under all these conditions, the isolated yields of 
the target compound were invariably poor. Though this survey of reductive cyclisation 
conditions was far from exhaustive, enough work was carried out to indicate that this 
route shown in Scheme 3.1 was unlikely to provide a serviceable means of obtaining 
tetrahydrocarbazole 199. Consequently, an alternative strategy, as described in the 
following section, was investigated.  
 
3.3.2 Bischler-Mohlau Approach 
 
Having been unable to obtain reasonable yields of compound 199 by the means detailed 
above, a second and, as it transpired, a more direct approach was pursued. Of all the 
methods potentially available for effecting the synthesis of compound 199, the Bischler-
Mohlau tetrahydrocarbazole synthesis had the greatest appeal because of its apparent 
simplicity. Accordingly, 5-bromo-2-methoxyaniline (85) was treated with 2-
chlorocyclohexanone (117)16 in the presence of Na2CO3 and so generating the 2-
arylaminoketone 201 in 65% yield (Scheme 3.2).17  
 
Scheme 3.2: Synthesis of 2-arylaminoketone 201 
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The spectral data obtained on this material were completely consistent with the assigned 
structure. For example, the IR spectrum of product 201 revealed a sharp absorption 
band at 1714 cm-1 and this corresponds to the carbonyl stretching frequency of the 
cyclic ketone. The full set of signals was observed in the 13C NMR spectrum including 
one at δ 208.0 that is due to the ketone carbonyl functionality. So, with the 2-
arylaminoketone 201 quite clearly in hand this was then subjected to a range of acidic 
conditions in an effort to achieve ring-closure to the target indole (Table 3.2).18  
 
Table 3.2: Acid-catalysed ring closure conditions 
 
entry catalyst solvent temperature 
(°C) 
reaction time 
(h) 
yield 
(%) 
1 ZnCl2 EtOH 78 12 0a 
2 ZnCl2 AcOH 118 1 17a 
3 ZnCl2 2-methoxyethanol 125 12 21a 
4 ZnCl2 2-ethoxyethanol 140 1 28a 
5 H2SO4 2-ethoxyethanol 140 4 36b 
6 MgCl2/C6H5NH2 AcOH 118 4 48 
7 MgCl2 2-ethoxyethanol 140 1 57 
adebrominated material 200 also isolated. bdecomposition products also observed. 
 
Ultimately, MgCl2 proved to be the most effective reagent for this purpose and the 
required indole 199 was thus obtained in 57% yield. This material proved identical with 
that obtained by the longer route described in the preceding section. 
 
Having prepared tetrahydrocarbazole 199 in increased yield, it was now possible to 
investigate its conversion into the arylstannane 202 that would be expected to undergo 
transmetallation to afford the desired aryllead triacetate 189.  
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The conditions examined in attempts to achieve the required transmetallation reaction 
are summarised in Table 3.3.19, 20  
 
Table 3.3: Attempted synthesis of arylstannane 202 
 
entry conditions product 
1 KH, ether, t-BuLi, (Bu)3SnCl, 
 -78°C → r.t. 
No reaction 
 
2 
 
KH, THF, t-BuLi, (Bu)3SnCl, 
-78°C → r.t. 
 (200) 
3 KH, (1:1 v/v) THF/HMPA, t-BuLi, (Bu)3SnCl, 
-78°C → r.t. 
(200) 
4 KH, (1:1 v/v) THF/HMPA, t-BuLi, (Bu)3SnCl, 
-78°C → reflux 
(200) 
5 Pd(PPh3)4, toluene, Bu3SnSnBu3, 
 reflux 
No reaction 
 
Unfortunately, all such attempts failed. This was a surprising situation, considering the 
successful implementation of closely related chemistry as outlined in Chapter Two. The 
recovery of the debrominated material, 200, from many of the reaction mixtures 
suggested that the initial lithium-for-bromine exchange had occurred but that the 
subsequent transmetallation step was failing. As a consequence of these difficulties, it 
was decided to use o-methoxyphenyllead triacetate (96) in place of the more complex 
but thus far inaccessible congener 189 and so as to generate a new target indole (3S)-
203. This last compound now incorporates the o-methoxyphenyl unit as a surrogate for 
the “lower” hemisphere of (+)-vinblastine (1) while retaining the 
carbomethoxyvelbamine subunit associated with the originally targeted analogue 44. 
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The β-ketoester 190 required for implementing the plan defined in Figure 3.1 and to be 
used in an α-alkylation reaction with compound 191 now needed to be prepared. Details 
of how this was achieved are provided in the following section.  
 
 
3.4 Attempted Development of Carbomethoxyvelbamine Framework 
of (+)-Vinblastine 
 
3.4.1 Synthesis of β-Ketoester 190 
 
The chemistry of Zibuck,8 as outlined in Scheme 3.3, was employed in order to generate 
the desired β-ketoester 190 and containing an olefinic residue as required  for 
participation in the key ring-closing metathesis reaction as defined in the original 
synthetic plan (Figure 3.1). Thus, (E)-crotylaldehyde (192) was subject to a base-
promoted aldol condensation reaction with methyl acetate (193) and thus affording 
methyl (E)-3-hydroxy-5-methyl-4-pentanoate (204). This β-hydroxyester was then 
subjected to a Jones’ oxidation and in this way the requisite β-ketoester (E)-methyl 3-
oxohex-4-enoate (190) was obtained in 65% overall yield.  
 
Scheme 3.3: Synthesis of methyl (E)-3-oxohex-4-enoate (190) 
 
Both compounds 1906 and 20421 have been reported previously but only the latter 
material had been fully characterised. The spectral data obtained on compound 204 
were in full accord with those reported in the literature.21 The 1H NMR spectrum of β-
ketoester 190 showed, inter alia, a singlet at δ 3.53 that corresponds to the two 
equivalent α-protons while, the 13C NMR spectrum contained the full set of signals 
including a resonance at δ 191.8 due to the newly formed ketone carbonyl unit. 
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Furthermore, the IR spectrum showed an absorption band at 1673 cm-1 that is indicative 
of the presence of an α,β-unsaturated enone carbonyl moiety. 
 
With the necessary β-ketoester 190 now clearly in hand, the next step in the 
development of the newly targetted vinblastine analogue (3S)-203 was the α-alkylation 
of 190 with (R)-(+)-N-allyl-3-piperidinylmethyl bromide (191) so as to install the intact 
piperidine ring. Utilising a protocol used by Magnus7 in his synthesis of 
desethyldihydronavelbine, commercially available (R)-(-)-ethyl nipecotate (205) was 
reduced to the corresponding alcohol and an allyl moiety then attached to the piperidine 
nitrogen so as to afford the N-allyl alcohol 206. Alcohol 206 was then converted into 
the desired alkyl bromide 191 (Scheme 3.4) by standard methods. The spectroscopic 
data obtained on compounds 206 and 191 were in full accord with those recorded in the 
literature.7  
 
Scheme 3.4: Synthesis of alkyl halide 1917  
 
In order to affect the α-alkylation of β-ketoester 190 with halide 191 various reaction 
conditions were examined (Table 3.4). Standard conditions employing hydride bases at 
low temperatures resulted in starting material being recovered, while only 
decomposition of β-ketoester 190 was observed at higher temperatures. Amide bases 
were then used and even with HMPA as a co-solvent, no characterisable reaction 
products were generated (entry 9). Once again, only decomposition of the starting β-
ketoester was observed under such conditions. Finally, the use of carbonates as bases 
was explored. Thus, a DMF solution of the starting materials was heated in the presence 
of potassium carbonate for 36 hours. Unfortunately, this also only led to the 
decomposition of the starting β-ketoester (entry 12). 
 
 
 
 
 
HN
EtO2C
N
HO
N
Br
1. LiAlH4, THF, 0oC
2. Allylbromide, Et3N,
     EtOH, reflux
77%
CBr4, PPh3, 
CH2Cl2, reflux
83%
(205) (206) (191)
  
 
78 
Table 3.4: Attempted α-alkylation of β-ketoester 190 with alkyl bromide 191  
 
entry base solvent temperature (°C) producta 
1 NaH THF 0 → 18 No reaction 
2 NaH THF 0 → 70 Decomposition 
3 NaH DMF 0 → 18 No reaction 
4 NaH DMF 0 → 160 Decomposition 
5 KH THF 0 → 70 Decomposition 
6 LDA THF 0 → 70 Decomposition 
7 LDA ether 0 → 40   No reaction 
8 LiHMDS THF 0 → 70 Decomposition 
9 LiHMDS (1:1 v/v) THF/HMPA 0 → 70 Decomposition 
10 NaHMDS THF 0 → 70 Decomposition 
11 KHMDS THF 0 → 70 Decomposition 
12 K2CO3 DMF 160 Decomposition 
13 Cs2CO3 DCM 50 No reaction 
aAll reaction outcomes are judged by analysis of the 1H NMR spectrum of the crude reaction mixture. 
 
Due to the failure of these α-alkylation methods to affect the desired transformation, 
attention was now directed towards using a more reactive alkylating agent, in particular 
the corresponding alkyl iodide. 
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Synthesis of Alkyl Iodide 208 
 
Due to the unexpected difficulties associated with trying to effect the pivotal α-
alkylation reaction as described in the preceding section, the studies in the area were 
continued by utilising the more readily available racemic alcohol 207 that would be 
replaced with the enantiopure material if and when effective methodology had been 
developed. Accordingly, alcohol 207 was treated with allyl bromide and triethylamine 
to afford the N-allyl derivative. This crude product was then treated with 
triphenylphosphine, imidazole and molecular iodine. In this manner the required alkyl 
iodide 208 was formed in 51% yield over two steps as illustrated in Scheme 3.5.22  
 
Scheme 3.5: Synthesis of alkyl iodide 208 
 
The 1H NMR spectrum of the product 208 lacked the broad singlet associated with the 
alcohol functionality of the starting material 207. The 70 eV electron impact mass 
spectrum of alkyl iodide 208 displayed the expected molecular ion at m/z 265, while the 
base peak in this spectrum appeared at m/z 139 and corresponds to the loss of an iodine 
radical from the parent ion. With alkyl iodide 208 now readily available by such means, 
the key α-alkylation reaction was re-examined and with various alkylation conditions 
being investigated (Table 3.5). 
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Table 3.5: Attempted α-alkylation of β-ketoester 190 with alkyl iodide 208 
 
entry base solvent temperature (°C) producta 
1 NaH THF 0 → 18 No reaction 
2 NaH THF 0 → 70 Decomposition 
3 NaH DMF 0 → 160 Decomposition 
4 KH THF 0 → 70 Decomposition 
5 t-BuOK t-BuOH 90 No reaction 
6 LDA THF  0 → 70 Decomposition 
7 LiHMDS THF 0 → 70 Decomposition 
8 LiHMDS (1:1 v/v) THF/HMPA 0 → 70 Decomposition 
9 NaHMDS THF 0 → 70 Decomposition 
10 KHMDS THF 0 → 70 Decomposition 
11 K2CO3 DMF 160 Decomposition 
12 Cs2CO3 DCM 50 No reaction 
13 n-BuLi ether 0 → 40 No reaction 
aAll reaction outcomes are as judged by analysis of 1H NMR spectrum of the crude reaction mixture. 
 
As can be seen, a wide range of bases and solvents was employed but in all cases no 
product was observed even after prolonged reaction periods. Again, it was thought that 
the alkyl halide and/or the enolate derived from substrate 190 was/were too unreactive.  
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Preparation of a New Alkylation Partner 
 
In a final effort to overcome the now significant difficulties that had been encountered 
in trying to alkylate the anion derived from the 1,3-dicarbonyl compound 190 with a 
piperidine-containing halomethyl electrophile, the N-Boc-protected compound 210 was 
sought (Scheme 3.6). To these ends, compound 207 was converted, in 79% yield over 
two steps, into the known, yet previously uncharacterised target halide 210.22 The 1H 
NMR spectrum of this product showed a resonance at δ 1.46 that is due to the tert-butyl 
protons of the tert-butoxycarbonyl group, while the 13C NMR spectrum displayed a 
signal at δ 154.7 that is attributed to the carbonyl unit of this same moiety. An accurate 
mass measurement on the molecular ion appearing at m/z 325 in the 70 eV electron 
impact mass spectrum showed that this compound was of the expected molecular 
composition. The base peak, at m/z 57, is assigned to the tert-butyl cation arising from 
cleavage of the Boc-group. 
 
 
Scheme 3.6: Synthesis of N-Boc-protected alkylation partner 210 
 
The α-alkylation was then undertaken with the new alkyl iodide 210 using the same 
conditions employed previously (Table 3.6). Once again, however, none of the desired 
alkylation product 211 formed. In partial contrast, at low reaction temperatures 
compound 212 was isolated. The acquisition of this compound reveals that an 
unexpected de-conjugation of the double bond in the sidechain had occurred during the 
course of the reaction.  
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Table 3.6: Attempted α-alkylation of β-ketoester 190 using alkyl iodide 210 
 
entry base solvent temperature (°C) product (yield) 
1 NaH DMF 0 → 18 212 (35%) 
2 NaH DMF 0 → 160 Decomposition 
3 NaH THF 0 → 70 No reaction 
4 NaH THF 0 → 70 Decomposition 
5 KH THF 0 → 18 212 (28%) 
6 LDA THF  0 → 70 Decomposition 
7 LDA THF 0 → 18 212 (80%) 
 
 
The 1H and 13C NMR spectra of compound 212 are shown in Figures 3.2 and 3.3, 
respectively. The former spectrum features multiplets at δ 5.60 and 5.27 that integrate 
for one and two protons, respectively, and these are attributed to the protons associated 
with the terminal olefin. Furthermore, the doublet of doublets observed at δ 3.52 (J = 
4.5 and 2.1 Hz) is assigned to the diastereotopic protons of the methylene group 
adjacent to the double bond. Another conspicuous feature was the lack of a signal 
associated with the methyl protons of the methyl unit of the starting material. The 13C 
NMR spectrum showed resonances due to the terminal olefinic carbons at δ 135.1 and 
119.8, while the signal at δ 55.0 is attributed to the methine α-carbon and thus 
indicating that α-alkylation had occurred.  
 
Clearly, the acquisition of this deconjugated product (viz. β,γ-unsaturated enone 212) 
precludes the foreshadowed use (Figure 3.1) of a RCM reaction to assemble the target 
carbomethoxyvelabamine core of analogues of (+)-vinblastine. Accordingly, new means 
for achieving such ends were sought. Details are provided in the following section. 
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Figure 3.2: 300 MHz 1H NMR spectrum of compound 212 recorded in CDCl3 at 18°C  
 
Figure 3.3: 75 MHz 12C NMR spectrum of compound 212 recorded in CDCl3 at 18°C 
(doubling of signals attributed to the presence of carbamate rotomers) 
 
 
ppm2.02.53.03.54.04.55.05.56.06.57.0
ppm5.255.305.355.405.455.505.555.605.655.70
BocN
O
CO2Me
(212)
ppm406080100120140160180200
BocN
O
CO2Me
(212)
  
 
84 
3.5 A Revised Synthetic Strategy 
 
In the light of the results revealed in the preceding section, a modified reaction scheme 
that did not require a RCM reaction was considered in a final attempt to obtain the 
target vinblastine analogue, (3R/S)-203. In this new synthetic strategy, the RCM 
reaction associated with the original approach (Figure 3.1) was to be replaced by an 
intramolecular N-alkylation reaction and so leading to the formation of this 
carbomethoxyvelbamine substructure associated with the targetted (+)-vinblastine 
analogues (Figure 3.4).   
 
 
Figure 3.4: Revised synthetic strategy for accessing the (+)-vinblastine analogue 
(3R/S)-203 
 
This approach is related to the final stage of Fukuyama’s stereocontrolled total synthesis 
of (+)-vinblastine (1) (Section 1.3.3) wherein the piperidine ring was formed through an 
intramolecular alkylation of nitrogen by the pendant tosyloxymethyl group in 
compound 220 and thus affording the natural product 1 (Scheme 3.7).  
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Scheme 3.7: The final stage of Fukuyama’s synthesis of (+)-vinblastine (1) 
incorporating an intramolecular N-alkylation 
 
The key intermediate, 214, required in the revised approach was to be generated through 
an intramolecular N-alkylation reaction then a Saegusa-type oxidation to install the 
double bond required for the Banwell-type indole annulation process.23 In order to 
attain this initial macrocyclic target, the alkyl halide 215 would be prepared using 
Appel-type chemistry described earlier (Section 3.4.3). Thus, the alkyl bromide 215 
would be obtained from the β-ketoester 216 containing a protected alcohol 
functionality, that should, in turn, be accessible through the α-alkylation of β-ketoester 
217. The synthesis of this last compound and its subsequent manipulations are 
described in the following section. 
 
 
3.5.1 Synthesis of β-Ketoester 217 
 
The first step in the development of a synthesis of the new vinblastine analogue (3R/S)-
203 was the preparation of known β-ketoester 21724 by the α′-alkylation of methyl 
acetoacetate (219) with (3-bromopropoxy)-tert-butyldimethylsilane (218) following the 
protocol of Moody (Scheme 3.8). The derived spectral data matched those reported.24 
 
Scheme 3.8: Synthesis of β-ketoester 217  
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With compound 217 in hand, the next step was the α-alkylation of this β-ketoester with 
the N-Boc-protected alkyl iodide 210. As with the α-alkylations already attempted, this 
reaction of β-ketoester 217 also proved problematic despite a range of bases and 
solvents being examined (Table 3.7). 
 
Table 3.7: α-Alkylation of β-ketoester 217 with alkyl iodide 210 
 
entry base solvent temperature (°C) yield (%) 
1 NaH DMF 0 → 18 4 
2 NaH DMF 0 → 90 12 
3 LDA THF 0 → 18 8 
4 LDA THF 0 → 70 16 
5 LDA (9:1 v/v) THF/HMPA 0 → 70 19 
6 LiHMDS THF 0 → 70 14 
7 KHMDS THF 0 → 70 35 
8 K2CO3 DMF 18 25 
9 K2CO3 DMF 90 75 
 
Clearly, the standard alkylation conditions employed earlier led to poor yields of 
product. In contrast, when potassium carbonate was used as a base, the target compound 
216 was obtained in 75% yield. The 300 MHz 1H NMR spectrum of this new material 
lacked the singlet that is attributed to the two equivalent acidic α-protons of the starting 
material. Furthermore, the presence of a resonance at δ 2.52 that corresponds to the α′-
methylene unit suggested α′-alkylation had not occurred. Finally, the singlets observed 
at δ 1.44, 0.87 and 0.03 indicated the compound contains a tert-butoxycarbonyl and a 
tert-butyldimethylsilyl protecting group. The DEPT 13C NMR spectrum showed the 
associated methyl carbon resonances at δ 28.4, 25.9 and –5.4, while a signal at δ 56.2 is 
attributed to the methine α-carbon and thus indicating α-alkylation had taken place. The 
70 eV mass spectrum displayed the expected molecular ion at m/z 485 and the base 
peak observed at m/z 57 corresponds to the tert-butyl cation. An accurate mass 
measurement on the molecular ion established that it was of the required composition, 
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namely C25H47NO6Si. With the key intermediate 216 now available, the Pinhey 
arylation reaction of this material was investigated and the outcomes of the relevant 
studies are presented in the following section. 
 
3.5.2 Pinhey Arylation 
 
As foreshadowed in the retrosynthetic analysis shown in Figure 3.4, the next step in the 
synthetic plan was to effect the Pinhey arylation of the β-ketoester 216 and so as to 
install a surrogate for the “lower” hemisphere of (+)-vinblastine (1) and thereby furnish 
the α-arylated product 221. However, when this material was treated with the 
plumbated aryl 96 under standard conditions5 only the starting nucleophile 216 was 
isolated from the reaction mixture.  
 
In contrast, when the β-ketoester 217 was α-arylated with o-methoxyphenyllead 
triacetate (96), then the α-arylated product 222 was formed, as a mixture of keto-enol 
tautomers, in 78% yield (Scheme 3.9). 
  
Scheme 3.9: α-Arylation of β-ketoester 217 with o-methoxyphenyllead triacetate (96) to 
synthesise α-arylated β-ketoester 222 
 
The 1H NMR spectrum of compound 222 displayed resonances at δ 2.48 and 2.05 that 
are assigned to the α′-methylene groups of its keto- and enol-forms, respectively. The 
keto-form predominates. The 13C NMR spectrum showed a signal at δ 204.4 that is 
indicative of the ketone carbonyl of the keto-form, with the signal of the matching 
carbon of the enol form being seen at δ 176.8. The 70 eV electron impact mass 
spectrum displayed the expected molecular ion at m/z 394 with the base peak appearing 
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at m/z 337. This presumably arises through the loss of a tert-butyl radical from the 
parent ion.  
 
The α-alkylation of compound 222 with alkyl halide 210 was then attempted but, as 
was the case with all the other α-alkylations tried, this also proved a disappointment 
(Table 3.8). 
 
Table 3.8: Attempted α-alkylation of β-ketoester 222 with alkyl iodide 210 
 
entry base solvent temperature (°C) producta 
1 K2CO3 DMF 90 Decomposition 
2 K2CO3 DMF 18 No reaction 
3 K2CO3 (9:1 v/v) DMF/DMPU 90 Decomposition 
4 K2CO3 DCM 50 No reaction 
5 Cs2CO3 DCM 50 No reaction 
6 LDA THF 70 Decomposition 
7 LDA THF 0 → 18 No reaction 
8 LDA (1:1 v/v) THF/HMPA 0 → 18 No reaction 
9 LiHMDS (1:1 v/v) THF/HMPA 0 → 18 No reaction 
10 KHMDS (1:1 v/v) THF/HMPA 0 → 18 No reaction 
11 NaHMDS (1:1 v/v) THF/HMPA 0 → 18 No reaction 
12 NaH THF 0 → 70 No reaction 
13 KH THF 0 → 70 No reaction 
14 NaH DMF 0 → 18 No reaction 
15 NaH DMF 0 → 90 Decomposition 
aAll reaction outcomes are as judged by analysis of the 1H NMR spectrum of the crude reaction mixture. 
 
Due to the failure of these α-alkylation reactions, work in this area was abandoned. 
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3.6 Summary 
 
This chapter details two approaches to the (+)-vinblastine analogues 44, (3S)-203 and 
(3R/S)-203 each of which incorporates the carbomethoxyvelbamine framework of the 
natural product 1. In the first approach, a ring-closing metathesis was envisaged as the 
key step to be used in forming the macrocycles 44 and (3S)-203. Unfortunately, the 
requisite α-alkylated β-ketoester 211 could not be prepared. In a second approach the 
projected ring-closing metathesis step was replaced with one involving N-alkylation of 
the piperidine ring to generate the macrocycle (3R/S)-203. Again, problems were 
encountered in this strategy, with the α-alkylation of β-ketoester 217 proving 
problematic. In a final attempt to construct the requisite quaternary centre, a reaction 
sequence involving successive α-arylation then α-alkylation of β-ketoester 217 was 
attempted. Disappointingly, this also failed.  
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Chapter Four 
The Development of a Chiral 
Auxiliary-based Diasteroselective 
Pinhey Arylation of Cyclic β-
Ketoesters 
 
4.1 Introduction 
 
4.1.1 Overview and Context 
Chapter Two described the use of the Pinhey arylation reaction for the preparation of 
indole-indoline analogues of (+)-vinblastine (1). Such chemistry was then exploited, as 
described in Chapter Three, in an attempt to prepare analogues of (+)-vinblastine 
incorporating the carbomethoxyvelbamine hemisphere of this alkaloid.  
 
As discussed in Section 1.3, one of the major difficulties associated with the synthesis 
of the dimeric Vinca alkaloids is the need to control the absolute stereochemistry at C-
16′, which must be of the S-configuration.1 Analogues of compound 1 incorporating the 
R-configuration at this centre lacked the therapeutically valuable cytotoxicity observed 
in the natural product.2, 3 This chapter details the development of chemistry that should 
allow for the installation of the correct absolute configuration at the equivalent to this 
centre in the abovementioned indole-indoline analogues.  
 
4.1.2 Background   
The stereoselective introduction of electrophiles at the carbon α-related to an enolisable 
carbonyl group is a central topic in asymmetric synthesis. Although highly 
stereoselective α-alkylation reactions of ketones are now well known,4-7 the analogous 
arylation processes remain underdeveloped. Following the studies described in Section 
2.2.1, the Pinhey arylation reaction was seen as representing the best approach for 
achieving such ends and efforts to do so are discussed in the following section.  
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Diastereoselective Pinhey α-Arylations 
 
One aspect of the Pinhey arylation reaction that has not been well studied is the control 
of the stereochemistry at a quaternary centre assembled by such means. Pinhey himself 
has described two examples of diastereoselective arylation reactions8, 9 and Moloney10, 
11
 has reported the same outcomes while preparing a series of glutamate analogues. 
Recently, Konopolski12, 13 has investigated the diastereoselectivity of the reaction of 5-
substituted methyl 2-oxo-cyclohexanecarboxylates 223 with p-methoxyphenyllead 
triacetate (224) as shown in Table 4.1. 
 
Table 4.1: Diastereoselectivity of the α-arylation of 5-substituted β-ketoesters 223 with 
p-methoxylead triacetate (224) 
 
entry R yield (%) d.r. 
1 OMe 96 4:1 
2 t-Bu 96 9:1 
3 OTBDMS 97 20:1 
4 OAc 64 4:1 
5 OPiv 68 6:1 
6 OTIPS 92 15:1 
7 OTBDPS 95 99:1 
8 OBn 85 6:1 
 
Clearly, the presence of more bulky R groups, especially silyl units, increased the 
stereoselectivity of this type of process. It has been postulated that the origin of this 
selectivity is an attractive electrostatic interaction and/or n, pi* orbital overlap between 
the carbanionic centre of the β-ketoester and the distal silyl group.  
 
R
O
CO2Me
O
R
CO2Me
OMe
py., CHCl3, r.t.
(223) (225)(224)
+
(AcO)3Pb
OMe
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Konopolski and Deng14 have extended this approach to assemble, in a diastereoselective 
manner, the quaternary carbon centre associated with the alkaloid N-
methylwelwitindolinone C isothiocyanate (229), a multidrug resistance reversal agent. 
As illustrated in Scheme 4.1, the indole-derived reagent 226 was treated, in chloroform 
containing three equivalents of pyridine, with the β-ketoester 227 and so forming 
product 228 in excellent yield (98%) and with very high diastereoselectivity (>30:1).  
 
Scheme 4.1: Use of aryllead triacetates in the diastereoselective formation of 
quaternary carbon centres 
 
Moloney10, 11 has studied the Pinhey arylation of constrained glutamate analogues 230 
(Scheme 4.2). In these systems, a diastereoselectivity of 4:1 for the desired product 232 
was observed when m-methoxyphenyllead triacetate (231) was employed as the 
arylation partner.  
 
Scheme 4.2: Diastereoselectivity of α-arylation of glutamate analogues 230 with m-
methoxylead triacetate (231) 
 
Interestingly, these particular conversions required higher temperatures and longer 
reaction times than normally needed for this class of arylation process.   
 
Another possible approach for establishing the desired stereochemistry would involve 
using β-ketoesters incorporating chiral alcohols since such systems might be expected 
to undergo diastereoselective Pinhey arylation reactions. Such possibilities are 
discussed in the next section. 
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4.2 The Use of Chiral Auxiliaries to Develop a Diastereoselective 
Pinhey Arylation of Cyclic β-Ketoesters 
 
In a study relevant to the present discussion, Ding and co-workers15 developed a 
rhodium-catalysed Barbier-Grignard-type arylation of chiral auxiliary-containing 
glyoxylates 234 with aryllead reagents 235. A particular focus of this study was an 
examination of the level of diastereoselectivity induced by the presence of chiral 
auxiliaries on the electrophile (Scheme 4.3). Thus, treatment of the hydrate of 
glyoxylate 234 [R* = (-)-8-phenylmenthyl] with phenyltrimethyl lead 235 (R = H) 
afforded the expected product in a d.e. of 77%. This compares with a 3% d.e. observed 
when glyoxylate 234 [R* = (-)- menthyl] was employed as the electrophile. 
 
Scheme 4.3: Diastereoselective rhodium-catalysed arylation of glyoxylates 234 with 
aryltrimethyl leads 235 
 
The high diastereoselectivity observed in the former case can be attributed to the 
phenyllead-Rh(I) complex 238 attacking that face of the aldehyde 237 that is not 
blocked by pi-stacking of this moiety with the tethered phenyl residue (Figure 4.1). 
 
 Figure 4.1: Attack from upper face of (-)-8-phenylmenthyl glyoxylate (237) by the 
phenyltrimethyllead-Rh(I) complex 238 
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O
Attack from upper face
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O
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(238)
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+ R* O
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O
H
R
R* = (-)-menthyl R = H, 75% yield, 3% d.e.
R* = (-)-8-phenylmenthyl R = H, 73% yield, 77% d.e.
                                                 R = m-Cl, 76% yield, 67% d.e.
                                                 R = Np, 77% yield, 84% d.e.
R
(Me)3Pb 77 - 73%
Rh2(COD)2Cl2, H2O,
50 - 60oC
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Bearing such results in mind, chiral auxiliaries were applied to the present work and in 
attempts to effect a diastereoselective Pinhey arylation reaction and so produce the 
required stereochemistry in the targetted analogues of the indole-indoline core of (+)-
vinblastine (1). In particular, a series of β-ketoesters, 239, containing chiral alcohol 
residues was sought and these would then be subjected to arylation with phenyllead 
triacetate (74) and to generate, hopefully with some reasonable levels of 
diastereoselection, α-arylated products of the type 240 and 241 (Scheme 4.4). The 
synthesis of the relevant chiral auxiliaries is discussed in the next section. 
 
Scheme 4.4: Proposed diastereoselective Pinhey arylation of chiral β-ketoesters 239 
with phenyllead triacetate (74) 
 
4.2.1 Preparation of Chiral Alcohols 
In order to investigate the utility of the abovementioned approach, 2-cyclohexen-1-one 
(77) would be acylated using a series of chiral cyanoformates to afford the desired 
auxiliary-containing β-ketoesters required for subjection to the Pinhey arylation 
reaction. Analogous protocols had been employed previously in the preparation of the 
racemic modifications of the cyclic β-ketoesters 75 and 79 (Section 2.2.1).  
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Based on the work of Ding,15 (-)-menthol (242), (-)-trans-2-(1-methyl-1-phenylethyl)-
cyclohexanol (243) and (+)-8-β-naphthylneomenthol (244) were sought as the sources 
of chirality. (+)-3-[N-Benzenesulfonyl-N-(3,5-dimethylphenyl)-amino]-2-bornanol 
(245) was also used. These alcohols would first be converted into the corresponding 
chloroformates and then transformed into their respective cyanoformates to permit 
acylation of 2-cyclohexen-1-one (77). The use of cyanoformates rather than the 
precursor chloroformates in such reactions follows from the observation that use of the 
latter type of electrophile often affords mixtures of O- and C-acylated products.16 
 
Alcohols 242, 243 and 245 were commercially available, while compound 244 was 
prepared using the protocol employed by Yang17 (Scheme 4.5). Thus, commercially 
available (R)-(+)-pulegone (246) was subject to a Cu(I)-promoted 1,4-addition of the 
Grignard reagent derived from 2-bromonaphthalene (247). In this manner, a mixture of 
the cis- and trans-isomers of cyclohexanone 248 was obtained. This mixture was then 
treated with base to effect epimerisation and thus affording the desired trans-compound 
248 in an exclusive manner. Cyclohexanone 248 was then reduced with lithium 
aluminium hydride to a 3:2 mixture of the corresponding alcohols 244 and 249.  
 
Scheme 4.5: Yang’s protocol for the synthesis of alcohol 244 
 
 
HO
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O
HO HOHO
(245)(244)(243)(242)
O O HO + HO
1. (247), Mg, I2, THF, -20oC
2. CuI
3. 10% KOH, EtOH, 80oC LiAlH4, THF, 0oC to r.t.
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60%
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These alcohols could be separated chromatographically and the 1H NMR spectrum of 
isomer 249 matched that reported in the literature,18 while the analogous spectrum of 
the epimer 244 featured a diagnostic resonance at δ 3.85 that corresponds to the 
oxymethine proton. In the 13C NMR spectrum of compound 244, the associated carbon 
signal was observed at δ 68.3 and so indicating that reduction of the carbonyl moiety 
had occurred. Furthermore, the IR spectrum displayed a broad hydroxyl group 
absorption band at 3435 cm-1. Finally, the 70 eV electron impact mass spectrum showed 
the expected molecular ion at m/z 282. The base peak observed at m/z 169 in this 
spectrum is attributed to a propan-2-yl-naphthalene cation arising from cleavage of the 
auxiliary.  
 
With the desired chiral alcohols in hand, the next step in the preparation of the desired 
chiral β-ketoesters was the synthesis of the corresponding chloroformates. Relevant 
details are provided in the following section. 
 
4.2.2 Preparation of Chiral Chloroformates 
The standard procedure for preparing chloroformates from the corresponding alcohols is 
through reaction with phosgene gas,19 a rather toxic reagent. Li has recently developed a 
much more convenient method for the synthesis of (-)-menthyl chloroformate involving 
replacement of phosgene gas by the synthetically equivalent triphosgene.20 
Accordingly, this protocol was applied to the present study and with pleasing results as 
shown in Table 4.2.  
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Table 4.2: Preparation of chiral chloroformates 250 – 253 
 
entry starting material  producta yield (%) 
 
1 
 (242)    (250) 
 
82 
 
2 
 (243) 
 (251) 
 
70 
 
 
3 
 (244)  (252) 
 
 
83b 
 
4 
 (245) 
 (253) 
 
73 
aMethod: triphosgene (0.4 eq.), py. (3.0 eq.), CH2Cl2, -20°C → r.t., 12 h. b(+)-2-(2-((R)-4-methylcyclohex-1-
enyl)propan-2-yl)naphthalene (254) also produced as a side product in 13% yield. 
 
While reference samples of chloroformate 250 were available through commercial 
suppliers, congeners 251 – 253, have never been prepared previously and were, 
therefore, fully characterised. The IR spectrum of each of these compounds showed an 
absorption band in the region 1760 cm-1 and this corresponds to the stretching mode of 
the chloroformate carbonyl moiety. Furthermore, the 1H NMR spectrum featured a 
signal in the region of δ 4.90 that corresponds to the methine proton attached to that 
ring-carbon bearing the chloroformate group. In the 13C NMR spectrum the appearance 
of a signal at approximately δ 150.0 and corresponding to the oxygenated ring-carbon 
was taken as being indicative of the presence of a chloroformate carbonyl unit.  
HO
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O
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The 1H and 13C NMR spectra of chloroformate 252 are illustrated in Figures 4.2 and 
4.3, respectively. 
Figure 4.2: 300 MHz 1H NMR spectrum of chloroformate 252 recorded in CDCl3 at 
18°C  
 
 
Figure 4.3: 75 MHz 13C NMR spectrum of chloroformate 252 recorded in CDCl3 at 
18°C 
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With these chiral chloroformates in hand, generation of the corresponding and targetted 
cyanoformates was then attempted. The protocols employed for this purpose are 
discussed in the following section. 
 
4.2.3 Preparation of Chiral Cyanoformates 
Following a procedure described by Kunish,21 the optically active chloroformates 250 – 
253 were transformed into their respective cyanoformates using conditions originally 
developed by Childs.22 Thus, these substrates were treated with potassium cyanide in 
the presence of 18-crown-6 ether which acts as a phase transfer catalyst. In this way, the 
target cyanoformates 255 – 258 were each obtained in excellent yield (Table 4.3).  
 
Compound 255 has been prepared previously, although not fully characterised,23 while 
congeners 256 – 258 have not been described before in the chemical literature. 
Accordingly, they were subject to full spectroscopic characterisation. The IR spectrum 
of each of these cyanoformates displayed a sharp absorption band in the region of 1740 
cm-1 that corresponds to the stretching mode of the carbonyl unit and this feature was 
used to monitor the progress of the formation of the target compound from the chloro-
precursor, which displays a carbonyl absorption band at around 1760 cm-1. 
Additionally, an absorption band in the region of 2240 cm-1 that is assigned to nitrile 
stretching was always observed for products 255 – 258. Moreover, the 13C NMR 
spectrum displayed a signal at ca. δ 110.0 and this is indicative of the presence of the 
nitrile moiety.  
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Table 4.3: Preparation of chiral cyanoformates 255 – 258 
 
entry starting material producta yield (%) 
 
1 
 (250)  (255) 
 
99 
 
2 
 (251)  (256) 
 
90 
 
 
3 
 (252) 
 (257) 
 
 
89 
 
 
4 
 (253)  (258) 
 
83 
aMethod: KCN (1.1 eq.), 18-crown-6 (0.4 eq.), CH2Cl2, r.t., 1 h. 
 
The 1H and 13C NMR spectra of cyanoformate 257 are shown in Figures 4.4 and 4.5, 
respectively and are representative of the class as a whole. 
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Figure 4.4: 300 MHz 1H NMR spectrum of cyanoformate 257 recorded in CDCl3 at 
18°C  
 
 
Figure 4.5: 75 MHz 13C NMR spectrum of cyanoformate 257 recorded in CDCl3 at 
18°C 
 
With the chiral cyanoformates now available, the synthesis of the derived β-ketoesters 
could be investigated. The outcomes of the relevant studies are outlined in the following 
section. 
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4.2.4 Preparation of Chiral β-Ketoesters 
Following a protocol previously employed in the synthesis of cyclic β-ketoesters 
(Section 2.1.2), 2-cyclohexen-1-one (77) was acylated using the optically active 
cyanoformates 255 – 258 and so as to form the expected set of chiral β-ketoesters 259 - 
262 and in preparatively useful yields (Table 4.4). 
 
Table 4.4: Preparation of chiral β-ketoesters 259 – 262 
 
entry starting material  producta yield (%)b 
 
1 
  (255)  (259) 
 
78 
 
2 
 (256)  (260) 
 
74 
 
 
3 
   (257)  (261) 
 
 
74 
 
4 
  (258)  (262) 
 
62 
aMethod: (i) n-BuLi (1.1 eq.), i-Pr2NH (1.1 eq.), THF, -20°C, 0.5 h; (ii) 2-cyclohexen-1-one (77) (1.1 eq.), -78°C → 
0°C, 1 h; (iii) HMPA (1.1 eq.), starting material (1.0 eq.), -78°C, 0.25 h; bproduct isolated as a mixture of 
diastereoisomers.  
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The β-ketoesters 259 – 262 were previously unreported and, therefore, subject to full 
characterisation. Each compound existed as a mixture of diastereoisomers with a 
resulting doubling of signals being observed in the relevant NMR spectra as would be 
expected for such a combination. Thus, the 1H NMR spectrum of each compound 
displayed multiplets in the region of δ 3.20 and 3.00 arising from the diastereotopic and 
acidic α-protons. The 13C NMR spectrum featured pairs of signals at approximately δ 
190.0 and 170.0 arising from the carbonyl groups of the α,β-unsaturated enone and 
ester functionalities, respectively. Furthermore, a pair of signals appearing at ca. δ 56.0 
was taken as being indicative of the methine α-carbon and so suggesting C-acylation 
had occurred. The IR spectrum displayed strong absorption bands in the region of 1735 
and 1680 cm-1 that correspond to the carbonyl stretching frequencies of the ester and 
α,β-unsaturated enone units, respectively.  
 
With the desired chiral β-ketoesters now quite clearly to hand, the diastereoselective 
Pinhey arylation reaction could be studied. Outcomes are detailed in the next section. 
 
4.2.5 Diastereoselective Pinhey α-Arylations 
Using standard Pinhey arylation reaction conditions,8 chiral β-ketoesters 259 – 262 
were treated with phenyllead triacetate (74) and the desired α-arylated β-ketoesters 263 
– 266 thus generated in reasonable yields. In the case of the 8-arylmenthyl-containing 
β-ketoesters, good diastereomeric ratios were also observed (Table 4.5).  
 
Compounds 263 – 266 had never been prepared before and were, therefore, fully 
characterised. The 13C NMR spectrum of each compound featured a pair of signals at 
approximately δ 60.0 that is assigned to the new quaternary α-carbon having the 
carboalkoxy and phenyl groups attached. Doubling of signals indicated the presence of 
diastereoisomers. As an example, the 1H and 13C NMR spectra of α-arylated enone 265 
are shown in Figures 4.6 and 4.7, respectively. The ratio of the product diastereoisomers 
was determined by the integration of the signals associated with the β-proton of the α,β-
unsaturated enone functionality in the 1H NMR spectrum of each mixture of α-arylated 
enones (See inset).  
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Table 4.5: Diastereoselective Pinhey arylations of chiral β-ketoesters 263 – 266 with 
phenyllead triacetate (74) 
 
entry starting material  product of arylationa yield (%)b d.r.c 
 
1 
  (259) 
 (263) 
 
57 
 
50:50 
 
2 
 (260) 
 (264) 
 
56 
 
87:13 
 
 
3 
   (261) 
  (265) 
 
 
76 
 
       
      90:10 
 
4 
  (262) 
 (266) 
 
90 
 
66:34 
aMethod: py. (3.0 eq.), CHCl3, 0.5 h; (ii) phenyllead triacetate (74) (1.1 eq.), 40°C, 12 h; bproduct isolated as a 
mixture of diastereoisomers; cAs determined by integration of the signals for the respective β-olefinic protons in the 
1H NMR spectrum. 
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Figure 4.6: 300 MHz 1H NMR spectrum of α-arylated enone 265 recorded in CDCl3 at 
18°C (doubling of signals due to presence of diastereoisomers) 
 
Figure 4.7: 75 MHz 13C NMR spectrum of α-arylated enone 265 recorded in CDCl3 at 
18°C (doubling of signals due to presence of diastereoisomers) 
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Attempts to separate the diastereoisomers using chromatographic methods failed, with 
the result that the absolute stereochemistry of the major diasteromeric form of these 
arylation products remains undetermined in any rigorous sense. 
 
In terms of the diasteromeric ratio, increasing the steric bulk on the chiral auxiliary led 
to an increase in the propensity of one diastereoisomer to be formed over the other. It is 
proposed that the increased size of the chiral auxiliary allows attack by the phenyl 
carbocation to occur, to an increasing extent, from one face of the enolate 267, so 
leading to one diastereoisomer being formed preferentially. In the case of the 8-β-
naphthyl-containing chiral auxiliary a pi-stacking interaction may facilitate the 
diastereoselectivity by shielding the lower face of enolate 267 (Figure 4.8). 
 
Figure 4.8: Proposed conformation of enolate 267 with a pi-stacking interaction 
shielding the lower face 
 
It is therefore proposed that for the 8-β-naphthylneomenthyl-containing system, the 
major product is compound 268, wherein the phenyl carbocation derived from aryllead 
74 attacked the face of the enolate 267 opposite to that shielded by the naphthyl ring.  
O
O
O
(268)
(267)
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The stereochemistry at the quaternary α-carbon of compound 268 is opposite that of the 
desired absolute stereochemistry required in (+)-vinblastine (1) at C-16′. However, use 
of the chiral β-ketoester derived from, for example, chiral alcohol 249 should allow for 
installation of the correct absolute chemistry at this stereocentre through shielding the 
upper face of the enolate and so forcing attack of the phenyl carbocation from that face 
necessary to establish the correct stereochemistry. 
 Effect of Coordinating Base  
 
A ligand-coupling mechanism has been proposed to explain the outcomes of the Pinhey 
arylation reaction.24 For β-ketoesters of the general form 269 either an oxygen-lead 
intermediate 270 or a carbon-lead intermediate 271 is possible. In the second step, 
ligand coupling with accompanying reductive elimination of the elements of Pb(OAc)2 
occurs and so affording the product 272 as illustrated Scheme 4.6. 
 
Scheme 4.6: Alternative intermediates in the α-arylation of β-ketoesters 269 with 
phenyllead triacetate (74) 
 
A general feature of the arylation reaction with aryllead triacetates is the need for the 
presence of a coordinating base or solvent like DMSO. Therefore, in the case of a 
coordinating base, the intermediate involved in the arylation must have two nitrogen 
ligands attached to lead. It is envisaged that in the case of diastereoselective arylations, 
replacing pyridine (273) with a more sterically demanding base such as 1,10-
phenanthroline (274) or 2,2′-bipyridine (275) might increase the steric crowding in the 
intermediate formed during the α-arylation of the β-ketoester 261 and thus lead to an 
increase in the diastereoselectivity observed. 
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However, as can clearly be seen from the results presented in Table 4.6, increasing the 
steric bulk of the coordinating base had little or no effect on the diastereoselectivity of 
the reaction and thus suggesting it is the choice of chiral auxiliary that determines the 
diastereoselectivity. 
 
Table 4.6: Effect of base on diastereoselectivity of Pinhey arylation between chiral β-
ketoester 261 and phenyllead triacetate (74) 
 
entry basea d.r.b 
 
1 
(273) 
 
90:10 
 
2 
(274) 
 
89:11 
 
3 
(275) 
 
87:13 
aMethod same as Table 4.5 except with replacement of pyridine with 3 equivalents of the appropriate base. cAs 
determined by integration of the signals for the respective β-olefinic protons in the 1H NMR spectrum. 
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4.3 Summary 
 
This chapter has detailed a method for controlling stereochemistry in a model system 
designed to mimic the indole-indoline core of (+)-vinblastine (1). A chiral auxiliary 
based on (+)-8-β-naphthylneomenthol proved most effective, affording a 9:1 ratio of the 
diastereomeric arylation products. Although the absolute stereochemistry of the major 
diastereoisomer was unable to be determined, it is postulated that this is as shown in 
compound 268 and where attack of the phenyl carbocation on the precursor enolate 267 
had occurred opposite to the face shielded by the bulky naphthyl ring. Compound 268 
had the opposite stereochemistry of that desired for the indole-indoline analogues of 
(+)-vinblastine. However, with the ability to control the stereochemistry at this centre 
now possible, the implementation of the chiral β-ketoester derived from chiral alcohol 
249 should allow for installation of the correct absolute chemistry at this stereocentre. 
 
4.4 Conclusions 
 
A series of small molecules resembling the indole-indoline core of (+)-vinblastine (1) 
was prepared by a process that involved a range of different pairings of aryl groups as 
surrogates for these heterocyclic units. A methodology was implemented and 
concerned, as its key steps, the Pinhey-type arylation of the appropriate cyclic β-
ketoester with the suitable aryllead triacetates and then a Pd[0]-catalysed Ullmann 
cross-coupling reaction to form the corresponding α′-arylated enones. A reductive 
cyclisation reaction then led to the synthesis of the desired analogues of the indole-
indoline core or “bridging region” of (+)-vinblastine (1). Studies on the installation of 
the correct stereochemistry at the equivalent of C-16′ of (+)-vinblastine (1) in these 
analogues led to the development of a diastereoselective Pinhey arylation reaction. 
Some success was achieved in the case of the 8-arylmenthol-based chiral auxiliaries. It 
is envisaged that the enantiomerically enriched analogues so formed will be tested to 
ascertain their value as anti-mitotic agents. The result reported herein also allow the 
possibility of developing more complex analogues of the Vinca alkaloid 1 and have 
greatly enhanced the prospects of developing a total synthesis of (+)-vinblastine (1). 
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Chapter Five 
Experimental Procedures Associated 
with Work Described in Chapters 
Two to Four 
 
5.1 General Procedures 
 
Unless otherwise indicated, proton (1H) and carbon (13C) NMR spectra were recorded at 
18°C in base-filtered CDCl3 on a Varian Mercury 300 spectrometer operating at 300 
MHz for proton and 75 MHz for carbon nuclei. Signals arising from residual protio-
forms of the solvent were used as the internal standard. 1H NMR data are recorded as 
follows: chemical shift (δ) [multiplicity, coupling constant(s), J Hz, relative integral] 
where multiplicity is defined as: s=singlet; d=doublet; t=triplet; q=quartet; p=pentet; 
sex=sextet; sept=septet; m=multiplet or combinations of the above. The central peak (δ 
77.0) of the CDCl3 ‘triplet’ was used as the reference in proton-decoupled 13C NMR 
spectra. For 13C NMR spectra, the data are given as: C=O = carbonyl; C = quaternary; 
CH = methine; CH2 = methylene; CH3 = methyl. The assignment of the observed signals 
in various spectra was often assisted by conducting distortionless enhancement of 
polarisation transfer (DEPT), homonuclear (1H/1H) correlation spectroscopy (COSY) 
and/or nuclear Overhauser effect (NOE) experiments. 
 
Infrared spectra (νmax) were recorded on a Perkin-Elmer 1800 Series FTIR 
spectrophotometer. Samples were analysed as thin films on NaCl plates. 
 
A VG Fisons Autospec three-sector (E/B/E) double-focussing mass spectrometer was 
used to obtain both low- and high-resolution electron impact (EI) mass spectra. Low- 
and high-resolution electrospray mass spectra were obtained on a VG Quattro II triple 
quadrapole MS instrument operating in either positive and/or negative ionisation 
modes. 
 
Unless otherwise stated, optical rotations were measured with a Perkin-Elmer 241 
polarimeter at the sodium D-line (589 nm) and the concentrations (c) (g/100 mL) 
indicated using spectroscopic grade chloroform as solvent. The measurements were 
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carried out in a cell with a path length (1) of 1 dm. Specific rotations α[ ]D20 were 
calculated at 18°C using the equation [α]D = 100.α/(c.l) and given in 10-1.deg.cm2.g-1. 
 
Melting points were measured on a Reichart hot-stage microscope and are uncorrected. 
 
Elemental analyses were performed by the Australian National University’s 
Microanalytical Services Unit based in the Research School of Chemistry. 
 
Analytical thin layer chromatography (TLC) was performed on aluminium backed 0.5 
mm thick silica gel 60 F254 plates as supplied by Merck. Eluted plates were visualised 
using a 254 nm UV lamp and/or by treatment with a suitable dip followed by heating. 
These dips included phosphomolybdic acid : ceric sulfate : sulfuric acid (conc) : water 
(37.5 g : 7.5 g : 37.5 g : 720 mL) or p-anisaldehyde : sulfuric acid (conc) : glacial acetic 
acid : ethanol (3.7 mL : 5 mL : 1.5 mL : 135 mL). Flash chromatography was performed 
using the analytical grade solvents indicated and silica gel 60 (0.040-0.0063 mm) as 
supplied by Lomb Scientific. 
 
Room temperature is assumed to be 18°C. 
 
Starting materials and reagents were generally available from Sigma-Aldrich, Merck, 
TCI, Strem or Lancaster Chemical Companies and were used as supplied or, in the case 
of some liquids, simply distilled prior to use. 
 
Drying agents and other inorganic salts were purchased from AJAX, BDH or Unilab 
Chemical Companies. Tetrahydrofuran (THF) and diethyl ether (ether) were distilled 
from sodium benzophenone ketyl. Methanol and ethanol were distilled from their 
respective magnesium alkoxide salts. Acetonitrile, chloroform and dichloromethane 
were distilled from calcium hydride, while toluene was distilled from sodium. N,N-
Dimethylformamide (DMF), pyridine, triethylamine, diisopropylamine were all distilled 
from and stored over potassium hydroxide pellets. 
 
Organic solutions obtained from the work-up of reaction mixtures were dried with 
magnesium sulfate (MgSO4) then filtered and concentrated under reduced pressure on a 
rotary evaporator with the water bath not exceeding 30°C unless otherwise specified.  
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5.2 Procedures Associated with Work Described in Chapter Two 
  
Methyl 2-oxo-cyclohept-3-ene carboxylate (79) 
 
Following a procedure developed by Mander et al,1 a magnetically stirred solution of 
diisopropylamine (3.02 mL, 21.0 mmol) in THF (40 mL) maintained at –20°C 
(NaCl/ice bath) under a nitrogen atmosphere was treated, dropwise, with n-butyllithium 
(13.5 mL of a 1.6 M solution in hexanes, 21.0 mmol). The resulting mixture was stirred 
for 0.5 h at –20°C then the temperature was reduced to –78°C (dry-ice/acetone bath) 
and a solution of enone 78 (2.00 g, 18.5 mmol) in THF (10 mL) was added via cannula. 
The resulting solution was then warmed to 0°C (ice/water bath), stirred at this 
temperature for 1 h, cooled again to –78°C and HMPA (1.75 mL, 21.0 mmol) and 
methyl cyanoformate (1.79 mL, 21.0 mmol) were added. After stirring for an additional 
0.25 h at –78°C, the reaction mixture was poured into cold water (150 mL) and 
extracted with ether (2 x 50 mL). The combined organic phases were washed with 
distilled water (3 x 50 mL) and the separated organic phase was then dried (MgSO4), 
filtered and concentrated under reduced pressure to give a clear, yellow oil. Subjection 
of this material to flash chromatography (silica, 5 → 20% v/v ethyl acetate/hexane 
gradient elution) provided, after concentration of the appropriate fractions, the title 
compound 79 (2.29 g, 74%) as a clear, yellow oil. 
 
Rf 0.6 (silica, 1:9 v/v ethyl acetate/hexane).  
1H NMR (300 MHz) (enolic form-major isomer) δ 6.26 (dt, J = 12.2 and 4.2 Hz, 1H), 
5.93 (dt, J = 14.4 and 2.1 Hz, 1H), 3.77 (s, 3H), 2.46–2.42 (complex m, 2H), 2.36–2.33 
(complex m, 2H), 1.87–1.83 (complex m, 2H), (OH proton exchanges with solvent). 
(keto form-minor isomer) δ 6.62 (pd, J = 4.8 and 1.2 Hz, 1H), 6.05 (complex m, 1H), 
3.73 (s, 3H), 3.64 (m, 1H), 2.21–1.98 (complex m, 6H).  
13C NMR (75 MHz) (enolic form-major isomer) δ 173.1 (C), 167.9 (C=O), 142.4 (CH), 
125.8 (CH), 102.5 (C), 51.7 (CH3), 32.1 (CH2), 27.6 (CH2), 24.2 (CH2). (keto form-
minor isomer) δ 198.6 (C=O), 170.8 (C=O), 146.7 (CH), 131.2 (CH), 58.8 (CH), 52.2 
(CH3), 29.9 (CH2), 25.2 (CH2), 24.5 (CH2).  
1. LDA, THF, 
   -78oC to 0oC, 1 h 
2. HMPA, NCCO2Me, 
   -78oC, 0.25 h
OO CO2Me
(78) (79)
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IR (NaCl, film) νmax 2951, 2930, 1747 (C=O), 1653 (C=O), 1600, 1441, 1362, 1312, 
1299, 1208, 1056, 834 cm-1.  
EIMS (70 eV) m/z 168 (M+•, 39%), 140 (55), 136 (42), 109 (30), 81 (100).  
HRMS Found: M+•, 168.0785. C9H12O3 requires M+•, 168.0786. 
 
5.2.1 Synthesis of Arylstannanes 92 - 95 
 
Tributyl(2,3,4-trimethoxyphenyl)stannane (92) 
 
Following a procedure developed by Sundburg et al,2 a magnetically stirred solution of 
arene 81 (5.00 g, 29.9 mmol) in THF (50 mL) maintained at –78°C (dry-ice/acetone 
bath) under a nitrogen atmosphere was treated, via cannula, with n-BuLi (20.5 mL of a 
1.6 M solution in hexane, 32.8 mmol). The resulting mixture was stirred for 0.5 h at –
78°C, then warmed to 18°C and stirred at this temperature for 2 h, then cooled again to 
–78°C (dry-ice/acetone bath) and tri-n-butylstannyl chloride (8.20 mL, 30.0 mmol) was 
added dropwise. The resulting mixture was stirred for a further 0.5 h at –78°C then 
allowed to warmed to 18°C and stirred at this temperature for an additional 2 h, then 
quenched with ammonium chloride (1 x 20 mL of a saturated aqueous solution) and 
extracted with ether (2 x 50 mL). The combined organic phases were washed with KF 
(1 x 50 mL of a saturated aqueous solution) and distilled water (2 x 50 mL). The 
separated organic phase was then dried (MgSO4), filtered and concentrated under 
reduced pressure to give a clear, yellow oil. Subjection of this material to flash 
chromatography (silica, 1 → 5% v/v ethyl acetate/hexane gradient elution) provided, 
after concentration of the appropriate fractions, the title compound 92 (7.68 g, 57%) as a 
clear, viscous oil. 
 
Rf 0.3 (silica, 5:95 v/v ethyl acetate/hexane). 
1H NMR (300 MHz) δ 6.98 (d, J = 8.0 Hz, 1H), 6.68 (d, J = 8.0 Hz, 1H), 3.87 (s, 3H), 
3.85 (s, 3H), 3.84 (s, 3H), 1.51 (complex m, 6H), 1.32 (complex m, 6H), 1.02 (complex 
m, 6H), 0.88 (t, J = 7.3 Hz, 9H). 
1. n-BuLi, THF, 
     -78oC to 18oC, 2.5 h
2. (Bu)3SnCl, -78oC to 18oC, 
     2.5 h
MeO MeO
OMe OMe
(81) (92)
MeO MeO
Sn(Bu)3
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13C NMR (75 MHz) δ 157.7 (C), 154.5 (C), 141.1 (C), 130.9 (CH), 126.1 (C), 107.9 
(CH), 60.6 (CH3), 60.5 (CH3), 55.9 (CH3), 29.1 (CH2), 27.4 (CH2), 13.7 (CH2), 9.8 
(CH3).  
IR (NaCl, film) νmax 2955, 1578, 1482, 1267, 1093 cm-1. 
EIMS (70 eV) m/z 401 [(M–Bu•)+, 100%], 345 (24), 287 (52).  
HRMS Found: (M–Bu•)+, 401.1139. C17H29O3120Sn requires (M–Bu•)+, 401.1139. 
 
Tributyl(3,4,5-trimethoxyphenyl)stannane (93) 
 
Following a procedure developed by Suginome et al,3 a magnetically stirred solution of 
bromoarene 82 (3.30 g, 13.0 mmol) in ether (50 mL) maintained at –78°C (dry-
ice/acetone bath) under a nitrogen atmosphere was treated, via cannula, with n-BuLi 
(10.0 mL of a 1.6 M solution in hexane, 16.0 mmol). The resulting mixture was stirred 
for 0.5 h at –78°C then warmed to 18°C and stirred at this temperature for 1 h. Tri-n-
butylstannyl chloride (3.52 mL, 13.0 mmol) was then added dropwise. The resulting 
mixture containing a yellow precipitate was heated to reflux and stirred at reflux for 1 h, 
then allowed to cooled to 18°C. The reaction mixture was then quenched with HCl (20 
mL of a 1 M aqueous solution) and extracted with ether (1 x 100 mL). The organic 
phase was washed with NaHCO3 (50 mL of a saturated aqueous solution) and distilled 
water (2 x 50 mL). The separated organic phase was then dried (MgSO4), filtered and 
concentrated under reduced pressure to give a clear, yellow oil. Subjection of this 
material to flash chromatography (silica, 1 → 10% v/v ethyl acetate/hexane gradient 
elution) provided, after concentration of the appropriate fractions, the title compound 93 
(2.40 g, 40%) as a clear, viscous oil. 
 
Rf 0.3 (silica, 1:9 v/v ethyl acetate/hexane).  
1H NMR (300 MHz) δ 6.64 (s, 2H), 3.87 (s, 6H), 3.85 (s, 3H), 1.67–1.51 (complex m, 
6H), 1.43–1.27 (complex m, 9H), 1.05 (complex m, 3H), 0.90 (t, J = 7.0 Hz, 9H).  
13C NMR (75 MHz) δ 152.9 (C), 138.1 (C), 136.7 (C), 112.7 (CH), 60.8 (CH3), 56.1 
(CH3), 29.0 (CH2), 27.3 (CH2), 13.7 (CH2), 9.7 (CH3).  
IR (NaCl, film) νmax 2956, 1569, 1499, 1464, 1298, 1127 cm-1. 
OMe
1. n-BuLi, ether, 
    -78oC to 18oC, 1.5 h
2. (Bu)3SnCl, 18oC to reflux
    1 h
MeO MeO
OMe
OMe
OMe
Br Sn(Bu)3
(82) (93)
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EIMS (70 eV) m/z 458 (M+•, >1%), 401 (100), 345 (61), 287 (85).  
HRMS Found: M+•, 458.1837. C21H38O3120Sn requires M+•, 458.1843. 
 
1-tert-Butoxycarbonyl-5-(tributylstannyl)-1H-indole (94) 
 
Following a procedure developed by Konopelski et al,4 a magnetically stirred and 
chilled (ice/water bath) suspension of KH (1.57 g of a 30% suspension in mineral oil, 
12.0 mmol) in ether (25 mL) maintained under a nitrogen atmosphere was treated, 
dropwise, over 0.25 h, with a solution of bromoindole 83 (1.96 g, 10.0 mmol) in ether 
(5 mL). After 0.5 h at ca. 0°C, the reaction mixture was cooled to –78°C (dry-
ice/acetone bath) and treated, via cannula, with t-BuLi (11.8 mL of a 1.7 M solution in 
hexane, 20.1 mmol) that had been cooled to –78°C (dry-ice/acetone bath). A white 
precipitate formed and the reaction mixture was kept at –78°C for 1 h. Tri-n-
butylstannyl chloride (6.57 g, 20.0 mmol) was then added in one portion. The resulting 
mixture was stirred at -78°C for an additional 1 h then allowed to warm to 18°C and 
quenched with ammonium chloride (1 x 20 mL of a saturated solution). The resulting 
solution was extracted with ether (2 x 25 mL) and the combined organic phases were 
washed with NaHCO3 (2 x 25 mL of a saturated solution) and distilled water (2 x 25 
mL). The separated organic phase was then dried (MgSO4), filtered and concentrated 
under reduced pressure to give 5-(tributylstannyl)-1H-indole as a clear, yellow oil.  
 
A solution of 5-(tributylstannyl)-1H-indole (prepared as described immediately above) 
in dichloromethane (5 mL) maintained under a nitrogen atmosphere was treated with 
Boc2O (2.61 g, 12.0 mmol) and DMAP (121 mg, 1.00 mmol). The resulting mixture 
was stirred at 18°C for 1 h then concentrated under reduced pressure. The residue thus 
obtained was diluted with ether (25 mL) and the organic phase was washed with water 
(2 x 25 mL), NaHCO3 (2 x 25 mL of a saturated aqueous solution) and brine (2 x 25 
mL). The separated organic phase was then dried (MgSO4), filtered and concentrated 
under reduced pressure to give clear colourless oil. Subjection of this material to flash 
chromatography (silica, 2 → 5% v/v ethyl acetate/hexane gradient elution) provided, 
N
H
Br
N
Boc
(Bu)3Sn
1. KH, ether, 0oC, 0.25 h 
2. t-BuLi, -78oC, 1 h
3. (Bu)3SnCl, -78oC to18oC, 1h 
4. Boc2O,  DMAP, 
    CH2Cl2, 18oC, 1 h
(94)(83)
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after concentration of the appropriate fractions, the title compound 94 (3.50 g, 69%) as a 
clear, viscous oil. 
 
Rf 0.6 (silica, 1:9 v/v ethyl acetate/hexane).  
1H NMR (300 MHz) δ 8.09 (d, J = 7.6 Hz, 1H), 7.66 (s, 1H), 7.56 (d, J = 3.7 Hz, 1H), 
7.37 (d, J = 7.6 Hz, 1H), 6.55 (d, J = 3.7 Hz, 1H), 1.67 (s, 9H), 1.57 (complex m, 6H), 
1.33 (p, J = 7.7 Hz, 6H), 1.90 (complex m, 6H), 0.89 (t, J = 7.2 Hz, 9H).  
13C NMR (75 MHz) δ 149.8 (C=O), 135.2 (C), 134.4 (C), 131.9 (CH), 130.7 (C), 129.0 
(CH), 125.3 (CH), 114.8 (CH), 107.1 (CH), 83.4 (C), 29.1 (CH2), 28.1 (CH3), 27.4 
(CH2), 13.7 (CH2), 9.6 (CH3).  
IR (NaCl, film) νmax 2926, 1738 (C=O), 1532, 1452, 1362, 1251, 767 cm-1. 
EIMS (70 eV) m/z 507 (M+•, >1%), 450 [(M–Bu•)+, 75], 394 (26), 338 (19), 279 (48), 
235 (35). 
HRMS Found: M+•, 507.2159. C25H41NO2120Sn requires M+•, 507.2159. 
 
Preparation of 1-tert-Butoxycarbonyl-5-(tributylstannyl)-6-methoxy-1H-
indole (95) 
 
4-Bromo-3-methoxy-N-methylsulfonylanilide (86) 
 
Following a procedure developed by Forbes et al,5 a magnetically stirred and chilled 
(ice/water bath) solution of aniline 85 (5.80 g, 28.7 mmol) and pyridine (2.40 mL, 28.7 
mmol) in dichloromethane (50 mL) maintained under a nitrogen atmosphere was slowly 
treated with methanesulfonyl chloride (2.30 mL, 29.8 mmol). The reaction mixture was 
then warmed to 18°C, stirred at this temperature for 13 h, then diluted with 
dichloromethane (1 x 250 mL) and the organic phase was washed with distilled water (3 
x 100 mL) then dried (MgSO4), filtered and concentrated under reduced pressure to give 
the title compound 86 (8.81 g, 98%) as a light-brown solid. 
 
Rf 0.5 (silica, 3:2 v/v ethyl acetate/hexane). 
m.p. 120–122°C (lit. 121 – 123°C).5 
NH2
Br
MeO
MsCl, py., CH2Cl2,
 0oC to 18oC., 13 h
NHMs
Br
MeO
(85) (86)
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1H NMR (300 MHz) δ 7.47 (d, J = 8.4 Hz, 1H), 6.91 (d, J = 2.3 Hz, 1H), 6.68 (dd, J = 
8.4 and 2.3 Hz, 1H), 3.90 (s, 3H), 3.02 (s, 3H). (NH proton exchanges with solvent). 
13C NMR (75 MHz) δ 156.7 (C), 137.2 (C), 133.8 (CH), 113.4 (CH), 107.9 (C), 104.9 
(CH), 56.3 (CH3), 39.2 (CH3). 
IR (NaCl, film) νmax 3271 (NH), 1594, 1489, 1322, 1151, 1049, 977 cm-1. 
EIMS (70 eV) m/z 281 and 279 (M+•, 66%), 202 and 200 (100), 189 and 187 (16).  
HRMS Found: M+•, 278.9566. C8H1079BrNSO3 requires M+•, 278.9565. 
 
2,2-Diethoxyethyl)trifluoromethanesulfonate (88) 
 
 
A magnetically stirred solution of acetal 87 (6.05 g, 44.8 mmol) and Et3N (7.05 mL, 
50.0 mmol) in dichloromethane (50 mL) maintained at –78°C (dry-ice/acetone bath) 
under a nitrogen atmosphere was treated, dropwise, with a solution of 
trifluromethanesulfonic anhydride (13.9 g, 49.2 mmol) in dichloromethane (50 mL) 
over 0.5 h. Stirring was continued for a further 1.5 h at -78°C. The reaction mixture was 
quenched with water (1 x 50 mL) and the organic phase was washed with distilled water 
(2 x 50 mL) then dried (MgSO4), filtered and concentrated under reduced pressure to 
give the title compound 88 (7.12 g, 72%) as a clear oil. 
 
Rf 0.4 (silica, 1:9 v/v ethyl acetate/hexane) 
1H NMR (300 MHz) δ 4.73 (d, J = 5.3 Hz, 1H), 4.75 (d, J = 5.3 Hz, 2H), 3.77–3.56 
(complex m, 4H), 1.23 (t, J = 7.1 Hz, 6H).  
13C NMR (75 MHz) δ 120.6 (CF3), 98.7 (CH), 73.9 (CH2), 64.9 (CH2), 15.1 (CH3).  
IR (NaCl, film) νmax 2984, 2904, 1417, 1247, 1147, 972 cm-1.  
EIMS (70 eV) m/z 221 [(M–EtO•)+, 36%], 193 (100).  
HRMS Found: (M–EtO•)+, 221.0081. C5H8SF3O4 requires (M–EtO•)+, 221.0095. 
 
 
 
 
 
 
OEtEtO
HO TfO
OEtEtOTf2O, Et3N,
CH2Cl2, -78OC, 1.5 h
(87) (88)
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4-Bromo-N-(2,2-diethoxyethyl)-3-methoxy-N-methylsulfonyl anilide (89) 
 
Following a procedure developed by Forbes et al,5 a magnetically stirred and chilled 
(ice/water bath) suspension of NaH (60% dispersion in oil, 800 mg, 20.0 mmol) in 
DMF (5 mL) maintained under a nitrogen atmosphere was treated with a solution of 
methylsulfonamide 85 (4.00 g, 14.29 mmol) in DMF (20 mL) over 0.5 h. After 
evolution of dihydrogen gas had ceased, trifluoromethanesulfonate 88 (4.60 g, 17.2 
mmol) was quickly added and the resulting solution warmed to 18°C and stirred at this 
temperature for 6 h, further quantities of NaH (0.06 g, 2.50 mmol) and 
trifluoromethanesulfonate 88 (500 mg, 1.93 mmol) were then added and stirring was 
continued for an additional 13 h. The reaction mixture was then quenched with water 
(50 mL) and extracted with toluene (1 x 200 mL). The separated organic phase was 
washed with distilled water (1 x 100 mL) and brine (3 x 100 mL) then dried (MgSO4), 
filtered and concentrated under reduced pressure. Recrystallisation from ethanol of this 
material afforded the title compound 89 (4.42 g, 98%) as a light-brown solid. 
 
Rf 0.4 (silica, 3:7 v/v ethyl acetate/hexane). 
m.p. 70–72°C (lit. 70 – 72°C).5 
1H NMR (300 MHz) δ 7.54 (d, J = 8.5 Hz, 1H), 6.96 (d, J = 2.3 Hz, 1H), 6.82 (dd, J = 
8.5 and 2.3 Hz, 1H), 4.61 (t, J = 5.5 Hz, 1H), 3.90 (s, 3H), 3.74 (d, J = 5.5 Hz, 2H), 
3.69–3.48 (complex m, 4H), 2.96 (s, 3H), 1.16 (t, J = 7.0 Hz, 6H). 
13C NMR (75 MHz) δ 156.4 (C), 140.6 (C), 133.4 (CH), 120.6 (CH), 113.3 (CH), 111.3 
(C), 100.9 (CH), 62.7 (CH2), 56.3 (CH3), 55.3 (CH2), 38.1 (CH3), 15.3 (CH3).  
IR (NaCl, film) νmax 2975, 1586, 1484, 1343, 1155, 968 cm-1.  
EIMS (70 eV) m/z 397 and 395 (M+•, 1%), 215 and 213 (27), 103 (100). 
HRMS Found: M+•, 395.0395. C14H2279BrNO5S requires M+•, 395.0402. 
 
 
 
 
 
 
NHMs
Br
MeO
Br
MeO N
Ms
(88), NaH, DMF, 
0oC to 18oC, 19 h
OEtEtO
(86) (89)
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5-Bromo-6-methoxy-1-methylsulfonylindole (90) 
 
Following a procedure developed by Forbes et al,5 a magnetically stirred and chilled 
(ice/water bath) solution of anilide 89 (4.53 g, 11.4 mmol) in toluene (220 mL) 
maintained under a nitrogen atmosphere was treated, dropwise, with a solution of 
titanium tetrachloride (1.88 mL, 5.43 mmol) in toluene (100 mL). The reaction mixture 
was then heated to 100°C, stirred at this temperature for 0.25 h, then cooled and washed 
with NaHCO3 (1 x 100 mL of a saturated aqueous solution), HCl (1 x 100 mL of a 1 M 
aqueous solution) and distilled water (1 x 100 mL), then dried (MgSO4), filtered and 
concentrated under reduced pressure. Recrystallisation from ether of this material 
afforded the title compound 90 (2.68 g, 89%) as a light-brown solid.  
 
Rf 0.4 (silica, 3:7 v/v ethyl acetate/hexane). 
m.p. 121–124°C (lit. 126–129°C).5  
1H NMR (300 MHz) δ 7.79 (s, 1H), 7.48 (s, 1H), 6.34 (d, J = 3.7 Hz, 1H). 6.61 (d, J = 
3.7 Hz, 1H), 3.97 (s, 3H), 3.08 (s, 3H).  
13C NMR (75 MHz) δ 153.8 (C), 134.8 (C), 125.6 (CH), 125.5 (CH), 125.0 (C), 108.7 
(C), 108.3 (CH), 96.7 (CH), 56.6 (CH3), 40.6 (CH3). 
IR (NaCl, film) νmax 2926, 1610, 1473, 1365, 1167, 767 cm-1.  
EIMS (70 eV) m/z 305 and 303 (M+•, 62%), 226 and 224 (75), 211 and 209 (85), 102 
(100).  
HRMS Found: M+•, 302.9558. C10H1079BrNO5S requires M+•, 302.9565. 
 
5-Bromo-6-methoxy-1H-indole (84) 
 
Following a procedure developed by Forbes et al,5 a magnetically stirred solution of 
sulfonamide 90 (1.42 g, 4.67 mmol) in a mixture of sodium hydroxide (10 mL of a 10% 
w/v aqueous solution) and ethanol (60 mL) was heated to reflux and stirred at reflux for 
N
Ms
Br
MeO
Br
MeO N
Ms
OEtEtO
(89) (90)
TiCl4, toluene,
 0oC to 100oC, 0.25 h
N
Ms
Br
MeO
Br
MeO N
H
(90) (84)
10% NaOH,
EtOH, reflux,
1.5 h
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1.5 h. The cooled reaction mixture was concentrated under reduced pressure to near 
dryness and the residue, so obtained was dissolved in ethyl acetate (1 x 100 mL) and 
washed with distilled water (3 x 50 mL). The separated organic phase was then dried 
(MgSO4), filtered and concentrated under reduced pressure to give a brown solid. 
Recrystallisation from ethanol afforded the title compound 84 (1.06 g, 100%) as a light-
brown solid.  
 
Rf 0.4 (silica, 3:7 v/v ethyl acetate/hexane). 
m.p. 110 –112°C (lit. 110–111°C).5 
1H NMR (300 MHz) δ 8.20 (s, 1H), 7.80 (s, 1H), 7.09 (t, J =3.9 Hz, 1H), 6.87 (s, 1H), 
6.43 (m, 1H), 3.87 (s, 3H).  
13C NMR (75 MHz) δ 151.8 (C), 135.4 (C), 124.5 (CH), 123.8 (CH), 122.9 (C), 104.9 
(C), 101.9 (CH), 94.5 (CH), 56.4 (CH3).  
IR (NaCl, film) νmax 3402 (NH), 2925, 1619, 1454, 1307, 1164, 1039, 816 cm-1.  
EIMS m/z 227 and 225 (M+•, 100%), 212 and 210 (85), 184 and 182 (60).  
HRMS Found: M+•, 224.9784. C9H879BrNO requires M+•, 224.9789. 
 
1-tert-Butoxycarbonyl-5-(tributylstannyl)-6-methoxy-1H-indole (95) 
 
A magnetically stirred and chilled (ice/water bath) suspension of KH (349 mg of a 30% 
suspension in mineral oil, 2.67 mmol) in THF (25 mL) maintained under a nitrogen 
atmosphere was treated, dropwise, over 0.25 h, with a solution of indole 845 (500 mg, 
2.25 mmol) in THF (5 mL). After stirring for an additional 0.5 h at ca. 0°C, the reaction 
mixture was cooled to –78°C (dry-ice/acetone bath) then treated, via cannula, with t-
BuLi (2.61 mL of a 1.7 M solution in hexane, 4.44 mmol) that had been cooled to –
78°C (dry-ice/acetone bath). A red precipitate formed and the reaction mixture was kept 
at -78°C for an additional 1 h. HMPA (1.15 mL, 13.8 mmol) followed by tri-n-
butylstannyl chloride (1.21 mL, 4.44 mmol) were then added, each in one portion. The 
resulting solution was heated to reflux and stirred at reflux for 3 h, then cooled and 
quenched with ammonium chloride (1 x 20 mL of a saturated solution) then extracted 
N
H
Br
N
Boc
(Bu)3Sn
1. KH, THF, 0oC , 0.25 h
2. t-BuLi, -78oC, 1 h
3. HMPA, (Bu)3SnCl,
    -78oC to reflux, 3 h 
4. Boc2O, DMAP, CH2Cl2, 
   18oC, 1 h
MeO MeO
(84) (95)
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with dichloromethane
 
(2 x 25 mL). The combined organic phases were washed with KF 
(1 x 25 mL of a saturated aqueous solution), NaHCO3 (2 x 25 mL of a saturated 
aqueous solution) and distilled water (2 x 25 mL). The separated organic phase was 
then dried (MgSO4), filtered and concentrated under reduced pressure to give 5-
(tributylstannyl)-6-methoxy-1H-indole a clear, yellow oil.  
 
A solution of 5-(tributyl-6-methoxy-1H-indole (prepared as described immediately 
above) in dichloromethane (5 mL) maintained under a nitrogen atmosphere was treated 
with Boc2O (580 mg, 2.25 mmol) and DMAP (30 mg, 0.25 mmol). The resulting 
mixture was stirred at 18°C for 1 h and diluted with dichloromethane
 
(25 mL). The 
organic phase was washed with KF (1 x 25 mL of a saturated aqueous solution), 
NaHCO3 (2 x 25 mL of a saturated aqueous solution) and brine (2 x 25 mL). The 
separated organic phase was then dried (MgSO4), filtered and concentrated under 
reduced pressure to give a clear, yellow oil. Subjection of this material to flash 
chromatography (silica, 1 → 5% v/v ethyl acetate/hexane gradient elution) provided, 
after concentration of the appropriate fractions, the title compound 95 (1.08 g, 90%) as a 
clear, viscous oil. 
 
Rf 0.4 (silica, 5:95 v/v ethyl acetate/hexane). 
1H NMR (300 MHz) δ 7.66 (s, 1H), 7.48 (s, 1H), 7.43 (d, J = 3.7 Hz, 1H), 6.46 (d, J = 
3.7 Hz, 1H), 3.83 (s, 3H), 1.66 (s, 9H), 1.52 (complex m, 6H), 1.32 (complex m, 6H), 
1.02 (complex m, 6H), 0.87 (t, J = 7.3 Hz, 9H).  
13C NMR (75 MHz) δ 161.1 (C), 153.3 (C=O), 149.9 (C), 128.7 (CH), 125.5 (C), 124.8 
(C), 123.9 (CH), 107.0 (CH), 96.3 (CH), 83.3 (C), 55.2 (CH3), 29.2 (CH2), 28.2 (CH3), 
27.4 (CH2), 13.7 (CH2), 9.8 (CH3).  
IR (NaCl, film) νmax 2923, 1734 (C=O), 1456, 1359, 1148 cm-1. 
EIMS (70 eV) m/z 537 (M+•, 27%), 482 (76), 422 (80), 367 (49), 310 (100).  
HRMS Found: M+•, 537.2272. C26H43NO3120Sn requires M+•, 537.2265. 
 
5.2.2 General Procedure for Synthesis of Aryllead Triacetates 97 – 99  
 
Following a procedure developed by Pinhey et al,6 a magnetically stirred solution of the 
appropriate arylstannane (1.00 mmol) in chloroform (5 mL) maintained under a 
nitrogen atmosphere was treated with lead (IV) tetraacetate (443 mg, 1.00 mmol) and 
mercury (II) trifluoroacetate (19.0 mg, 0.05 mmol). The reaction mixture was heated to 
40°C, stirred at this temperature for 12 h, then cooled and filtered through a pad of 
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Celite. The filtrate was then concentrated under reduced pressure to give viscous, 
yellow oil. The oil was washed with petroleum ether (5 x 20 mL) to afford the relevant 
aryllead triacetate as a pale yellow solid. 
 
(2,3,4-Trimethoxyphenyl)lead triacetate (97) 
 
Yield 75% 
m.p. 151–153°C.  
1H NMR (300 MHz) δ 7.46 (d, J = 8.9 Hz, 1H), 6.82 (d, J = 8.9 Hz, 1H), 4.04 (s, 3H), 
3.89 (s, 3H), 3.86 (s, 3H), 2.10 (s, 9H). 
13C NMR (75 MHz) δ 179.9 (C=O), 157.2 (C), 152.0 (C), 146.7 (C), 142.0 (C), 126.1 
(CH), 108.7 (CH), 61.8 (CH3), 61.0 (CH3), 56.4 (CH3), 20.4 (CH3).  
IR (NaCl, film) νmax 2943, 1563 (C=O), 1406, 1085, 692 cm-1. 
EIMS (70 eV) m/z 493 [(M–AcO•)+, >1%], 267 (100). 
HRMS Found: (M–AcO•)+, 493.0395. C19H13O8NPb requires (M–AcO•)+, 493.0377. 
 
(3,4,5-Trimethoxyphenyl)lead triacetate (98) 
 
Yield 81% 
m.p. 125–127°C (lit. m.p. 123–125°C).7 
1H NMR (300 MHz) δ 6.88 (s, 2H), 3.90 (s, 6H), 3.86 (s, 3H), 2.13 (s, 9H).  
13C NMR (75 MHz) δ 180.1 (C=O), 154.4 (C), 109.5 (C), 107.8 (CH), 106.1 (C), 61.0 
(CH3), 56.5 (CH3), 20.4 (CH3).  
IR (NaCl, film) νmax 2935, 1582 (C=O), 1492, 1403, 1232, 1122 cm-1. 
EIMS (70 eV) m/z 552 (M+• >1%), 493 [(M–AcO•)+, >1%], 267 (100).  
HRMS Found: (M–AcO•)+, 493.0739. C19H13NO8Pb requires (M–AcO•)+, 493.0741. 
 
Sn(Bu)3 Pb(OAc)3
OMeOMe
OMe
Pb(OAc)4, Hg(OTf)2, 
CHCl3, 40oC, 12 h
OMe
MeOMeO
(93) (98)
Sn(Bu)3 Pb(OAc)3
OMeOMe
Pb(OAc)4, Hg(OTf)2, 
CHCl3, 40oC, 12 h
MeO
MeO
MeO
MeO
(92) (97)
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1-tert-Butoxycarbonyl-5-indole lead triacetate (99) 
 
Yield 78% 
m.p. 92–94°C. 
1H NMR (300 MHz) δ 8.35 (d, J = 9.2 Hz, 1H), 7.87 (s, 1H), 7.71 (d, J = 3.9 Hz, 1H), 
7.53 (d, J = 9.2 Hz, 1H), 6.64 (d, J = 3.9 Hz, 1H), 2.11 (s, 9H), 1.68 (s, 9H). 
13C NMR (75 MHz) δ 179.0 (C=O), 155.8 (C), 149.1 (C=O), 136.6 (C), 132.1 (C), 
127.8 (CH), 125.2 (CH), 123.9 (CH), 117.3 (CH), 107.4 (CH), 84.7 (C), 28.1 (CH3), 
20.4 (CH3).  
IR (NaCl, film) νmax 2979, 1738 (C=O), 1557, 1466, 1372, 1251, 1159, 1020 cm-1. 
EIMS (70 eV) m/z 601 (M+•, >1%), 542 [(M–AcO•)+, 4], 267 (100).  
Elemental Analysis Found: C, 36.90, H, 3.99, N, 2.44, Pb, 31.59. Calcd: C19H23NO8Pb: 
C, 36.89, H, 4.07, N, 2.26, Pb, 33.49%. 
 
5.2.3 General Procedure for Synthesis of Cyclic α-Arylated β-Ketoesters 
76, 101 – 110 
 
Following a procedure developed by Pinhey et al,8 a magnetically stirred solution of the 
appropriate β-ketoester (1.00 mmol) in chloroform (2 mL) at 18°C under a nitrogen 
atmosphere was treated with pyridine (0.26 mL, 3.28 mmol) and the resulting mixture 
stirred for 0.5 h then treated with the appropriate aryllead triacetate (1.10 mmol). The 
resulting mixture was heated to 40°C and stirred at this temperature for 12 h, then 
cooled, quenched with HCl (drop of 1 M aqueous solution) and diluted with ethyl 
acetate (1 x 50 mL). The organic phase was washed with HCl (1 x 25 mL of a 1 M 
aqueous solution) and distilled water (2 x 25 mL). The separated organic phase was 
then dried (MgSO4), filtered and concentrated under reduced pressure to give a clear, 
yellow oil. Subjection of this material to flash chromatography (silica, 10 → 30% v/v 
ethyl acetate/petroleum spirit gradient elution) provided, after concentration of the 
appropriate fractions, the relevant cyclic α-arylated β-ketoester as either a colourless 
solid or oil.  
 
 
Pb(OAc)4, Hg(OTf)2, 
CHCl3, 40oC, 12 h
(Bu)3Sn (AcO)3Pb
N
Boc
N
Boc
(94) (99)
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Methyl 1-(2-methoxyphenyl)-2-oxocyclopentanecarboxylate (101) 
 
Colourless oil 
Yield 72% 
Rf 0.5 (silica, 3:7 v/v ethyl acetate/hexane). 
1H NMR (300 MHz) δ 7.28–7.22 (complex m, 1H), 6.92–6.86 (complex m, 3H), 3.76 
(s, 3H), 3.71 (s, 3H), 2.94 (p, J = 6.7 Hz, 1H), 2.47 (td, J = 7.6 and 3.3 Hz, 2H), 2.26 (p, 
J = 6.7 Hz, 1H), 2.00–1.85 (complex m, 2H). 
13C NMR (75 MHz) δ 213.8 (C=O), 170.6 (C=O), 156.4 (C), 128.7 (CH), 128.5 (C), 
127.5 (CH), 120.6 (CH), 111.7 (CH), 64.5 (C), 55.3 (CH3), 52.7 (CH3), 38.5 (CH2), 
35.2 (CH2), 19.7 (CH2). 
IR (NaCl, film) νmax 2953, 1751 (C=O), 1725 (C=O), 1493, 1241, 1107, 754 cm-1. 
EIMS (70 eV) m/z 248 (M+•, 100%), 189 (58), 133 (81). 
HRMS Found: M+•, 248.1053. C14H16O4 requires M+•, 248.1049. 
 
N-tert-Butoxycarbonyl-5-(1-carbomethoxy-2-oxocyclopentyl)-1H-indole 
(102) 
 
Colourless oil 
Yield 81% 
Rf 0.4 (silica, 3:7 v/v ethyl acetate/hexane). 
1H NMR (300 MHz) δ 8.08 (d, J = 8.8 Hz, 1H), 7.58 (s, 2H), 7.31 (d, J = 8.8 Hz, 1H), 
6.51 (d, J = 3.7 Hz, 1H), 3.66 (s, 3H), 2.89–2.83 (complex m, 1H), 2.61–2.57 (complex 
m, 1H), 2.50–2.33 (complex m, 2H), 2.00–1.84 (complex m, 2H), 1.62 (s, 9H). 
13C NMR (75 MHz) δ 212.0 (C=O), 171.2 (C=O), 149.3 (C=O), 134.1 (C), 130.4 (C), 
130.0 (C), 126.1 (CH), 123.3 (CH), 119.5 (CH), 115.0 (CH), 107.2 (CH), 83.5 (C), 64.6 
(C), 52.6 (CH3), 37.4 (CH2), 34.9 (CH2), 27.5 (CH3), 19.0 (CH2). 
IR (NaCl, film) νmax 2977, 1732 (C=O), 1371, 1164, 730 cm-1. 
1. py., CHCl3, 18oC, 0.5 h
2. (96), 40oC, 12 h
OO
CO2Me
CO2Me
MeO
(70) (101)
CO2Me
1. py., CHCl3, 18oC, 0.5 h
2. (99), 40oC, 12 h CO2Me
N
Boc
O O
(70) (102)
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EIMS (70 eV) m/z 357 (M+•, 24%), 301 (100), 257 (26). 
HRMS Found: M+•, 357.1580. C20H23NO5 requires M+•, 357.1576. 
 
Methyl 2-oxo-1-phenyl-cyclohex-3-ene carboxylate (76) 
 
Colourless oil 
Yield 79% 
Rf 0.3 (silica, 3:7 v/v ethyl acetate/hexane). 
1H NMR (300 MHz) δ 7.38–7.18 (complex m, 5H), 6.85 (dt, J = 10.2 and 4.1 Hz, 1H), 
6.17 (dt, J = 10.2 and 1.9 Hz, 1H), 3.72 (s, 3H), 2.88–2.79 (complex m, 1H), 2.61–2.55 
(complex m, 1H), 2.42–2.40 (complex m, 1H), 2.24–2.22 (complex m, 1H). 
13C NMR (75 MHz) δ 195.5 (C=O), 171.6 (C=O), 149.7 (CH), 136.0 (C), 129.1 (CH), 
128.3 (CH), 127.6 (CH), 127.4 (CH), 62.8 (C), 52.7 (CH3), 31.9 (CH2), 23.7 (CH2).  
IR (NaCl, film) νmax 2952, 1731 (C=O), 1677 (C=O), 1247, 1209, 698 cm-1. 
EIMS (70 eV) m/z 230 (M+•, 50%), 198 (11), 171 (33), 162 (42). 
HRMS Found: M+•, 230.0942. C14H14O3 requires M+•, 230.0943. 
 
Methyl 1-(2-methoxyphenyl)-2-oxo-cyclohex-3-ene carboxylate (103) 
 
Colourless oil 
Yield 76% 
Rf 0.4 (silica, 3:7 v/v ethyl acetate/hexane). 
m.p. 100–102°C. 
1H NMR (300 MHz) δ 7.30–7.24 (complex m, 1H), 6.97–6.86 (complex m, 4H), 6.20 
(dt, J = 8.4 and 1.7 Hz, 1H), 3.76 (s, 3H), 3.72 (s, 3H), 2.80–2.74 (complex m, 1H), 
2.67–2.58 (complex m, 1H), 2.40–2.32 (complex m, 1H), 2.03–2.01 (complex m, 1H). 
13C NMR (75 MHz) δ 195.7 (C=O), 171.8 (C=O), 157.2 (C), 150.4 (CH), 129.5 (CH), 
128.9 (CH), 127.8 (CH), 126.6 (C), 120.4 (CH), 111.6 (CH), 61.8 (C), 55.5 (CH3), 52.4 
(CH3), 30.6 (CH2), 23.8 (CH2).  
1. py., CHCl3, 18oC, 0.5 h 
2. (74), 40oC, 12 h
OO
CO2Me
CO2Me
(75) (76)
1. py., CHCl3, 18oC, 0.5 h
2. (96), 40oC, 12 h
OO
CO2Me
CO2Me
MeO
(75) (103)
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IR (NaCl, film) νmax 2950, 1734 (C=O), 1678 (C=O), 1493, 1250, 754 cm-1. 
EIMS (70 eV) m/z 260 (M+•, 80%), 201 (36), 192 (100).  
HRMS Found: M+•, 260.1053. C15H16O4 requires M+•, 260.1049. 
 
Methyl 1-(2,3,4-trimethoxyphenyl)-2-oxo-cyclocyclohex-3-ene carboxylate 
(104) 
 
Colourless oil 
Yield 75% 
Rf 0.5 (silica, 3:2 v/v ethyl acetate/hexane). 
1H NMR (300 MHz) δ 6.94–6.86 (complex m, 1H), 6.59 (d, J = 8.8 Hz, 1H), 6.52 (d, J 
= 8.8 Hz, 1H), 6.14 (dt, J = 8.8 and 1.7 Hz, 1H), 3.80 (s, 6H), 3.78 (s, 3H), 3.72 (s, 3H), 
2.65–2.56 (complex m, 2H), 2.34–2.32 (complex m, 1H), 2.11–2.00 (complex m, 1H). 
13C NMR (75 MHz) δ 195.3 (C=O), 171.6 (C=O), 153.0 (C), 151.8 (C), 149.9 (CH), 
141.8 (C), 129.3 (CH), 124.0 (C), 121.8 (CH), 105.9 (CH), 61.3 (C), 60.3 (CH3), 60.1 
(CH3), 55.7 (CH3), 52.4 (CH3), 31.6 (CH2), 23.8 (CH2). 
IR (NaCl, film) νmax 2938, 1735 (C=O), 1680 (C=O), 1466, 1265, 732 cm-1. 
EIMS (70 eV) m/z 320 (M+•, 42%), 252 (100). 
HRMS Found: M+•, 320.1265. C17H20O6 requires M+•, 320.1260. 
 
Methyl 1-(3,4,5-trimethoxyphenyl)-2-oxo-cyclocyclohex-3-ene carboxylate 
(105) 
 
Colourless oil 
Yield 84% 
Rf 0.4 (silica, 3:2 v/v ethyl acetate/hexane). 
1. py., CHCl3, 18oC, 0.5 h
2. (97), 40oC, 12 h
OO
CO2Me
CO2Me
MeO
OMe
OMe
(75) (104)
1. py., CHCl3, 18oC, 0.5 h
2. (98), 40oC, 12 h
OO
CO2Me
CO2Me
OMe
OMe
OMe
(75) (105)
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1H NMR (300 MHz) δ 6.92–6.88 (complex m, 1H), 6.40 (s, 2H), 6.15 (dt, J = 10.2 and 
1.8 Hz, 1H), 3.83 (s, 3H), 3.81 (s, 6H), 3.74 (s, 3H), 2.86–2.80 (complex m, 1H), 2.56–
2.31 (complex m, 3H). 
13C NMR (75 MHz) δ 195.0 (C=O), 171.5 (C=O), 153.0 (C), 149.9 (CH), 137.0 (C), 
131.5 (C), 129.2 (CH), 105.1 (CH), 62.7 (C), 60.8 (CH3), 56.1 (CH3), 52.9 (CH3), 32.2 
(CH2), 23.8 (CH2). 
IR (NaCl, film) νmax 2922, 1730 (C=O), 1677 (C=O), 1588, 1246, 1127 cm-1. 
EIMS (70 eV) m/z 320 (M+•, 33%), 252 (100), 237 (55).  
HRMS Found: M+•, 320.1246. C17H20O6 requires M+•, 320.1260. 
 
1-tert-Butoxycarbonyl-5-(1-carbomethoxy-2-oxocyclohex-3-enyl-1H-indole 
(106) 
 
Colourless oil 
Yield 71% 
Rf 0.4 (silica, 3:7 v/v ethyl acetate/hexane). 
1H NMR (300 MHz) δ 8.09 (d, J = 8.4 Hz, 1H), 7.57 (d, J = 3.6 Hz, 1H), 7.37 (d, J = 
2.0 Hz, 1H), 7.17 (dd, J = 8.4 and 2.0 Hz, 1H), 6.83 (dt, J = 10.1 and 4.1 Hz, 1H), 6.51 
(d, J = 3.7 Hz, 1H), 6.15 (dt, J = 10.1 and 1.9 Hz, 1H), 3.71 (s, 3H), 2.87–2.83 (complex 
m, 1H), 2.69–2.64 (complex m, 1H), 2.40–2.37 (complex m, 1H), 2.23–2.19 (complex 
m, 1H), 1.64 (s, 9H).  
13C NMR (75 MHz) δ 195.5 (C=O), 171.9 (C=O), 149.7 (CH), 149.5 (C=O), 134.3 (C), 
130.4 (C), 130.0 (C), 129.9 (CH), 126.3 (CH), 123.6 (CH), 120.0 (CH), 115.0 (CH), 
107.3 (CH), 83.7 (C), 62.6 (C), 52.6 (CH3), 31.9 (CH2), 28.0 (CH3), 23.6 (CH2). 
IR (NaCl, film) νmax 2953, 1731 (C=O), 1677 (C=O), 1470, 1371, 1166, 731 cm-1. 
EIMS (70 eV) m/z 369 (M+•, 17%), 313 (42), 245 (92), 201 (100).  
HRMS Found: M+•, 369.1576. C21H23NO5 requires M+•, 369.1576. 
 
 
 
 
 
1. py., CHCl3, 18oC, 0.5 h
2. (99), 40oC, 12 h
OO
CO2Me
CO2Me
N
Boc
(75) (106)
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1-tert-Butoxycarbonyl-5-(1-carbomethoxy-2-oxocyclohex-3-enyl)-6-
methoxy-1H-indole (107) 
 
Colourless oil 
YieldΩ 82% 
Rf 0.4 (silica, 3:7 v/v ethyl acetate/hexane). 
1H NMR (300 MHz) δ 7.74 (s, 1H), 7.40 (d, J = 3.6 Hz, 1H), 7.06 (s, 1H), 6.95 
(complex m, 1H), 6.38 (d, J = 3.6 Hz, 1H), 6.19 (dt, J = 9.2 and 1.4 Hz, 1H), 3.81 (s, 
3H), 3.69 (s, 3H), 2.80–2.78 (complex m, 1H), 2.67–2.65 (complex m, 1H), 2.33–2.20 
(complex m, 2H), 1.62 (s, 9H).  
13C NMR (75 MHz) δ 196.0 (C=O), 172.1 (C=O), 155.2 (C), 150.8 (C=O), 150.7 (CH), 
149.5 (C), 129.4 (CH), 128.7 (C), 124.4 (CH), 122.3 (C), 119.8 (CH), 107.1 (CH), 98.8 
(CH), 83.4 (C), 61.8 (C), 55.6 (CH3), 52.3 (CH3), 30.5 (CH2), 27.9 (CH3), 23.8 (CH2).  
IR (NaCl, film) νmax 2951, 1734 (C=O), 1677 (C=O), 1474, 1156 cm-1. 
EIMS (70 eV) m/z 399 (M+•, 24%), 343 (67), 275 (100).  
HRMS Found: M+•, 399.1683. C22H25NO6 requires M+•, 399.1682. 
 
Methyl 2-oxo-1-phenyl-cyclohept-3-ene carboxylate (108) 
 
Colourless oil 
Yield 63% 
Rf 0.5 (silica, 3:7 v/v ethyl acetate/hexane).  
1H NMR (300 MHz) δ 7.37–7.17 (complex m, 5H), 6.37 (dt, J = 12.5 and 5.0 Hz, 1H), 
6.15 (dt, J = 12.5 and 1.8 Hz, 1H), 3.72 (s, 3H), 2.75–2.65 (complex m, 1H), 2.46–2.34 
(complex m, 3H), 1.93–1.83 (complex m, 2H).  
                                                 
Ω
 Yield over two steps 
1. py., CHCl3, 18oC, 0.5 h
2. (100), 40oC, 12 h
OO
CO2Me
CO2Me
N
BocMeO
(75) (107)
1. py., CHCl3, 18oC, 0.5 h
2. (74), 40oC, 12 h
O OCO2Me
CO2Me
(79) (108)
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13C NMR (75 MHz) δ 200.5 (C=O), 172.7 (C=O), 142.8 (CH), 138.5 (C), 131.4 (CH), 
128.3 (CH), 127.9 (CH), 127.4 (CH), 68.9 (C), 52.7 (CH3), 32.3 (CH2), 31.0 (CH2), 
22.6 (CH2).  
IR (NaCl, film) νmax 2927, 1733 (C=O), 1655 (C=O), 1448, 1230, 1018, 696 cm-1. 
EIMS (70 eV) m/z 244 (M+•, 7%), 216 (46), 185 (56), 103 (100). 
HRMS Found: M+•, 244.1098. C15H16O3 requires M+•, 244.1099. 
 
Methyl 1-(2-methoxyphenyl)-2-oxocyclohept-3-ene carboxylate (109) 
 
Colourless solid 
Yield 70% 
Rf 0.3 (silica, 30:70 v/v ethyl acetate/hexane).  
m.p. 81–83°C.  
1H NMR (300 MHz) δ 7.27 (td, J = 7.3 and 1.6 Hz, 1H), 7.02–6.88 (complex m, 3H), 
6.40–6.33 (complex m, 1H), 6.15 (dt, J = 12.7 and 1.9 Hz, 1H), 3.75 (s, 3H), 3.70 (s, 
3H), 2.56–2.47 (complex m, 2H), 2.32–2.26 (complex m, 1H), 1.77–1.74 (complex m, 
2H), 1.44–1.24 (m, 1H).  
13C NMR (75 MHz) δ 200.6 (C=O), 172.4 (C=O), 157.0 (C), 142.7 (CH), 131.5 (C), 
128.9 (CH), 128.6 (CH), 128.3 (CH), 120.6 (CH), 111.7 (CH), 67.3 (C), 55.5 (CH3), 
52.4 (CH3), 31.0 (CH2), 30.7 (CH2), 21.9 (CH2).  
IR (NaCl, film) νmax 2948, 1733 (C=O), 1660 (C=O), 1493, 1248, 1027, 755 cm-1. 
EIMS (70 eV) m/z 274 (M+•, 69%), 246 (36), 215 (46), 133 (100).  
HRMS Found: M+•, 274.1205. C16H18O4 requires M+•, 274.1205. 
 
 
 
 
 
 
 
 
1. py., CHCl3,18oC, 0.5 h
2. (96), 40oC, 12 h
O OCO2Me
CO2Me
MeO
(79) (109)
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1-tert-Butoxycarbonyl-5-(1-carbomethoxy-2-oxocyclohept-3-enyl)-1H-
indole (110) 
 
Colourless oil 
Yield 71% 
Rf 0.4 (silica, 3:7 v/v ethyl acetate/hexane).  
1H NMR (300 MHz) δ 8.08 (d, J = 8.7 Hz, 1H), 7.58 (d, J = 3.7 Hz, 1H), 7.36 (s, 1H), 
7.14 (dd, J = 8.7 and 1.9 Hz, 1H), 6.52 (d, J = 3.7 Hz, 1H), 6.35 (dt, J = 12.4 and 4.8 
Hz, 1H), 6.14 (J = 12.4 and 1.4 Hz, 1H), 3.70 (s, 3H), 2.72–2.68 (complex m, 1H), 
2.52–1.85 (complex m, 5H), 1.64 (s, 9H).  
13C NMR (75 MHz) δ 200.7 (C=O), 172.8 (C=O), 149.5 (C=O), 142.7 (CH), 134.0 (C), 
132.5 (C), 131.2 (CH), 130.3 (C), 126.2 (CH), 124.1 (CH), 120.2 (CH), 114.9 (CH), 
107.3 (CH), 83.6 (C), 68.6 (C), 52.5 (CH3), 32.0 (CH2), 30.6 (CH2), 28.0 (CH3), 22.3 
(CH2).  
IR (NaCl, film) νmax 2951, 1732 (C=O), 1659 (C=O), 1470, 1371, 1257, 1164, 730 cm-1. 
EIMS (70 eV) m/z 383 (M+•, 31%), 327 (36), 299 (40), 268 (74), 240, (100).  
HRMS Found: M+•, 383.1729. C22H25NO5 requires M+•, 383.1733. 
 
5.2.4 General Procedure for Synthesis of Cyclic Arylated Trimethyl Silyl 
Enol Ethers 143 – 145 
 
A magnetically stirred solution of diisopropylamine (0.50 mL, 3.53 mmol) and 
chlorotrimethylsilane (0.24 mL, 1.77 mmol) in DMF (2 mL) at 18°C under a nitrogen 
atmosphere was treated with a solution of the appropriate α-arylated cyclic ketone (1.00 
mmol) in DMF (2 mL). The resulting mixture was heated to 110°C and stirred at this 
temperature for 3 h then cooled and diluted with pentane
 
(2 x 50 mL). The combined 
organic phases were washed with NaHCO3 (3 x 25 mL of a saturated aqueous solution), 
then dried (MgSO4), filtered and concentrated under reduced pressure to give a clear, 
yellow oil. Subjection of this material to flash chromatography (silica, 0 → 10% v/v 
ethyl acetate/petroleum spirit gradient elution) provided, after concentration of the 
appropriate fractions, the relevant arylated trimethyl silyl enol ether as a clear oil. 
 
1. py., CHCl3, 18oC, 0.5 h
2. (99), 40oC, 12 h
O OCO2Me
CO2Me
N
Boc(79) (110)
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Methyl 1-phenyl-2-(trimethyl-silanoxy)-cyclopent-2-ene carboxylate (143) 
 
Yield 72% 
Rf 0.3 (silica, 5:95 v/v ethyl acetate/hexane). 
1H NMR (300 MHz) δ 7.32–7.28 (complex m, 5H), 4.89 (t, J = 2.5 Hz, 1H), 3.71 (s, 
3H), 2.84–2.77 (complex m, 1H), 2.33 (complex m, 3H), 0.16 (s, 9H). 
13C NMR (75 MHz) δ 174.8 (C=O), 153.5 (C), 141.8 (C), 128.0 (CH), 127.2 (CH), 
126.6 (CH), 104.8 (CH), 63.7 (C), 52.2 (CH3), 37.0 (CH2), 26.0 (CH2), -0.2 (CH3). 
IR (NaCl, film) νmax 2954, 1732 (C=O), 1645, 1435, 1253, 872, 698 cm-1. 
EIMS (EI, 70eV) m/z 290 (M+•, 9%), 231 (100), 218 (29).  
HRMS Found: M+•, 290.1337. C16H22O3Si requires M+•, 290.1338. 
 
Methyl 1-(2-methoxyphenyl)-2-(trimethyl–silanoxy)-cyclopent-2-ene 
carboxylate (144) 
 
Yield 96% 
Rf 0.4 (silica, 1:9 v/v ethyl acetate/hexane). 
1H NMR (300 MHz) δ 7.32–7.23 (complex m, 2H), 6.98–6.87 (complex m, 2H), 5.02 
(t, J = 2.3 Hz, 1H), 3.79 (s, 3H), 3.67 (s, 3H), 3.16–3.09 (complex m, 1H), 2.37–2.35 
(complex m, 1H), 2.17–2.13 (complex m, 1H), 1.92–1.87 (complex m, 1H), 0.26 (s, 
9H). 
13C NMR (75 MHz) δ 174.8 (C=O), 156.7 (C), 152.3 (C), 131.5 (C), 127.7 (CH), 127.3 
(CH), 120.2 (CH), 110.7 (CH), 106.1, (CH), 61.4 (C), 55.1 (CH3), 51.8 (CH3), 34.9 
(CH2), 25.7 (CH2), -0.3 (CH3). 
IR (NaCl, film) νmax 2955, 1732 (C=O), 1646, 1491, 1246, 1030, 871 cm-1. 
EIMS (70 eV) m/z 320 (M+•, 30%), 305 (12), 261 [(M–CO2Me•)+, 100]. 
HRMS Found: M+•, 320.1444. C17H24O4Si requires M+•, 320.1444. 
 
CO2Me
TMSO
CO2Me
O
(71) (143)
TMSCl, i-Pr2NH,
DMF, 110oC, 3 h
CO2Me
TMSO
MeO
CO2Me
O
MeO
(101) (144)
TMSCl, i-Pr2NH,
DMF, 110oC, 3 h
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1-tert-Butoxycarbonyl-5-(1-carbomethoxy-2-trimethyl-silanoxy-cyclopent-
2-enyl)-1H-indole (145) 
 
Yield 72% 
Rf 0.5 (silica, 1:9 v/v ethyl acetate/hexane). 
1H NMR (300 MHz) δ 8.08 (d, J = 8.7 Hz, 1H), 7.58 (d, J = 3.7 Hz, 1H), 7.51 (d, J = 
1.9 Hz, 1H), 7.25 (dd, J = 8.7 and 1.9 Hz, 1H), 6.54 (d, J = 3.7 Hz, 1H), 4.92 (t, J = 2.2 
Hz, 1H), 3.72 (s, 3H), 2.94–2.84 (complex m, 1H), 2.40–2.29 (complex m, 3H), 1.67 (s, 
9H), 0.19 (s, 9H). 
13C NMR (75 MHz) δ 175.0 (C=O), 153.8 (C), 149.8 (C=O), 136.3 (CH), 133.7 (C), 
130.3 (C), 125.9 (C), 123.8 (CH), 119.2 (CH), 114.7 (CH), 107.5 (CH), 104.8 (CH), 
83.5 (C), 63.6 (C), 52.2 (CH3), 37.3 (CH2), 28.1 (CH3), 25.9 (CH2), -0.1 (CH3). 
IR (NaCl, film) νmax 2955, 1732 (C=O), 1645, 1470, 1327, 1164, 846 cm-1. 
EIMS (70 eV) m/z 429 (M+•, 23%), 370 (40), 314 (100), 270 (65). 
HRMS Found: M+•, 429.1963. C23H31NO5Si requires M+•, 429.1972. 
 
5.2.5 General Procedure for Synthesis of Cyclic α-Arylated Enones 146 - 
148 
 
Following a procedure developed by Saegusa et al,9 a magnetically stirred solution of 
Pd(OAc)2 (112 mg, 0.50 mmol) and p-benzoquinone (54.0 mg, 0.50 mmol) in 
acetonitrile (5 mL) at 18°C under a nitrogen atmosphere was treated with the 
appropriate cyclic α-arylated trimethyl silyl enol ether (1.00 mmol). Stirring was 
continued at 18°C for 3 h then the solvent was then evaporated under reduced pressure. 
Subjection of this material to flash chromatography (silica, 40% v/v ethyl 
acetate/petroleum spirit elution) provided, after concentration of the appropriate 
fractions, the relevant cyclic α-arylated enone as either a clear, yellow oil or solid.  
 
 
 
 
 
CO2Me
TMSO
CO2Me
O N
Boc
N
Boc
(102) (145)
TMSCl, i-Pr2NH,
DMF, 110oC, 3 h
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Methyl 2-oxo-1-phenylcyclopent-3-ene carboxylate (146)  
 
Clear, yellow oil 
Yield 97% 
Rf 0.5 (silica, 3:7 v/v ethyl acetate/hexane). 
1H NMR (300 MHz) δ 7.81 (complex m, 1H), 7.35–7.28 (complex m, 5H), 6.26 
(complex m, 1H), 3.83 (dt, J = 19.1 and 2.5 Hz, 1H), 3.74 (s, 3H), 3.07 (dt, J = 19.1 and 
2.5 Hz, 1H). 
13C NMR (75 MHz) δ 203.3 (C=O), 170.5 (C=O), 163.2 (CH), 138.6 (C), 132.1 (CH), 
128.7 (CH), 127.5 (CH), 127.1 (CH), 62.7 (C), 53.3 (CH3), 43.6 (CH2).  
IR (NaCl, film) νmax 2954, 1738 (C=O), 1709 (C=O), 1594, 1207, 1154, 698 cm-1.  
EIMS (70eV) m/z 216 (M+•, 66%), 188 (7), 184 (27), 156 (100). 
HRMS Found: M+•, 216.0784. C13H12O3 requires M+•, 216.0786. 
 
Methyl 1-(2-methoxyphenyl)-2-oxocyclopent-3-ene carboxylate (147) 
 
Yellow solid 
Yield 61% 
Rf 0.5 (silica, 3:7 v/v ethyl acetate/hexane). 
m.p. 77–79°C. 
1H NMR (300 MHz) δ 7.79 (complex m, 1H), 7.26 (t, J = 7.7 Hz, 1H), 7.06 (d, J = 6.6 
Hz, 1H), 6.90 (t, J = 7.7 Hz, 2H), 6.24 (complex m, 1H), 3.99 (dt, J = 19.9 and 2.2 Hz, 
1H), 3.78 (s, 3H), 3.68 (s, 3H), 2.68 (dt, J = 19.9 and 2.2 Hz, 1H). 
13C NMR (75 MHz) δ 204.2 (C=O), 170.2 (C=O), 164.7 (CH), 157.1 (C), 131.5 (CH), 
129.0 (C), 128.6 (CH), 127.1 (CH), 120.6 (CH), 110.9 (CH), 61.2 (C), 55.3 (CH3), 53.0 
(CH3), 43.5 (CH2). 
IR (NaCl, film) νmax 2951, 1729 (C=O), 1708 (C=O), 1492, 1256, 1154, 755 cm-1. 
EIMS (70 eV) m/z 246 (M+•, 100%), 214 (56), 186 (94), 171 (26).  
(143) (146)
CO2Me CO2Me
Pd(OAc)2, p-BQ, 
MeCN, 18oC., 3 h
OTMSO
CO2Me CO2MePd(OAc)2, p-BQ, 
MeCN, 18oC, 3 h
OTMSO
MeO MeO
(144) (147)
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HRMS Found: M+•, 246.0890. C14H14O4 requires M+•, 246.0892. 
 
1-tert-Butoxycarbonyl-5-(1-carbomethoxy-2-oxo-cyclopent-3-enyl)-1H-
indole (148) 
 
Clear, yellow oil 
Yield 60% 
Rf 0.4 (silica, 3:7 v/v ethyl acetate/hexane). 
1H NMR (300 MHz) δ 8.08 (d, J = 8.9 Hz, 1H), 7.80 (dt, J = 5.8 and 2.5 Hz, 1H), 7.58 
(d, J = 3.6 Hz, 1H), 7.53 (d, J = 2.0 Hz, 1H), 7.22 (dd, J = 8.9 and 2.0 Hz, 1H), 6.52 (d, 
J = 3.6 Hz, 1H), 6.27 (dt, J = 5.8 and 2.5 Hz, 1H), 3.87 (dt, J = 19.6 and 2.7 Hz, 1H), 
3.73 (s, 3H), 2.68 (dt, J = 19.6 and 2.7 Hz, 1H), 1.62 (s, 9H). 
13C NMR (75 MHz) δ 203.6 (C=O), 170.9 (C=O), 163.1 (CH), 149.6 (C=O), 133.8 (C), 
133.0 (CH), 132.1 (C), 130.6 (C), 126.4 (CH), 123.6 (CH), 119.3 (CH), 115.4 (CH), 
107.4 (CH), 83.8 (C), 62.5 (C), 53.3 (CH3), 44.0 (CH2), 28.1 (CH3). 
IR (NaCl, film) νmax 2979, 1733 (C=O), 1371, 1257, 1166, 766 cm-1. 
EIMS (70 eV) m/z 355 (M+•, 20%), 299 (49), 255 (21), 239 (24), 195 (34), 57 (100). 
HRMS Found: M+•, 355.1419. C20H21NO5 requires M+•, 355.1420. 
 
5.2.6 General Procedure for Synthesis of α′-Iodinated Cyclic Enones 138, 
149 - 159 
 
Following a procedure developed by Johnson et al,10 a magnetically stirred and cooled 
(ice/water bath) solution of the appropriate α-arylated cyclic enone (1.00 mmol) in 1:1 
v/v pyridine/CCl4 (4 mL) maintained under a nitrogen atmosphere was treated, 
dropwise, with a solution of molecular iodine (1.02 g, 4.00 mmol) dissolved in 
pyridine/CCl4 (4 mL of a 1:1 v/v/ mixture). The resulting mixture was warmed to 18°C 
and stirred at this temperature for 16 h, then diluted with ether (1 x 100 mL). The 
organic phase was washed with HCl (2 x 50 mL of a 1 M aqueous solution), distilled 
water (1 x 50 mL) and Na2SO3 (1 x 50 mL of a 1 M solution). The separated organic 
phase was then dried (MgSO4), filtered and concentrated under reduced pressure to give 
a clear, yellow oil. Subjection of this material to flash chromatography (silica, 10 → 
CO2Me CO2Me
Pd(OAc)2, p-BQ, 
MeCN, 18oC, 3 h
N
BocNBoc
OTMSO
(145) (148)
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30% v/v ethyl acetate/hexane gradient elution) provided, after concentration of the 
appropriate fractions, the relevant α′-iodinated cyclic enone as either a clear, yellow oil 
or colourless solid.  
 
Methyl 3-iodo-2-oxo-1-phenylcyclopent-3-ene carboxylate (149) 
 
Clear, yellow oil  
Yield 60% 
Rf 0.5 (silica, 3:7 v/v ethyl acetate/hexane). 
1H NMR (300 MHz) δ 8.09 (t, J = 3.0 Hz, 1H), 7.35-7.28 (complex m, 5H), 3.86 (dd, J 
= 22.2 and 3.0 Hz, 1H), 3.74 (s, 3H), 3.13 (dd, J = 22.2 and 3.0 Hz, 1H).  
13C NMR (75 MHz) δ 197.8 (C=O), 169.8 (C=O), 167.8 (CH), 137.8 (C), 128.8 (CH), 
127.8 (CH), 127.0 (CH), 99.3 (C), 60.1 (C), 53.6 (CH3), 45.6 (CH2).  
IR (NaCl, film) νmax 2961, 2921, 1744 (C=O), 1720 (C=O), 1580, 1261, 800 cm-1. 
EIMS (70 eV) m/z 342 (M+•, 25%), 283 (39), 215 (58), 183 (100).  
HRMS Found: M+•, 341.9750. C13H11127IO3 requires M+•, 241.9753. 
 
Methyl 3-iodo-1-(2-methoxyphenyl)-2-oxocyclopent-3-ene carboxylate 
(150) 
 
Clear, yellow oil 
Yield 96% 
Rf 0.5 (silica, 3:7 v/v ethyl acetate/hexane).  
1H NMR (300 MHz) δ 7.98 (t, J = 3.0 Hz, 1H), 7.22–7.20 (complex m, 1H), 6.91–6.80 
(complex m, 3H), 3.95 (dd, J = 18.7 and 3.0 Hz, 1H), 3.71 (s, 3H), 3.62 (s, 3H), 2.68 
(dd, J = 18.7 and 3.0 Hz, 1H).  
CO2Me CO2Me
I2, (1:1 v/v) CCl4/py., 
0oC to  18oC, 16 h
I
OO
(146) (149)
CO2Me CO2MeI2, (1:1 v/v) CCl4/py.,
0oC to 18oC, 16 h
I OO MeOMeO
(147) (150)
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13C NMR (75 MHz) δ 198.5 (C=O), 169.5 (C=O), 169.1 (CH), 156.8 (C), 129.0 (CH), 
128.2 (C), 127.2 (CH), 120.8 (CH), 111.1 (CH), 98.2 (C), 58.9 (C), 55.4 (CH3), 53.3 
(CH3), 45.6 (CH2).  
IR (NaCl, film) νmax 2951, 1716 (C=O), 1493, 1255, 1027, 754 cm-1. 
EIMS (70 eV) m/z 372 (M+•, 46%), 340 (10), 313 (39), 245 (31). 213 (100).  
HRMS Found: M+•, 371.9862. C14H13127IO4 requires M+•, 371.9859. 
 
1-tert-Butoxycarbonyl-3-iodo-5-(1-carbomethoxy-2-oxocyclopent-3-enyl)-
1H-indole (151) 
 
Clear, yellow oil 
Yield 93% 
Rf 0.2 (silica, 1:9 v/v ethyl acetate/hexane). 
1H NMR (300 MHz) δ 8.10–8.08 (complex m, 2H), 7.59 (d, J = 3.7 Hz, 1H), 7.50 (s, 
1H), 7.20 (dd, J = 8.7 and 1.8 Hz, 1H), 6.53 (d, J = 3.7 Hz, 1H), 3.93 (dd, J = 19.3 and 
2.8 Hz, 1H), 3.73 (s, 3H), 3.18 (dd, J = 19.3 and 2.8 Hz, 1H), 1.66 (s, 9H).  
13C NMR (75 MHz) δ 198.1 (C=O), 170.1 (C=O), 167.8 (CH), 149.5 (C=O), 134.3 (C), 
132.1 (C), 130.7 (C), 126.6 (CH), 123.3 (CH), 119.3 (CH), 115.6 (CH), 107.4 (CH), 
99.3 (C), 83.9 (C), 59.9 (C), 53.3 (CH3), 46.0 (CH2), 28.1 (CH3).  
IR (NaCl, film) νmax 2978, 1732 (C=O), 1371, 1259, 1167, 730 cm-1. 
EIMS (70 eV) m/z 481 (M+•, 31%), 425 (63), 381 (29), 322 (26), 266 (41), 57 (100).  
HRMS Found: M+•, 481.0390. C20H20127INO5 requires M+•, 481.0386. 
 
Methyl 3-iodo-2-oxo-1-phenyl-cyclohex-3-ene carboxylate (138) 
 
Clear, yellow oil 
Yield 60% 
CO2Me CO2MeI2, (1:1 v/v) CCl4/py.,
0oC to 18oC, 16 h
N
Boc
N
Boc
OO
I
(148) (151)
I2, (1:1 v/v) CCl4/py.,
 0oC to 18oC, 16 h
O
I
O
CO2Me CO2Me
(76) (138)
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Rf 0.6 (silica, 3:7 v/v ethyl acetate/hexane). 
1H NMR (300 MHz) δ 7.58 (t, J = 3.9 Hz, 1H), 7.39–7.33 (complex m, 3H), 7.15–7.12 
(complex m, 2H), 3.73 (s, 3H), 2.91–2.86 (complex m, 1H), 2.69–2.64 (complex m, 
1H), 2.52–2.50 (complex m, 1H), 2.43–2.31 (complex m, 1H).  
13C NMR (75 MHz) δ 189.0 (C=O), 171.0 (C=O), 158.1 (CH), 135.3 (C), 128.5 (CH), 
128.0 (CH), 127.3 (CH), 101.6 (C), 62.5 (C), 53.0 (CH3), 31.5 (CH2), 27.6 (CH2).  
IR (NaCl, film) νmax 2951, 1734 (C=O), 1689 (C=O), 1447, 1247, 1048, 698 cm-1. 
EIMS (70 eV) m/z 356 (M+•, 51%), 297 (11), 194 (100).  
HRMS Found: M+•, 355.9906. C14H13127IO3 requires M+•, 322.9910. 
 
Methyl 3-iodo-1-(2-methoxyphenyl)-2-oxo-cyclohex-3-ene carboxylate 
(152) 
 
Clear, yellow oil 
Yield 60% 
Rf 0.2 (silica, 1:9 v/v ethyl acetate/hexane).  
1H NMR (300 MHz) δ 7.66 (t, J = 3.7 Hz, 1H), 7.32–7.27 (complex m, 1H), 6.92–6.78 
(complex m, 3H), 3.76 (s, 3H), 3.72 (s, 3H), 2.88–2.82 (complex m, 1H), 2.72–2.66 
(complex m, 1H), 2.44–2.33 (complex m, 1H), 2.13–2.04 (complex m, 1H). 
13C NMR (75 MHz) δ 189.2 (C=O), 171.2 (C=O), 158.6 (CH), 157.0 (C), 129.2 (CH), 
127.7 (CH), 126.0 (C), 120.6 (CH), 111.8 (CH), 102.3 (C), 61.4 (C), 55.6 (CH3), 52.6 
(CH3), 30.6 (CH2), 27.8 (CH2).  
IR (NaCl, film) νmax 2950, 1733 (C=O), 1689 (C=O), 1493, 1251, 1022, 752 cm-1. 
EIMS (70 eV) m/z 386 (M+•, 77%), 326 (46), 192 (100). 
HRMS Found: M+•, 386.0017. C15H15127IO4 requires M+•, 386.0015. 
 
 
 
 
 
 
I2, (1:1 v/v) CCl4/py., 
0oC to 18oC, 16 h
O
I
CO2Me
MeO
O
CO2Me
MeO
(103) (152)
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Methyl 3-iodo-1-(2,3,4-trimethoxyphenyl)-2-oxo-cyclohex-3-ene 
carboxylate (153) 
 
Clear, yellow oil 
Yield 75% 
Rf 0.5 (silica, 3:2 v/v ethyl acetate/hexane). 
1H NMR (300 MHz) δ 7.56 (t, J = 4.1 Hz, 1H), 6.51 (complex m, 2H), 3.77 (s, 6H), 
3.73 (s, 3H), 3.69 (s, 3H), 2.70–2.58 (complex m, 2H), 2.32–2.30 (complex m, 1H), 
2.14–2.05 (complex m, 1H). 
13C NMR (75 MHz) δ 188.8 (C=O), 171.0 (C=O), 157.9 (CH), 153.4 (C), 151.5 (C), 
141.7 (C), 123.3 (C), 121.5 (CH), 106.0 (CH), 102.0 (C), 60.7 (C), 60.3 (CH3), 60.1 
(CH3), 55.6 (CH3), 52.5 (CH3), 31.4 (CH2), 27.6 (CH2). 
IR (NaCl, film) νmax 2945, 1734 (C=O), 1692 (C=O), 1495, 1235, 1074, 735 cm-1. 
EIMS (70 eV) m/z 446 (M+•, 100%), 259 (67), 252 (72).  
HRMS Found: M+•, 446.0229. C17H19127IO6 requires M+•, 446.0226. 
 
Methyl 3-iodo-1-(3,4,5-trimethoxyphenyl)-2-oxo-cyclohex-3-ene 
carboxylate (154) 
 
Colourless solid 
Yield 98% 
Rf 0.4 (silica, 3:2 v/v ethyl acetate/hexane).  
m.p. 81–83°C.  
1H NMR (300 MHz) δ 7.49 (t, J = 4.1 Hz, 1H), 6.23 (s, 2H), 3.75 (s, 3H), 3.73 (s, 6H), 
3.66 (s, 3H), 2.83–2.76 (complex m, 1H), 2.60–2.54 (complex m, 1H), 2.39–2.27 
(complex m, 2H).  
I2, (1:1 v/v) CCl4/py., 
0oC to 18oC, 16 h
O
I
CO2Me
MeO
O
CO2Me
MeO
OMe
OMe
OMe
OMe
(104) (153)
I2, (1:1 v/v) CCl4/py., 
0oC to 18oC, 16 h
O
I
CO2Me
O
CO2Me
OMe
OMe
OMe
OMe
OMeOMe
(105) (154)
 143
13C NMR (75 MHz) δ 188.9 (C=O), 170.6 (C=O), 158.0 (C), 152.7 (CH), 137.4 (C), 
130.3 (C), 104.6 (CH), 101.0 (C), 62.1 (C), 60.4 (CH3), 55.8 (CH3), 52.7 (CH3), 31.1 
(CH2), 27.5 (CH2).  
IR (NaCl, film) νmax 2922, 1735 (C=O), 1686 (C=O), 1590, 1257, 1129 cm-1. 
EIMS (70 eV) m/z 446 (M+•, 85%), 252 (100).  
Elemental Analysis Found: C, 45.79, H, 4.45, I, 30.52. Calcd: C17H19IO6, C, 45.76, H, 
4.29, I, 28.44%. 
 
1-tert-Butoxycarbonyl-3-iodo-5-(1-carbomethoxy-2-oxocyclohex-3-enyl)-
1H-indole (155) 
 
Clear, yellow oil 
Yield 73% 
Rf 0.7 (silica, 3:7 v/v ethyl acetate/hexane).  
1H NMR (300 MHz) δ 8.10 (d, J = 8.8 Hz, 1H), 7.60 (d, J = 3.6 Hz, 1H), 7.54 (t, J = 
4.1 Hz, 1H), 7.29 (s, 1H), 7.10 (d, J = 8.2 Hz, 1H), 6.54 (d, J = 3.6 Hz, 1H), 3.71 (s, 
3H), 2.94–2.71 (complex m, 1H), 2.49–2.41 (complex m, 1H), 2.33–2.24 (complex m, 
2H), 1.66 (s, 9H).  
13C NMR (75 MHz) δ 189.4 (C=O), 171.4 (C=O), 158.1 (CH), 149.5 (C=O), 134.4 (C), 
130.5 (C), 129.2 (C), 126.5 (CH), 123.4 (CH), 119.8 (CH), 115.5 (CH), 107.3 (CH), 
101.5 (C), 83.8 (C), 62.4 (C), 52.9 (CH3), 31.5 (CH2), 28.0 (CH3), 27.6 (CH2).  
IR (NaCl, film) νmax 2954, 1732 (C=O), 1471, 1258, 1166, 731 cm-1. 
EIMS m/z 495 (M+•, 13%), 439 (27), 395 (19), 201 (100).  
HRMS Found: M+•, 495.0546. C21H22127INO5 requires M+•, 495.0543. 
 
 
 
 
 
 
I2, (1:1 v/v) CCl4/py., 
0oC to 18oC, 16 h
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1-tert-Butoxycarbonyl-3-iodo-5-(1-carbomethoxy-2-oxocyclohex-3-enyl)-6-
methoxy-1H-indole (156) 
 
Clear, yellow oil 
Yield 70% 
Rf 0.5 (silica, 3:7 v/v ethyl acetate/hexane).  
1H NMR (300 MHz) δ 7.76 (s, 1H), 7.65 (t, J = 4.3 Hz, 1H), 7.43 (d, J = 3.7 Hz, 1H), 
6.92 (s, 1H), 6.43 (d, J = 3.7 Hz, 1H), 3.82 (s, 3H), 3.70 (s, 3H), 2.88–2.83 (complex m, 
1H), 2.71–2.69 (complex m, 1H), 2.38–2.35 (complex m, 1H), 2.09–2.06 (complex m, 
1H), 1.64 (s, 9H).  
13C NMR (75 MHz) δ 190.0 (C=O), 171.5 (C=O), 159.5 (C), 159.0 (CH), 155.0 (C), 
149.5 (C=O), 124.7 (CH), 123.3 (C), 121.7 (CH), 119.8 (CH), 107.2 (C), 102.3 (C), 
99.0 (CH), 83.6 (C), 61.6 (C), 55.8 (CH3), 52.5 (CH3), 30.6 (CH2), 28.0 (CH3), 27.8 
(CH2).  
IR (NaCl, film) νmax 2925, 1732 (C=O), 1684 (C=O), 1473, 1369, 1155 cm-1. 
EIMS (70 eV) m/z 525 (M+•, 24%), 469 (100), 275 (27)  
HRMS Found: M+•, 525.0649. C22H24127INO6 requires M+•, 525.0648. 
 
Methyl 3-iodo-2-oxo-1-phenyl-cyclohept-3-ene carboxylate (157) 
 
Clear, yellow oil 
Yield 58% 
Rf 0.2 (silica, 1:9 v/v ethyl acetate/hexane).  
1H NMR (300 MHz) δ 7.39–7.23 (complex m, 5H), 7.10 (t, J = 5.0 Hz, 1H), 3.73 (s, 
3H), 2.89–2.79 (complex m, 1H), 2.42–2.33 (complex m, 2H), 2.27–2.22 (complex m, 
1H), 2.00–1.83 (complex m, 2H).  
I2, (1:1 v/v) CCl4/py.,
 0oC to 18oC, 16 h
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13C NMR (75 MHz) δ 196.4 (C=O), 171.9 (C=O), 149.7 (CH), 137.8 (C), 128.7 (CH), 
128.3 (CH), 128.0 (CH), 99.1 (C), 67.8 (C), 52.8 (CH3), 33.0 (CH2), 32.9 (CH2), 22.9 
(CH2).  
IR (NaCl, film) νmax 2924, 2853, 1739 (C=O), 1447, 1238, 698 cm-1. 
EIMS (70 eV) m/z 310 [(M–CO2Me•)+, 9], 243 (24), 155 (100). 
HRMS Found: (M–CO2Me•)+, Found 310.9934. C13H12127IO2 requires (M–CO2Me•)+, 
310.9933. 
 
Methyl 3-iodo-2-oxo-1-(2-methoxyphenyl)-2-cyclohept-3-ene carboxylate 
(158) 
 
Clear, yellow oil 
Yield 68% 
Rf 0.5 (silica, 3:7 v/v ethyl acetate/hexane). 
1H NMR (300 MHz) δ 7.32–7.22 (complex m, 2H), 7.04–6.89 (complex m, 3H), 3.78 
(s, 3H), 3.73 (s, 3H), 2.66–2.43 (complex m, 2H), 2.24 (p, J = 6.1 Hz, 1H), 1.90–1.63 
(complex m, 3H).  
13C NMR (75 MHz) δ 195.7 (C=O), 171.5 (C=O), 156.9 (C), 149.7 (CH), 129.0 (CH), 
128.2 (C), 127.7 (CH), 120.6 (CH), 111.8 (CH), 102.6 (C), 65.4 (C), 55.7 (CH3), 52.6 
(CH3), 32.2 (CH2), 31.0 (CH2), 21.9 (CH2).  
IR (NaCl, film) νmax 2929, 1733 (C=O), 1691 (C=O), 1493, 1250, 1026, 754 cm-1. 
EIMS (70 eV) m/z 400 (M+•, 16%), 313 (5), 274 (14) 213 (100). 
HRMS Found: M+•, 400.0176. C16H17127IO4 requires M+•, 400.0172. 
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1-tert-Butoxycarbonyl-3-iodo-2-oxocyclohept-3-enyl-1H-indole-1-
carboxylate (159) 
 
Clear, yellow oil 
Yield 61% 
Rf 0.3 (silica, 1:9 v/v ethyl acetate/hexane).  
1H NMR (300 MHz) δ 8.08 (d, J = 8.7 Hz, 1H), 7.59 (d, J = 3.7 Hz, 1H), 7.44 (d, J = 
1.9 Hz, 1H), 7.20 (dd, J = 8.7 and 1.9 Hz, 1H), 7.08 (t, J = 5.6 Hz, 1H), 6.55 (d, J = 3.7 
Hz, 1H), 3.70 (s, 3H), 2.88–2.83 (complex m, 1H), 2.51–2.44 (complex m, 1H), 2.35–
2.31 (complex m, 1H), 2.23–2.19 (complex m, 1H), 1.99–1.87 (complex m, 2H), 1.66 
(s, 9H). 
13C NMR (75 MHz) δ 196.8 (C=O), 171.1 (C=O), 149.7 (CH), 149.5 (C=O), 134.2 (C), 
131.7 (C), 130.3 (C), 126.4 (CH), 124.3 (CH), 120.4 (CH), 114.8 (CH), 107.4 (CH), 
99.3 (C), 83.8 (C), 67.5 (C), 52.7 (CH3), 32.8 (CH2), 31.6 (CH2), 28.0 (CH3), 22.7 
(CH2).  
IR (NaCl, film) νmax 2931, 1736 (C=O), 1469, 1371, 1164, 731 cm-1. 
EIMS (70 eV) m/z 509 (M+•, 53%), 453 (20), 409 (17), 350 (19), 326 (56), 298 (75), 
266 (60), 222 (66), 194 (100). 
HRMS Found: M+•, 509.0701. C22H24127INO5 requires M+•, 509.0699. 
 
5.2.7 General Procedure for Pd[0]-catalysed Ullmann Cross-Coupling  
 
Following a procedure developed by Banwell et al,11 a magnetically stirred mixture of 
o-iodonitrobenzene (137) (518 mg, 2.00 mmol), the appropriate α′-iodinated cyclic 
ketone (1.00 mmol), copper powder (310 mg of 99% material, CAS No. 7440-50-8, 
5.00 mmol) and Pd2(dba)3 (10.0 mg, 10.0 µmol) in DMSO (8 mL) all maintained under 
a nitrogen atmosphere, was heated to 75°C and stirred at this temperature for 2 – 3 h, 
then cooled and diluted with ether (30 mL). The resulting mixture was then filtered 
through a pad of Celite and the solids thus retained washed with ether (1 x 80 mL). 
The combined filtrates were washed with distilled water (2 x 50 mL) and brine (1 x 50 
I2, (1:1 v/v) CCl4/py.,
 0oC to 18oC, 16 h
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mL) and the separated organic phase was then dried (MgSO4), filtered and concentrated 
under reduced pressure to give a clear, yellow oil. Subjection of this material to flash 
chromatography (silica, 10 → 40% v/v ethyl acetate/hexane gradient elution) provided, 
after concentration of the appropriate fractions, the relevant Ullmann cross-coupling 
product as either a clear, yellow oil or solid.  
 
Methyl 1-phenyl-3-(2-nitrophenyl)-2-oxocyclopent-3-ene carboxylate (160) 
 
Clear, yellow oil 
Yield 60% 
Rf 0.2 (silica, 3:7 v/v ethyl acetate/hexane). 
1H NMR (300 MHz) δ 8.07 (dd, J = 8.1 and 1.2 Hz, 1H), 7.78 (t, J = 2.9 Hz, 1H), 7.64 
(td, J = 7.5 and 1.2 Hz, 1H), 7.53 (td, J = 8.1 and 1.2 Hz, 1H), 7.39–7.29 (complex m, 
6H), 3.97 (dd, J =19.5 and 3.0 Hz, 1H), 3.77 (s, 3H), 3.13 (dd, J = 19.5 and 3.0 Hz, 1H).  
13C NMR (75 MHz) δ 198.9 (C=O), 170.0 (C=O), 157.2 (CH), 148.3 (C), 141.9 (C), 
138.3 (C), 133.2 (CH), 131.6 (CH), 129.7 (CH), 128.8 (CH), 127.5 (CH), 127.3 (CH), 
126.7 (C), 124.8 (CH), 63.7 (C), 55.5 (CH3), 41.9 (CH2).  
IR (NaCl, film) νmax 2954, 1746 (C=O), 1722 (C=O), 1526 (NO2), 1353, 699 cm-1. 
EIMS (70 eV) m/z 337 (M+•, >1%), 305 [(M–CH3OH)+, 100], 278 (28), 204 (52).  
HRMS Found: M+•, 337.0958. C19H15NO5 requires M+•, 337.0950. 
 
Methyl 1-(2-methoxyphenyl)-3-(2-nitrophenyl)-2-oxocyclopent-3-ene 
carboxylate (161) 
 
 
Clear, yellow oil 
Yield 58% 
Rf 0.2 (silica, 3:7 v/v ethyl acetate/hexane).  
CO2Me CO2Me
OOI
o-iodonitrobenzene
Pd2(dba)3, Cu, DMSO, 75oC, 2 h
NO2
MeO MeO
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1H NMR (300 MHz) δ 8.07 (d, J = 8.5 Hz, 1H), 7.78 (t, J = 2.6 Hz, 1H), 7.64 (t, J = 7.6 
Hz, 1H), 7.53 (t, J = 7.6 Hz, 1H), 7.40 (d, J = 7.6 Hz, 1H), 7.29 (t, J = 6.6 Hz, 1H), 7.22 
(d, J = 6.6 Hz, 1H), 6.97 (t, J = 7.6 Hz, 1H), 6.90 (d, J = 8.5 Hz, 1H), 4.09 (dd, J =19.8 
and 2.8 Hz, 1H), 3.80 (s, 3H), 3.71 (s, 3H), 2.81 (dd, J = 19.8 and 2.8 Hz, 1H).  
13C NMR (75 MHz) δ 199.7 (C=O), 170.0 (C=O), 158.8 (CH), 157.0 (C), 148.4 (C), 
141.4 (C), 133.2 (CH), 131.7 (CH), 129.5 (CH), 128.8 (C), 128.6 (CH), 127.5 (CH), 
127.0 (C), 124.8 (CH), 121.0 (CH), 111.0 (CH), 62.2 (C), 55.5 (CH3), 55.3 (CH3), 41.8 
(CH2).  
IR (NaCl, film) νmax 2952, 1714 (C=O), 1527 (NO2), 1354, 1248, 732 cm-1. 
EIMS (70 eV) m/z 367 (M+•, 35%), 335 (67), 308 (54), 290 (18), 135 (100).  
HRMS Found: M+•, 367.1053. C20H17NO6 requires M+•, 367.1056. 
 
1-tert-Butoxycarbonyl-3-(2-nitrophenyl)-5-(1-carbomethoxy-2-oxo 
cyclopent-3-enyl)-1H-indole (162) 
 
Clear, yellow oil 
Yield 86% 
Rf 0.3 (silica, 3:7 v/v ethyl acetate/hexane).  
1H NMR (300 MHz) δ 8.10 (complex m, 2H), 7.79 (t, J = 2.8 Hz, 1H), 7.65 – 7.52 
(complex m, 4H), 7.39 (dd, J = 7.6 and 1.9 Hz, 1H), 7.29 (d, J = 1.9 Hz, 1H), 6.55 (d, J 
= 3.7 Hz, 1H), 4.04 (dd, J = 19.2 and 3.0 Hz, 1H), 3.77 (s, 3H), 3.19 (dd, J = 19.2 and 
3.0 Hz, 1H), 1.66 (s, 9H).  
13C NMR (75 MHz) δ 199.1 (C=O), 170.3 (C=O), 157.1 (CH), 149.6 (C), 148.4 (C=O), 
141.9 (C), 134.2 (C), 133.2 (CH), 132.7 (C), 131.6 (CH), 130.7 (C), 129.6 (CH), 126.8 
(C), 126.5 (CH), 124.8 (CH), 123.5 (CH), 119.5 (CH), 115.5 (CH), 107.6 (CH), 83.8 
(C), 63.6 (C), 53.5 (CH3), 42.3 (CH2), 28.1 (CH3). 
IR (NaCl, film) νmax 2925, 1732 (C=O), 1527 (NO2), 1470, 1370, 1258, 1141, 730 cm-1. 
EIMS (70 eV) m/z 476 (M+•, 56%), 316 (100). 
HRMS Found: M+•, 476.1584. C26H24N2O7 requires M+•, 476.1584. 
 
 
 
CO2Me CO2Me
OOI
o-iodonitrobenzene
Pd2(dba)3, Cu, DMSO, 75oC, 2 h
NO2
N
BocNBoc
(151) (162)
 149
Methyl 1-phenyl-3-(2-nitro-phenyl)-2-oxo-cyclohex-3-ene carboxylate 
(139) 
 
Clear, yellow solid 
Yield 58% 
Rf 0.2 (silica, 3:7 v/v ethyl acetate/hexane).  
m.p. 161–163°C.  
1H NMR (300 MHz) δ 8.02 (d, J = 6.5 Hz, 1H), 7.61 (t, J = 6.5 Hz, 1H), 7.49 (t, J = 6.5 
Hz, 1H), 7.39–7.19 (complex m, 6H), 6.94 (t, J = 4.0 Hz, 1H), 3.77 (s, 3H), 3.00–2.92 
(complex m, 1H), 2.77–2.63 (complex m, 2H), 2.53–2.44 (complex m, 1H). 
13C NMR (75 MHz) δ 191.8 (C=O), 171.1 (C=O), 146.5 (CH), 138.8 (C), 136.4 (C), 
133.1 (CH), 131.7 (CH), 131.5 (C), 129.0 (CH), 128.4 (CH), 127.8 (CH), 127.5 (CH), 
124.8 (CH), 100.0 (C), 62.8 (C), 52.9 (CH3), 32.1 (CH2), 24.1 (CH2).  
IR (NaCl, film) νmax 2927, 1733 (C=O), 1675 (C=O), 1525 (NO2), 1353, 700 cm-1. 
EIMS (70 eV) m/z 351 (M+•, >1%), 292 (13), 275 (55), 230 (36), 215 (16), 115 (100). 
HRMS Found: M+•, 351.1106. C20H17NO5 requires M+•, 351.1107. 
 
Methyl 1-(2-methoxyphenyl)-3-(2-nitrophenyl)-2-oxocyclohex-3-ene 
carboxylate (166) 
 
Yellow solid 
Yield 56% 
Rf 0.21 (silica, 3:7 v/v ethyl acetate/hexane). 
m.p. 156–158°C.  
1H NMR (300 MHz) δ 8.01 (d, J = 6.4 Hz, 1H), 7.61 (t, J = 6.4 Hz, 1H), 7.48 (t, J = 6.4 
Hz, 1H), 7.33–7.28 (complex m, 3H), 7.02 (m, 3H), 3.77 (s, 3H), 3.74 (s, 3H), 2.90–
2.60 (complex m, 3H), 2.37–2.35 (complex m, 1H).  
O
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13C NMR (75 MHz) δ 191.7 (C=O), 171.2 (C=O), 157.2 (C), 149.1 (C), 147.2 (CH), 
138.8 (C), 132.9 (CH), 131.8 (CH), 131.7 (C), 129.0 (CH), 128.8 (CH), 127.9 (CH), 
127.3 (C), 124.2 (CH), 120.6 (CH), 111.9 (CH), 61.7 (C), 55.6 (CH3), 52.6 (CH3), 30.8 
(CH2), 24.2 (CH2).  
IR (NaCl, film) νmax 2950, 1734 (C=O), 1678 (C=O), 1527 (NO2), 1251, 752 cm-1. 
EIMS (70 eV) m/z 381 (M+•, 27%), 349 (12), 322 (15), 305 (66), 276 (40), 145 (100). 
HRMS Found: M+•, 381.1213. C21H19NO6 requires M+•, 381.1212. 
 
Methyl 1-(2,3,4-trimethoxyphenyl)-3-(2-nitrophenyl)-2-oxocyclohex-3-ene 
carboxylate (167) 
 
Clear, yellow oil 
Yield 56% 
Rf (0.4 (silica, 3:2 v/v ethyl acetate/hexane). 
1H NMR (300 MHz) δ 7.96 (d, J = 8.1 Hz, 1H), 7.58 (t, J = 7.4 Hz, 1H), 7.45 (t, J = 8.1 
Hz, 1H), 7.29 (d, J = 7.4 Hz, 1H), 6.96 (t, J = 3.8 Hz, 1H), 6.70 (d, J = 8.8 Hz, 1H), 
6.57 (d, J = 8.8 Hz, 1H), 3.81 (s, 6H), 3.78 (s, 3H), 3.69 (s, 3H), 2.80–2.60 (complex m, 
3H), 2.41–2.38 (complex m, 1H). 
13C NMR (75 MHz) δ 191.6 (C=O), 171.2 (C=O), 153.4 (C), 151.8 (C), 148.9 (C), 
146.6 (CH), 141.9 (C), 138.7 (C), 132.9 (CH), 131.8 (CH), 131.7 (CH), 128.7 (C), 
124.5 (C), 124.0 (CH), 121.8 (CH), 106.2 (CH), 61.7 (C), 60.4 (CH3), 60.3 (CH3), 55.8 
(CH3), 52.5 (CH3), 31.8 (CH2), 24.1 (CH2).  
IR (NaCl, film) νmax 2947, 1734 (C=O), 1685 (C=O), 1527 (NO2), 1354, 1103 cm-1. 
EIMS (70 eV) m/z 441 (M+•, 65%), 409 (33), 348 (35), 157 (100). 
HRMS Found: M+•, 441.1422. C23H23NO8 requires M+•, 441.1424. 
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Methyl 1-(3,4,5-trimethoxyphenyl)-3-(2-nitrophenyl)-2-oxocyclohex-3-ene 
carboxylate (168) 
 
Clear, yellow oil 
Yield 56% 
Rf 0.4 (silica, 3:2 v/v ethyl acetate/hexane). 
1H NMR (300 MHz) δ 8.00 (dd, J = 8.1 and 1.3 Hz, 1H), 7.59 (td, J = 7.6 and 1.3 Hz, 
1H), 7.48 (td, J = 8.1 and 1.3 Hz, 1H), 7.24 (dd, J = 7.6 and 1.3 Hz, 1H), 6.99 (t, J = 4.0 
Hz, 1H), 6.42 (s, 2H), 3.83 (s, 3H), 3.81 (s, 6H), 3.75 (s, 3H), 2.91 (complex m, 1H), 
2.70–2.64 (complex m, 3H).  
13C NMR (75 MHz) δ 191.7 (C=O), 170.9 (C=O), 152.9 (C), 148.9 (C), 146.9 (CH), 
138.8 (C), 137.5 (C), 133.1 (CH), 131.8 (C), 131.6 (CH), 131.4 (C), 129.0 (CH), 124.2 
(CH), 105.0 (CH), 62.7 (C), 61.0 (CH3), 56.1 (CH3), 52.9 (CH3), 32.5 (CH2), 24.1 
(CH2).  
IR (NaCl, film) νmax 2932, 1733 (C=O), 1675 (C=O), 1527 (NO2), 1251, 1128 cm-1. 
EIMS (70 eV) m/z 441 (M+•, 100%), 382 (27), 348 (25). 
HRMS Found: M+•, 441.1418. C23H23NO8 requires M+•, 441.1424. 
 
1-tert-Butoxycarbonyl-3-(2-nitrophenyl)-5-(1-carbomethoxy-2-oxo 
cyclohex-3-enyl)-1H-indole (169) 
 
Clear, yellow oil 
Yield 62% 
Rf 0.3 (silica, 3:7 v/v ethyl acetate/hexane).  
1H NMR (300 MHz) δ 8.10 (d, J = 8.7 Hz, 1H), 8.01 (dd, J = 8.1 and 1.4 Hz, 1H), 
7.63–7.57 (complex m, 2H), 7.49 (td, J = 7.6 and 1.4 Hz, 1H), 7.40 (d, J = 8.1 and 1.4 
Hz, 1H), 7.24 (dd, J = 7.6 and 1.4 Hz, 1H), 7.17 (dd, J = 8.7 and 1.4 Hz, 1H), 6.92 (t, J 
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= 3.8 Hz, 1H), 6.54 (d, J = 3.8 Hz, 1H), 3.76 (s, 3H), 3.06–2.99 (complex m, 1H), 2.85–
2.64 (complex m, 2H), 2.52–2.50 (complex m, 1H), 1.66 (s, 9H). 
13C NMR (75 MHz) δ 192.2 (C=O), 171.5 (C=O), 149.6 (C), 149.0 (C=O), 146.5 (CH), 
138.7 (CH), 134.4 (C), 133.0 (CH), 131.7 (CH), 131.6 (C), 130.6 (C), 130.3 (C), 128.9 
(CH), 126.4 (C), 124.2 (CH), 123.8 (CH), 120.1 (CH), 115.1 (CH), 107.4 (CH), 83.8 
(C), 62.6 (C), 53.8 (CH3), 32.0 (CH2), 28.1 (CH3), 24.1 (CH2).  
IR (NaCl, film) νmax 2929, 1733 (C=O), 1688 (C=O). 1528 (NO2), 1371, 731 cm-1. 
EIMS (70 eV) m/z 490 (M+•, 15%), 390 (11), 57 (100). 
HRMS Found: M+•, 490.1742. C27H26N2O7 requires M+•, 490.1740. 
 
1-tert-Butoxycarbonyl-3-(2-nitrophenyl)-5-(1-carbomethoxy-2-oxo 
cyclohex-3-enyl)-6-methoxy-1H-indole (170) 
 
Clear, yellow oil 
Yield 91% 
Rf 0.2 (silica. 3:7 v/v ethyl acetate/hexane).  
1H NMR (300 MHz) δ 7.99 (d, J = 8.2 Hz, 1H), 7.77 (s, 1H), 7.61 (t, J = 7.5 Hz, 1H), 
7.51–7.43 (complex m, 2H), 7.33 (d, J = 7.5 Hz, 1H), 7.17 (s, 1H), 7.02 (t, J = 4.0 Hz, 
1H), 6.45 (d, J = 4.0 Hz, 1H), 3.82 (s, 3H), 3.76 (s, 3H), 2.99–2.96 (complex m, 1H), 
2.86–2.81 (complex m, 1H), 2.57–2.30 (complex m, 2H), 1.65 (s, 9H). 
13C NMR (75 MHz) δ 192.2 (C=O), 171.6 (C=O), 155.3 (C), 149.7 (C), 149.1 (C=O), 
147.5 (CH), 138.8 (CH), 135.5 (C), 132.9 (CH), 131.9 (CH), 131.6 (C), 128.8 (CH), 
124.6 (CH), 124.1 (CH), 123.5 (C), 123.0 (C), 120.0 (CH), 107.3 (C), 99.1 (CH), 83.5 
(C), 61.8 (C), 55.8 (CH3), 52.5 (CH3), 30.9 (CH2), 28.1 (CH3), 24.2 (CH2).  
IR (NaCl, film) νmax 2930, 1732 (C=O), 1676 (C=O), 1528 (NO2), 1370, 1258 cm-1. 
EIMS (70 eV) m/z 520 (M+•, 36%), 464 (100), 420 (63).  
HRMS Found: M+•, 520.1848. C28H28N2O8 requires M+•, 520.1846. 
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Methyl 1-phenyl-3-(2-nitro-phenyl)-2-oxo-cyclohept-3-ene carboxylate 
(178) 
 
Clear, yellow oil 
Yield 68% 
Rf 0.2 (silica, 3:7 v/v ethyl acetate/hexane).  
1H NMR (300 MHz) δ 7.97 (d, J = 8.1 Hz, 1H), 7.58 (t, J = 7.5 Hz, 1H), 7.45 (t, J = 7.5 
Hz, 1H), 7.36–7.20 (complex m, 6H), 6.60 (t, J = 6.3 Hz, 1H), 3.72 (s, 3H), 2.88–2.81 
(complex m, 1H), 2.72–2.63 (complex m, 1H), 2.44–2.22 (complex m, 2H), 2.07–1.91 
(complex m, 2H). 
13C NMR (75 MHz) δ 198.1 (C=O), 172.3 (C=O), 148.6 (C), 142.1 (CH), 141.1 (C), 
137.7 (C), 135.0 (C), 132.9 (CH), 132.2 (CH), 128.5 (CH), 128.2 (CH), 127.9 (CH), 
127.5 (CH), 124.2 (CH), 68.0 (C), 52.7 (CH3), 30.1 (CH2), 27.3 (CH2), 22.0 (CH2). 
IR (NaCl, film) νmax 2951, 1734 (C=O), 1659 (C=O), 1562 (NO2), 1233, 736 cm-1. 
EIMS (70 eV) m/z 365 (M+•, >1%), 288 (28), 115 (100).  
HRMS Found: M+•, 365.1256. C21H19NO5 requires M+•, 365.1263. 
 
Methyl 1-(2-methoxyphenyl)-3-(2-nitro-phenyl)-2-oxo-cyclohept-3-ene 
carboxylate (179) 
 
Yellow solid 
Yield 56% 
Rf 0.2 (silica, 3:7 v/v ethyl acetate/hexane). 
m.p. 92–94°C. 
1H NMR (300 MHz) δ 8.00 (d, J = 8.0 Hz, 1H), 7.58 (t, J = 7.4 Hz, 1H), 7.45 (t, J = 7.4 
Hz, 1H), 7.36–7.30 (complex m, 2H), 7.05 (d, J = 6.6 Hz, 1H), 6.96–6.89 (complex m, 
O
CO2Me
O
CO2Me
o-iodonitrobenzene
Pd2(dba)3, Cu, DMSO, 75oC, 2 h
NO2
I
(157) (178)
O
CO2Me
O
CO2Me
o-iodonitrobenzene
Pd2(dba)3, Cu, DMSO, 75oC, 2 h
I
MeO NO2 MeO
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2H), 6.63 (complex m, 1H), 3.74 (s, 3H), 3.68 (s, 3H), 2.92–2.86 (complex m, 1H), 
2.68–2.58 (complex m, 1H), 2.37–2.24 (complex m, 2H), 1.89–1.67 (complex m, 2H).  
13C NMR (75 MHz) δ 198.4 (C=O), 172.1 (C=O), 157.7 (C), 148.9 (C), 142.6 (CH), 
141.2 (C), 135.5 (C), 132.8 (CH), 132.3 (CH), 133.1 (CH), 128.9 (CH), 128.4 (CH), 
127.1 (C), 124.1 (CH), 120.8 (CH), 111.7 (CH), 66.7 (C), 55.6 (CH3), 52.5 (CH3), 29.0 
(CH2), 27.1 (CH2), 21.0 (CH2).  
IR (NaCl, film) νmax 2929, 1734 (C=O), 1658 (C=O), 1525 (NO2), 1354, 1024 cm-1. 
EIMS (70 eV) m/z 395 (M+•, 10%), 318 (72), 274 (46), 146 (100). 
HRMS Found: M+•, 395.1368. C22H21NO6 requires M+•, 395.1369. 
 
1-tert-Butoxycarbonyl-3-(2-nitrophenyl)-5-(1-carbomethoxy-2-oxo 
cyclohept-3-enyl)-1H-indole (180) 
 
Clear, yellow oil 
Yield 56% 
Rf 0.3 (silica, 3:7 v/v ethyl acetate/hexane).  
1H NMR (300 MHz) δ 8.08 (d, J = 8.5 Hz, 1H), 7.98 (dd, J = 8.1 and 1.2 Hz, 1H), 
7.61–7.55 (complex m, 2H), 7.43 (td, J = 8.1 and 1.2 Hz, 1H), 7.39 (d, J = 1.9 Hz, 1H), 
7.32 (dd, J = 7.6 and 1.5 Hz, 1H), 7.18 (dd, J = 8.5 and 1.9 Hz, 1H), 6.60 (t, J = 6.1 Hz, 
1H), 6.53 (d, J = 3.7 Hz, 1H), 3.70 (s, 3H), 2.91–2.86 (complex m, 1H), 2.76–2.71 
(complex m, 1H), 2.36–2.33 (complex m, 1H), 2.32–2.20 (complex m, 1H), 1.99–1.94 
(complex m, 2H), 1.66 (s, 9H).  
13C NMR (75 MHz) δ 198.6 (C=O), 172.6 (C=O), 149.6 (C), 148.7 (C=O), 142.3 (CH), 
141.1 (CH), 135.0 (C), 134.2 (C), 132.9 (CH), 132.2 (CH), 131.6 (C), 130.5 (C), 128.5 
(CH), 126.3 (C), 124.3 (CH), 124.1 (CH), 120.3 (CH), 115.0 (CH), 107.5 (CH), 83.7 
(C), 67.9 (C), 52.7 (CH3), 30.0 (CH2), 28.1 (CH3), 27.2 (CH2), 21.9 (CH2). 
IR (NaCl, film) νmax 2978, 1733 (C=O), 1659 (C=O), 1527 (NO2), 1166, 731 cm-1. 
EIMS (70 eV) m/z 504 (M+•, 8%), 404 (4), 387 (13), 57 (100). 
HRMS Found: M+•, 504.1894. C28H28N2O7 requires M+•, 504.1897. 
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5.2.8 General Procedure for Reductive Cyclisation of (o-
Nitrophenyl)cycloalkenones 139, 160 – 163, 166 – 170 and 178 – 181 
 
Following a procedure developed by Banwell et al,11 a magnetically stirred solution of 
the appropriate Ullmann cross-coupling product (1.00 mmol) and 10% Pd/C (50.0 mg, 
0.50 mmol) in methanol (5 mL) was treated with one to three atmospheres of 
dihydrogen at 18°C and stirred at this temperature for 1 – 24 h, then filtered through a 
pad of Celite. The solids thus retained was washed with methanol (3 x 10 mL) and the 
combined filtrates were concentrated under reduced pressure to give a clear green oil. 
Subjection of this material to flash chromatography (silica, 30 → 70% v/v ethyl 
acetate/hexane gradient elution provided, after concentration of the appropriate 
fractions, the relevant indole as either a green solid or oil.  
 
Methyl 1,2,3,4-tetrahydro-3-phenylcyclopenta[b]indole-3-carboxylate 
(163) 
 
Green oil 
Yield 97% 
Rf 0.6 (silica, 3:7 v/v ethyl acetate/hexane). 
1H NMR (300 MHz) δ 8.23 (s, 1H), 7.53 (d, J = 8.0 Hz, 1H), 7.37 (d, J = 7.4 Hz, 1H), 
7.30–7.08 (complex m, 7H), 3.77 (s, 3H), 3.51 (pd, J = 6.3 and 4.8 Hz, 1H), 2.91–2.82 
(complex m, 2H), 2.68–2.61 (complex m, 1H). 
13C NMR (75 MHz) δ 173.5 (C=O), 143.0 (C), 141.2 (C), 140.9 (C), 128.7 (CH), 127.2 
(CH), 125.8 (CH), 124.1 (C), 121.83 (CH), 121.8 (C), 119.8 (CH), 119.3 (CH), 111.9 
(CH), 59.6 (C), 52.7 (CH3), 43.7 (CH2), 22.8 (CH2).  
IR (NaCl, film) νmax 3393 (NH), 2951, 1725 (C=O), 1449, 1232, 743 cm-1. 
EIMS (70 eV) m/z 291 (M+•, 56%), 232 (100). 
HRMS Found: M+•, 291.1252. C19H17NO2 requires M+•, 291.1259. 
 
 
 
CO2Me
O
NO2
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H2, 1 atm., MeOH, 
18oC, 12 h
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H
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Methyl 1,2,3,4-tetrahydro-3-(2-methoxyphenyl)cyclopenta[b]indole-3-
carboxylate (164) 
 
Green oil 
Yield 98% 
Rf 0.5 (silica, 3:7 v/v ethyl acetate/hexane).  
1H NMR (300 MHz) δ 8.13 (s, 1H), 7.52 (d, J = 7.8 Hz, 1H), 7.35 (d, J = 7.8 Hz, 1H), 
7.15 (sept, J = 9.3 Hz, 3H), 6.94–6.82 (complex m, 3H), 3.82 (s, 3H), 3.71 (s, 3H), 3.71 
(complex m, 1H), 3.00–2.96 (complex m, 1H), 2.88–2.86 (complex m, 1H), 2.61–2.56 
(complex m, 1H). 
13C NMR (75 MHz) δ 174.0 (C=O), 156.2 (C), 141.1 (C), 141.0 (C), 132.3 (C), 128.5 
(CH), 126.9 (CH), 124.3 (C), 121.9 (C), 121.6 (CH), 120.7 (CH), 119.7 (CH), 119.3 
(CH), 111.8 (CH), 111.1 (CH), 59.7 (C), 55.6 (CH3), 52.4 (CH2), 41.1 (CH2), 23.2 
(CH2).  
IR (NaCl, film) νmax 3369 (NH), 2949, 1728 (C=O), 1490, 1246, 739 cm-1. 
EIMS (70 eV) m/z 321 (M+•, 40%), 262 (73), 84 (100). 
HRMS Found: M+•, 321.1370. C20H19NO3 requires M+•, 321.1365. 
 
Methyl 3-[1-(1-tert-Butoxycarbonyl)-1H-indol-5-yl]-1,2,3,4-tetrahydro 
cyclopenta[b]indole-3-carboxylate (165) 
 
Green oil 
Yield 87% 
Rf 0.6 (silica, 3:7 v/v ethyl acetate/hexane). 
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1H NMR (300 MHz) δ 8.28 (s, 1H), 8.02 (d, J = 8.0 Hz, 1H), 7.58–7.54 (complex m, 
2H), 7.42 (d, J = 8.0 Hz, 1H), 7.24–7.09 (complex m, 4H), 6.46 (d, J = 3.7 Hz, 1H), 
3.77 (s, 3H), 3.55 (complex m, 1H), 2.91–2.82 (complex m, 2H), 2.70–2.64 (complex 
m, 1H), 1.65 (s, 9H). 
13C NMR (75 MHz) δ 173.8 (C=O), 149.6 (C=O), 141.2 (CH), 137.4 (C), 134.1 (C), 
130.8 (C), 127.5 (C), 126.5 (CH), 124.2 (C), 122.1 (CH), 121.8 (CH), 119.8 (CH), 
119.3 (CH), 118.6 (C), 118.1 (CH), 115.4 (CH), 111.9 (CH), 107.3 (CH), 83.8 (C), 59.5 
(C), 52.7 (CH3), 44.0 (CH2), 28.1 (CH3), 22.8 (CH2).  
IR (NaCl, film) νmax 3385 (NH), 2950, 1733 (C=O), 1467, 1371, 1257, 731 cm-1. 
EIMS (70 eV) m/z 430 (M+•, 16%), 371 (17), 315 (66).  
HRMS Found: M+•, 430.1892. C26H26N2O4 requires M+•, 430.1893 
 
Methyl 1-phenyl-2,3,4,9-tetrahydro-1H-carbazole-1-carboxylate (171) 
 
Green solid 
Yield 95% 
Rf 0.5 (silica, 3:7 v/v ethyl acetate/hexane) 
m.p. 36–38°C. 
1H NMR (300 MHz) δ 8.74 (s, 1H), 7.56 (d, J = 7.6 Hz, 1H), 7.35–7.00 (complex m, 
8H), 3.81 (s, 3H), 2.97 (t, J = 7.7 Hz, 1H), 2.10 (complex m, 1H), 1.88–1.68 (complex 
m, 4H). 
13C NMR (75 MHz) δ 174.1 (C=O), 144.0 (C), 135.9 (C), 130.9 (C), 128.4 (CH), 127.1 
(CH), 126.9 (C), 126.7 (CH), 122.2 (CH), 119.2 (CH), 118.6 (CH), 114.2 (C), 110.9 
(CH), 53.4 (C), 52.7 (CH3), 36.8 (CH2), 20.9 (CH2), 19.8 (CH3).  
IR (NaCl, film) νmax 3410 (NH), 2934, 1732 (C=O), 1448, 1238, 1039, 743 cm-1. 
EIMS (70 eV) m/z 305 (M+•, 34%), 246 (100).  
HRMS Found: M+•, 305.12419. C20H19NO2 requires M+•, 305.1416. 
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Methyl 1-phenyl-2,3,4,9-tetrahydro-1-(2-methoxyphenyl)-1H-carbazole-1-
carboxylate (172) 
 
Green solid 
Yield 95% 
Rf 0.5 (silica, 3:7 v/v ethyl acetate/hexane). 
m.p. 34–36°C.  
1H NMR (300 MHz) δ 8.22 (s, 1H), 7.56 (d, J = 7.7 Hz, 1H), 7.32–7.09 (complex m, 
3H), 6.90 (d, J = 8.3 Hz, 1H), 6.76 (td, J = 7.7 and 1.4 Hz, 1H), 6.48 (dd, J = 7.7 and 
1.4 Hz, 1H), 3.85 (s, 3H), 3.78 (s, 3H), 3.09 (q, J = 7.4 Hz, 1H), 2.82–2.68 (complex m, 
3H), 2.22–2.15 (complex m, 1H), 1.93–1.87 (complex m, 2H). 
13C NMR (75 MHz) δ 174.4 (C=O), 155.9 (CH), 135.8 (C), 132.7 (C), 130.4 (C), 129.9 
(C), 129.8 (CH), 128.4 (CH), 127.2 (C), 122.1 (CH), 120.3 (CH), 119.2 (CH), 118.5 
(CH), 114.3 (C), 110.9 (CH), 55.4 (C), 52.4 (CH3), 50.8 (CH3), 32.1 (CH2), 21.0 (CH2), 
19.5 (CH2).  
IR (NaCl, film) νmax 3387 (NH), 2947, 1729 (C=O), 1461, 1243, 1042, 738 cm-1. 
EIMS (70 eV) m/z 335 (M+•, 35%), 276 (100).  
HRMS Found: M+•, 335.1522. C21H21NO3 requires M+•, 335.1521. 
 
Methyl 1-phenyl-2,3,4,9-tetrahydro-1-(2,3,4-trimethoxyphenyl)-1H-
carbazole-1-carboxylate (173) and Methyl 1-phenyl-2,3,4,9-tetrahydro-1-
(2,3,4-trimethoxyphenyl)-1-hydroxy-carbazole-1-carboxylate (177) 
 
Compound 173: 
 
Green solid 
10% Pd/C
H2, 1 atm., MeOH,
 18oC, 12 h
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Yield 67% 
Rf 0.6 (silica, 3:2 v/v ethyl acetate/hexane). 
m.p. 56–59°C. 
1H NMR (300 MHz) δ 8.26 (s, 1H), 7.55 (d, J = 7.7 Hz, 1H), 7.30–7.09 (complex m, 
3H), 6.40 (d, J = 8.7 Hz, 1H), 6.19 (d, J = 8.7 Hz, 1H), 3.94 (s, 3H), 3.86 (s, 3H), 3.81 
(s, 3H), 3.80 (s, 3H), 2.80–2.71 (complex m, 4H), 2.11–1.91 (complex m, 2H). 
13C NMR (75 MHz) δ 174.7 (C=O), 153.1 (C), 150.4 (C), 141.6 (C), 135.8 (C), 130.7 
(C), 130.2 (C), 127.1 (C), 123.8 (CH), 122.1 (CH), 119.2 (CH), 118.5 (C), 114.3 (CH), 
110.9 (CH), 105.5 (CH), 60.5 (C), 60.4 (CH3), 55.8 (CH3), 52.5 (CH3), 50.7 (CH3), 33.5 
(CH2), 20.9 (CH2), 19.5 (CH2).  
IR (NaCl, film) νmax 3400 (NH), 2945, 1738 (C=O), 1493, 1274, 1101, 910, 734 cm-1. 
EIMS (70 eV) m/z 395 (M+•, 24%), 336 (100). 
HRMS Found: M+•, 395.1736. C23H25NO5 requires M+•, 395.1733. 
 
Compound 177: 
 
Green solid 
Yield 12% 
Rf 0.6 (silica, 3:2 v/v ethyl acetate/hexane). 
m.p. 68–71°C. 
1H NMR (300 MHz) δ 9.27 (s, 1H), 7.53 (d, J = 8.1 Hz, 1H), 7.47 (d, J = 8.1 Hz, 1H), 
7.24 (m, 1H), 7.09 (m, 1H), 6.50 (d, J = 1.8 Hz, 2H), 3.91 (s, 3H), 3.87 (s, 3H), 3.86 (s, 
3H), 3.82 (s, 3H), 2.87–2.72 (complex m, 3H), 1.84–1.79 (complex m, 3H). 
13C NMR (75 MHz) δ 177.5 (C=O), 153.1 (C), 150.4 (C), 141.6 (C), 133.4 (C), 128.9 
(C), 128.5 (C), 122.9 (CH), 122.3 (CH), 121.7 (C), 118.9 (CH), 118.2 (CH), 110.8 (C), 
108.8 (CH), 106.4 (CH), 60.63 (C), 60.6 (CH3), 55.8 (CH3), 53.2 (CH3), 51.0 (CH3), 
36.3 (CH2), 21.11 (CH2), 21.08 (CH2).  
IR (NaCl, film) νmax 3234 (NOH), 2944, 1687 (C=O), 1493, 1287, 1101, 736 cm-1. 
EIMS (70 eV) m/z 411 (M+•, 92%), 351 (100), 336 (76), 243 (88). 
HRMS Found: M+•, 411.1682. C23H25NO6 requires M+•, 411.1682. 
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Methyl 1-phenyl-2,3,4,9-tetrahydro-1-(3,4,5-trimethoxyphenyl)-1H-
carbazole-1-carboxylate (174) 
 
Green solid 
Yield 95% 
Rf 0.5 (silica, 3:2 v/v ethyl acetate/hexane). 
m.p. 59–61°C. 
1H NMR (300 MHz) δ 8.46 (s, 1H), 7.58 (m, 1H), 7.34 (dt, J = 8.3 and 0.8 Hz, 1H), 
7.21 (m, 1H), 7.14 (m, 1H), 6.23 (s, 2H), 3.83 (s, 3H), 3.81 (s, 3H), 3.70 (s, 6H), 2.82–
2.64 (complex m, 3H), 2.18 – 2.05 (complex m, 1H), 1.89–1.78 (complex m, 2H). 
13C NMR (75 MHz) δ 173.9 (C=O), 153.1 (C), 139.6 (C), 137.2 (C), 136.0 (C), 130.6 
(C), 126.9 (C), 122.2 (CH), 119.2 (CH), 118.6 (CH), 114.4 (C), 110.9 (CH), 104.2 
(CH), 60.8 (C), 56.2 (CH3), 53.5 (CH3), 52.7 (CH3), 36.9 (CH2), 20.9 (CH2), 20.0 
(CH2).  
IR (NaCl, film) νmax 3401 (NOH), 2937, 1731 (C=O), 1589, 1455, 1239, 739 cm-1. 
EIMS (70 eV) m/z 395 (M+•, 82%), 336 (100). 
HRMS Found: M+•, 395.1736. C23H25NO5 requires M+•, 395.1733. 
 
Methyl 1-[1-(1-tert-Butoxycarbonyl)-1H-indol-5-yl]-2,3,4,9–tetrahydro-1H- 
carbazole-1–carboxylate (175) 
 
Green oil 
Yield 87% 
Rf 0.6 (silica, 7:3 v/v ethyl acetate/hexane). 
10% Pd/C
H2, 1 atm., MeOH,
 18oC, 12 h
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1H NMR (300 MHz) δ 8.51 (s, 1H), 8.03 (d, J = 8.9 Hz, 1H), 7.60–7.58 (complex m, 
2H), 7.36 (d, J = 7.8 Hz, 1H), 7.25–7.12 (complex m, 3H), 7.01 (dd, J = 8.9 and 1.8 Hz, 
1H), 6.45 (d, J = 3.6 Hz, 1H), 3.83 (s, 3H), 2.81–2.69 (complex m, 4H), 2.21–2.05 
(complex m, 1H), 1.86–1.68 (complex m, 1H), 1.65 (s, 9H). 
13C NMR (75 MHz) δ 174.4 (C=O), 149.7 (C=O), 138.5 (CH), 135.9 (C), 131.3 (C), 
130.5 (C), 129.0 (C), 127.0 (C), 126.5 (C), 122.8 (CH), 122.1 (CH), 119.4 (CH), 119.2 
(CH), 118.6 (CH), 115.4 (CH), 114.1 (C), 111.0 (CH), 107.4 (CH), 83.8 (C), 53.3 (C), 
52.7 (CH3), 37.0 (CH2), 28.1 (CH3), 21.0 (CH2), 19.7 (CH2).  
IR (NaCl, film) νmax 3403 (NH), 2935, 1733 (C=O), 1464, 1371, 1255, 1143, 731 cm-1. 
EIMS m/z 444 (M+•, 88%), 385 (42), 329 (100). 
HRMS Found: M+•, 444.2048. C27H28N2O4 requires M+•, 444.2049. 
 
Methyl 1-[1-(tert-butoxycarbonyl)-5-methoxy-1H-indol-4-yl]–2,3,4,9-tetra 
hydro-1H-carbazole-1-carboxylate (176) 
 
Green oil 
Yield 75% 
Rf 0.5 (silica, 3:7 v/v ethyl acetate/hexane). 
1H NMR (300 MHz) δ 8.27 (s, 1H), 7.80 (s, 1H), 7.60 (d, J = 7.4 Hz, 1H), 7.48 (d, J = 
3.7 Hz, 1H), 7.33 (d, J = 7.4 Hz, 1H), 7.24–7.13 (complex m, 2H), 6.67 (s, 1H), 6.31 (d, 
J = 3.7 Hz, 1H), 3.93 (s, 3H), 3.79 (s, 3H), 2.80–2.76 (complex m, 3H), 2.25 (complex 
m, 2H), 1.87 (complex m, 1H), 1.67 (s, 9H). 
13C NMR (75 MHz) δ 175.0 (C=O), 154.4 (C=O), 149.8 (C), 135.8 (C), 130.7 (C), 
128.9 (C), 127.3 (C), 124.5 (CH), 123.3 (C), 122.0 (C), 121.8 (CH), 119.2 (CH), 118.5 
(CH), 118.2 (C), 114.3 (CH), 111.0 (CH), 107.4 (CH), 98.3 (CH), 83.5 (C), 55.7 (C), 
52.4 (CH3), 51.0 (CH3), 32.1 (CH2), 28.1 (CH3), 21.0 (CH3), 19.3 (CH2).  
IR (NaCl, film) νmax 3400 (NH), 2945, 1733 (C=O), 1623 (C=O), 1535, 1373 cm-1. 
EIMS (70 eV) m/z 474 (M+•, 91%), 415 (53), 374 (100), 359 (100). 
HRMS Found: M+•, 474.2145. C28H30N2O5 requires M+•, 474.2155. 
10% Pd/C
H2, 1 atm., MeOH,
 18oC, 12 h
O
CO2Me
NO2 N
Boc
NH
CO2Me
N
Boc
MeO
MeO
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Methyl 5,6,7,8,9,10-hexahydro-6-phenylcyclohepta[b]indole-6-
carboxylate (181) 
 
Green solid 
Yield 71% 
Rf 0.6 (silica, 3:7 v/v ethyl acetate/hexane). 
m.p. 52–54°C. 
1H NMR (300 MHz) δ 8.24 (s, 1H), 7.56 (d, J = 8.4 Hz, 1H), 7.33–7.03 (complex m, 
8H), 3.81 (s, 3H), 2.90–2.85 (complex m, 2H), 2.66–2.27 (complex m, 4H), 1.86–1.62 
(complex m, 2H). 
13C NMR (75 MHz) δ 174.6 (C=O), 142.6 (C), 134.5 (C), 133.5 (C), 128.5 (CH), 127.8 
(CH), 127.23 (CH), 127.19 (C), 121.8 (CH), 119.1 (CH), 118.4 (CH), 116.4 (C), 110.7 
(CH), 58.1 (C), 52.8 (CH3), 36.9 (CH2), 26.9 (CH2), 24.9 (CH2), 22.9 (CH2).  
IR (NaCl, film) νmax 3401 (NH), 2924, 1733 (C=O), 1460, 1232 cm-1. 
EIMS (70 eV) m/z 319 (M+•, 30%), 260 (82). 
HRMS Found: M+•, 319.1579. C21H21NO2 requires M+•, 319.1572. 
 
Methyl 5,6,7,8,9,10-hexahydro-6-(2-methoxyphenyl)cyclohept[b]indole-6- 
carboxylate (182) 
 
Green oil 
Yield 95% 
Rf 0.5 (silica, 3:7 v/v ethyl acetate/hexane). 
1H NMR (300 MHz) δ 8.37 (s, 1H), 7.58 (d, J = 6.7 Hz, 1H), 7.27–7.11 (complex m, 
3H), 6.90 (d, J = 8.2 Hz, 2H), 6.77 (t, J = 7.7 Hz, 1H), 6.56 (dd, J = 7.7 and 1.5 Hz, 
10% Pd/C
H2, 3 atm., MeOH,
 18oC, 1 h
O
NO2
CO2Me
N
H
CO2Me
(178) (181)
O
CO2Me
NO2 MeO
10% Pd/C
H2, 3 atm., MeOH,
 18oC, 1 h
NH
CO2Me
(179) (182)
MeO
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1H), 3.83 (s, 3H), 3.79 (s, 3H), 2.94–2.90 (complex m, 2H), 2.71–2.69 (complex m, 
2H), 1.80–1.72 (complex m, 4H). 
13C NMR (75 MHz) δ 175.2 (C=O), 156.3 (C), 134.7 (C), 132.2 (C), 131.1 (C), 129.9 
(CH), 128.4 (CH), 125.5 (C), 121.9 (CH), 120.4 (CH), 119.0 (CH), 118.4 (CH), 117.4 
(C), 111.0 (CH), 110.7 (CH), 55.8 (C), 55.5 (CH3), 52.5 (CH3), 31.2 (CH2), 26.2 (CH2), 
23.2 (CH2), 21.7 (CH2).  
IR (NaCl, film) νmax 3396 (NH), 2934, 1736 (C=O), 1460, 1244, 1028, 734 cm-1. 
EIMS (70 eV) m/z 349 (M+•, 51%), 290 [(M–CO2Me•)+, 100]. 
HRMS Found: M+•, 349.1682. C22H23NO3 requires M+•, 349.1678. 
 
Methyl 6-[1-(1-tert-Butoxycarbonyl)-1H-indol-5-yl]-5,6,7,8,10-hexahydro 
hepta[b]indole-6-carboxylate (183) 
 
Green oil 
Yield 88% 
Rf 0.7 (silica, 3:7 v/v ethyl acetate/hexane). 
1H NMR (300 MHz) δ 8.28 (s, 1H), 8.05 (d, J = 8.2 Hz, 1H), 7.60–7.58 (complex m, 
2H), 7.24–7.03 (complex m, 5H), 6.48 (d, J = 3.6 Hz, 1H), 3.82 (s, 3H), 2.91–2.85 
(complex m, 2H), 2.70–2.60 (complex m, 2H), 2.27–1.84 (complex m, 2H), 1.72–1.68 
(complex m, 2H), 1.66 (s, 9H). 
13C NMR (75 MHz) δ 174.9 (C=O), 149.7 (C=O), 136.8 (C), 134.4 (C), 134.0 (C), 
130.7 (C), 128.5 (C), 126.5 (CH), 125.5 (C), 123.3 (CH), 121.7 (CH), 119.8 (CH), 
119.0 (CH), 118.4 (CH), 116.2 (C), 115.2 (CH), 110.7 (CH), 107.4 (CH), 83.9 (C), 57.9 
(C), 52.9 (CH3), 37.0 (CH2), 28.1 (CH3), 26.9 (CH2), 25.0 (CH2), 22.9 (CH2).  
IR (NaCl, film) νmax 3401 (NH), 2922, 1734 (C=O), 1462, 1371, 1143 cm-1. 
EIMS (70 eV) m/z 458 (M+•, >1%), 446 (1), 299 (24), 205 (100).  
HRMS Found: M+•, 458.2214. C28H30N2O4 requires M+•, 458.2206. 
 
 
10% Pd/C
H2, 3 atm., MeOH,
 18oC, 1 h
O
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5.2.9 Titanium Trichloride-mediated Reductive Cyclisation  
 
Methyl 5,6,7,8,9,10-hexahydro-9-(2-methoxyphenyl)-10-oxocyclohepta[b] 
indole-9-carboxylate (184) 
 
Following a procedure developed by Rawal et al,12 a magnetically stirred solution of 
titanium trichloride-tetrahydrofuran complex (750 mg, 1.80 mmol) in H2O (2 mL) and 
maintained under a nitrogen atmosphere was treated with NH4OAc (3.00 mL of a 2.5 M 
solution, 7.50 mmol) and acetone (3.5 mL) at 18°C, stirring was continued at this 
temperature for 0.25 h. The resulting dark blue solution was treated, dropwise, with a 
solution of α′-(o-nitrophenyl) enone 179 (90.0 mg, 0.23 mmol) in acetone (2.5 mL). 
After an additional 0.25 h the reaction mixture was diluted with water (1 x 5 mL) and 
extracted with ethyl acetate (3 x 25 mL). The combined organic phases were washed 
with NaHCO3 (2 x 50 mL of a saturated aqueous solution). The separated organic phase 
was then dried (MgSO4), filtered and concentrated under reduced pressure to give a 
clear, yellow oil. Subjection of this material to flash chromatography (silica, 20 → 40% 
v/v ethyl acetate/hexane gradient elution) provided, after concentration of the 
appropriate fractions, the title compound 184 (57.0 mg, 68%) as a green solid.  
  
Rf 0.1 (silica, 3:7 v/v ethyl acetate/hexane). 
m.p. 46–48°C. 
1H NMR (300 MHz) δ 8.79 (s, 1H), 8.47 (dd, J = 6.7 and 1.8 Hz, 1H), 7.28–7.17 
(complex m, 4H), 7.04 (dd, J = 7.7 and 1.8 Hz, 1H), 6.90 (dd, J = 8.3 and 1.0 Hz, 1H), 
6.73 (td, J = 7.7 and 1.2 Hz, 1H), 3.78 (s, 3H), 3.72 (s, 3H), 2.99 (dt, J = 14.8 and 4.7 
Hz, 1H), 2.82–2.74 (complex m, 1H), 2.63–2.47 (complex m, 2H), 1.87–1.82 (complex 
m, 1H), 1.62–1.58 (complex m, 1H). 
13C NMR (75 MHz) δ 196.0 (C=O), 173.6 (C=O), 157.8 (C), 146.0 (C), 134.9 (C), 
129.2 (CH), 128.7 (CH), 128.4 (C), 127.5 (C), 123.1 (CH), 122.5 (CH), 122.3 (CH), 
120.8 (CH), 114.2 (C), 111.2 (CH), 110.5 (CH), 67.2 (C), 55.5 (CH3), 52.4 (CH3), 30.3 
(CH2), 27.3 (CH2), 21.3 (CH2). 
O
CO2Me
NO2 MeO
TiCl3.THF, NH4OAc, 
H2O, acetone, 
18oC, 0.5 h
N
H
MeO2C
O
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IR (NaCl, film) νmax 3306 (NH), 2948, 1732 (C=O), 1600 (C=O), 1455, 1250, 752 cm-1. 
EIMS (70 eV) m/z 363 (M+•, 30%), 331 (10), 83 (95), 43 (100). 
HRMS Found: M+•, 363.1470. C22H21NO4 requires M+•, 363.1471. 
 
5.3 Procedures Associated with Work Described in Chapter 
Three 
 
5.3.1 Synthesis of 3-Bromo-6,7,8,9-tetrahydro-2-methoxy-5H-carbazole 
(199) 
 
First Approach 
 
N-(3-Bromo-4-methoxyphenyl)acetamide (195) 
 
Following a procedure developed by Lauer et al,13 a magnetically stirred and cooled 
(ice/water bath) solution of acetanilide 194 (4.62 g, 28.0 mmol) in glacial acetic acid 
(13 mL) maintained under a nitrogen atmosphere was treated, dropwise, with molecular 
bromine (1.42 mL, 28.2 mmol) at such a rate that the internal temperature did not 
exceed 50°C. The resulting mixture was warmed to 18°C and stirred at this temperature 
for 2 h, at which time a yellow precipitate had formed. The mixture was then poured 
into ice water (140 mL) containing sodium bisulfite (500 mg) and the mixture stirred 
until the yellow colour had been discharged. The resulting solution was left to stand for 
13 h at 0°C and filtered and the yellow solid retained. Recrystallisation from (4:1 v/v) 
ethanol/water afforded the title compound 195 (6.38 g, 87%) as a crystalline, white 
solid.  
 
Rf 0.4 (silica, 3:7 v/v ethyl acetate/hexane). 
m.p. 107–109°C (lit. 109–111°C).13 
1H NMR (300 MHz) δ 7.68 (d, J = 2.6 Hz, 1H), 7.44 (dd, J = 8.8 and 2.6 Hz, 1H), 7.09 
(s, 1H), 6.85 (d, J = 8.8 Hz, 1H), 3.87 (s, 3H), 2.16 (s, 3H). 
13C NMR (75 MHz) δ 168.2 (C=O), 152.8 (C), 131.6 (C), 125.5 (CH), 120.6 (CH), 
111.9 (CH), 111.5 (CH), 56.5 (CH3), 24.4 (CH3).  
Br2, AcOH, 
0oC to 18oC, 2 h
MeO
NHAc
MeO
NHAcBr
(194) (195)
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IR (NaCl, film) νmax 3306 (NH), 1663 (C=O), 1496, 1252, 1054 cm-1.  
EIMS (70 eV) m/z 245 and 243 (M+•, 68%), 203 and 201 [(M–Ac•)+, 71)], 186 and 188 
(100).  
HRMS Found: M+•, 244.9866. C9H1081BrNO2 requires M+•, 244.9874. 
 
N-(5-Bromo-4-methoxy-2-nitrophenyl)acetamide (196) 
 
Following a procedure developed by Bindal et al,14 a magnetically stirred and cooled 
(ice/water bath) solution of acetamide 195 (1.78 g, 7.28 mmol) in acetic anhydride (10 
mL) maintained under a nitrogen atmosphere was treated, dropwise, with fuming nitric 
acid (0.82 mL, 11.9 mmol) at such a rate that the internal temperature did not exceed 
10°C. The resulting mixture was poured into ice water (140 mL) and the yellow solid, 
thus obtained was filtered and washed with distilled water. Recrystallisation from 
ethanol afforded the title compound 196 (1.38 g, 66%) as yellow needles.  
 
Rf 0.4 (silica, 3:7 v/v ethyl acetate/hexane). 
m.p. 173–175°C (lit. 175°C).14  
1H NMR (300 MHz) δ 9.09 (s, 1H), 7.67 (s, 1H), 3.95 (s, 3H), 2.23 (s, 3H). (NH proton 
exchanged with solvent). 
13C NMR (75 MHz) δ 168.8 (C=O), 151.4 (C), 135.3 (C), 128.9 (C), 126.7 (CH), 121.6 
(C), 106.7 (CH), 56.7 (CH3), 25.5 (CH3). 
IR (NaCl, film) νmax 3362 (NH), 2925, 1698 (C=O), 1579, 1506 (NO2), 1306, 892 cm-1. 
EIMS (70 eV) m/z 290 and 288 (M+•, 28%), 248 and 246 (100), 233 and 231 (41). 
HRMS Found: M+•, 287.9749. C9H979BrNO4 requires M+•, 287.9746. 
 
 
 
 
 
 
 
HNO3, Ac2O, 10oC
MeO
NHAc
MeO
NHAcBrBr
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1-Bromo-5-iodo-2-methoxy-4-nitrobenzene (197) 
 
A magnetically stirred solution of acetamide 196 (1.15 g, 4.00 mmol) and HCl (1.00 mL 
of a concentrated aqueous solution), 12.0 mmol) in distilled water (1 mL) maintained 
under a nitrogen atmosphere was heated to reflux and stirred at reflux for 0.5 h, then 
cooled to 0°C (ice/water bath). The resulting reaction mixture was treated, dropwise, 
with a cold solution of sodium nitrite (340 mg, 4.80 mmol) in distilled water (6 mL). 
The solution was stirred at this temperature for an additional 0.5 h and then added 
dropwise to a solution of potassium iodide (960 mg, 6.00 mmol) in distilled water (6 
mL). The resulting mixture was heated to reflux and stirred at reflux for 2 h then, cooled 
and diluted with ether (1 x 100 mL). The separated organic phase was washed with HCl 
(1 x 100 mL of a 1 M aqueous solution) and Na2SO3 solution (50 mL of a saturated 
aqueous solution) then dried (MgSO4), filtered and concentrated under reduced pressure 
to give a clear, yellow oil. Subjection of this material to flash chromatography (silica, 5 
→ 20% v/v ether/hexane gradient elution) provided, after concentration of the 
appropriate fractions, the title compound 197 (1.82 g, 72%) as a yellow solid. 
 
Rf 0.4 (silica, 1:9 v/v ethyl acetate/hexane). 
m.p. 159–161°C. 
1H NMR (300 MHz) δ 8.19 (s, 1H), 7.46 (s, 1H), 3.96 (s, 3H). 
13C NMR (75 MHz) δ 156.5 (C), 152.2 (C), 144.7 (CH), 118.0 (C), 108.8 (CH), 75.3 
(C), 56.8 (CH3). 
IR (NaCl, film) νmax 2930, 1520 (NO2), 1471, 1300, 1055, 884 cm-1.  
EIMS (70 eV) m/z 357 and 359 (M+•, 100%), 311 and 313 (25), 296 and 298 (16), 184 
and 186 (16).  
HRMS Found: M+•, 356.8488. C7H579Br127INO3 requires M+•, 356.8498. 
 
 
 
 
 
1. HCl, H2O,reflux, 0.5 h
2. NaNO2, 0oC, 0.5 h
3. KI, 0oC to reflux, 2 h
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2-Iodocyclohexen-2-one (121) 
 
Following a procedure developed by Johnson et al,10 a magnetically stirred and cooled 
(ice/water bath) solution of the cyclohexanone (77) (960 mg, 10.0 mmol) in 
pyridine/CCl4 (40 mL of a 1:1 v/v mixture) maintained under a nitrogen atmosphere 
was treated, dropwise, with a solution of molecular iodine (10.2 g, 40.0 mmol) 
dissolved in pyridine/CCl4 (40 mL of 1:1 v/v/ mixture). The resulting mixture was 
warmed to 18°C and stirred at this temperature for 16 h, then diluted with ether (300 
mL). The organic phase was washed with HCl (2 x 250 mL of a 1 M aqueous solution), 
distilled water (1 x 250 mL) and Na2SO3 (1 x 250 mL of a 1 M solution), then dried 
(MgSO4), filtered and concentrated under reduced pressure to give a clear, yellow oil. 
Subjection of this material to flash chromatography (silica, 10 → 30% v/v ethyl 
acetate/hexane gradient elution) provided, after concentration of the appropriate 
fractions, the title compound 121 (1.46 g, 66%) as a white solid.  
 
Rf 0.4 (silica, 3:7 v/v ethyl acetate/hexane). 
m.p. 44–46°C (lit. 47–49°C).10  
1H NMR (300 MHz) δ 7.26 (t, J = 4.4 Hz, 1H), 2.68–2.63 (complex m, 2H), 2.46–2.41 
(complex m, 2H), 2.12–2.06 (complex m, 2H). 
13C NMR (75 MHz) δ 192.2 (C=O), 159.4 (CH), 103.8 (C), 37.2 (CH2), 29.9 (CH2), 
22.8 (CH2).  
IR (NaCl, film) νmax 2934, 1676 (C=O), 1585, 1422, 1315, 1121, 915 cm-1. 
EIMS (70 eV) m/z 222 (M+•, 87%), 193 (83), 67 (100).  
HRMS Found: M+•, 221.9543. C6H7127IO requires M+•, 221.9542. 
 
 
 
 
 
 
 
I2, (1:1 v/v) CCl4/py., 
0oC to 18oC, 16 h
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I
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2-(5-Bromo-4-methoxy-2-nitrophenyl)cyclohex-2-enone (198) 
 
Following a procedure developed by Banwell et al,11 a magnetically stirred mixture of 
nitrobenzene 197 (1.00 g, 2.80 mmol), iodoenone 121 (410 mg, 1.85 mmol), copper 
powder (590 mg of 99% material, CAS No. 7440-50-8), 9.25 mmol) and Pd2(dba)3 
(85.0 mg, 85.0 µmol) in DMSO (10 mL) all maintained under a nitrogen atmosphere 
was heated to 75°C and stirred at this temperature for 2 h, then diluted with  ether (50 
mL). The resulting mixture was then filtered through a pad of Celite and the solids 
thus retained washed with ether (1 x 200 mL). The filtrate was washed with distilled 
water (2 x 100 mL) and brine (1 x 100 mL). The separated organic phase was then dried 
(MgSO4), filtered and concentrated under reduced pressure to give a clear, yellow oil. 
Subjection of this material to flash chromatography (silica, 20 → 40% v/v ethyl 
acetate/hexane gradient elution) provided, after concentration of the appropriate 
fractions, the title compound 198 (375 mg, 66%) as a yellow solid.  
 
Rf 0.5 (silica, 3:7 v/v ethyl acetate/hexane). 
m.p. 161–163°C.  
1H NMR (300 MHz) δ 7.57 (s, 1H), 7.45 (s, 1H), 6.99 (t, J = 7.0 Hz, 1H), 3.98 (s, 3H), 
2.59–2.54 (complex m, 4H), 2.13 (t, J = 6.6 Hz, 2H). 
13C NMR (75 MHz) δ 196.5 (C=O), 155.8 (CH), 147.8 (C), 146.7 (C), 138.2 (C), 135.7 
(CH), 125.3 (C), 117.4 (C), 107.4 (CH), 56.8 (CH3), 38.2 (CH2), 26.2 (CH2), 22.5 
(CH2).  
IR (NaCl, film) νmax 2927, 1680 (C=O), 1525 (NO2), 1490, 1346, 1240, 1038, 800 cm-1. 
EIMS (70 eV) m/z 327 and 325 (M+•, 45%), 280 and 278 (100).  
HRMS Found: M+•, 324.9953. C13H1279BrNO4 requires M+•, 324.9950. 
 
 
 
 
 
 
 
 
(121), Pd2(dba)3, 
Cu, DMSO, 75oC, 2 h
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Second approach 
 
2-(4-Bromo-3-methoxyphenylamino)cyclohexanone (201) 
 
Following a procedure developed by Campbell et al,15 a magnetically stirred solution of 
methoxyaniline 85 (5.00 g, 25.0 mmol) in 2-ethoxyethanol (100 mL) maintained under 
a nitrogen atmosphere was treated with sodium carbonate (5.25 g, 50.0 mmol) and 
chlorocyclohexanone 117 (3.93 g, 30.0 mmol). The resulting mixture was heated to 
130°C and stirred at this temperature for 1 h, then, cooled and filtered. The filtrate was 
concentrated under reduced pressure to give a viscous, brown oil. Subjection of this 
material to flash chromatography (silica, 2 → 5% v/v ethyl acetate/hexane gradient 
elution) provided, after concentration of the appropriate fractions, the title compound 
201 (4.83 g, 65%) as a white solid. 
 
Rf 0.45 (silica, 3:7 v/v ethyl acetate/hexane). 
m.p. 107–109°C. 
1H NMR (300 MHz) δ 7.26 (d, J = 8.5 Hz, 1H), 6.19 (d, J = 2.5 Hz, 1H), 6.07 (dd, J = 
8.5 and 2.5 Hz, 1H), 3.98 (complex m, 1H), 3.83 (s, 3H), 2.67–2.55 (complex m, 2H), 
2.43–2.41 (complex m, 1H), 2.19–2.14 (complex m, 1H), 1.91–1.68 (complex m, 3H), 
1.43 (qd, J = 12.9 and 3.8 Hz, 1H), (NH proton exchanges for solvent). 
13C NMR (75 MHz) δ 208.0 (C=O), 156.4 (C), 147.0 (C), 135.2 (C), 133.4 (CH), 105.5 
(CH), 98.4 (CH), 61.6 (CH), 56.0 (CH3), 41.1 (CH2), 35.5 (CH2), 28.0 (CH2), 23.9 
(CH2). 
IR (NaCl, film) νmax 3379 (NH), 2935, 1714 (C=O), 1598, 1491, 1219, 818 cm-1.  
EIMS (70 eV) m/z 299 and 297 (M+•, 100%), 271 and 269 (67), 242 and 240 (76). 
HRMS Found: M+•, 297.0372. C13H1679BrNO2 requires M+•, 297.0364. 
 
 
 
 
 
NH2MeO
Br
N
H
MeO
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117, Na2CO3, 
2-ethoxyethanol, 
130oC, 1 h
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3-Bromo-6,7,8,9-tetrahydro-2-methoxy-5H-carbazole (199)  
 
Following a procedure developed by Campiagne et al,16 a magnetically stirred solution 
of cyclohexanone 201 (4.01 g, 13.5 mmol) in 2-ethoxyethanol (20 mL) maintained 
under a nitrogen atmosphere was treated with anhydrous magnesium chloride (2.50 g, 
26.9 mmol). The resulting reaction mixture was heated to 140°C, stirred at this 
temperature for 1 h, then cooled and diluted with dichloromethane (200 mL). The 
organic phase was washed with distilled water (3 x 250 mL). The separated organic 
phase was then dried (MgSO4), filtered and concentrated under reduced pressure to give 
a clear, yellow oil. Subjection of this material to flash chromatography (silica, 10 → 
20% v/v ethyl acetate/petroleum spirit gradient elution) provided, after concentration of 
the appropriate fractions, the title compound 199 (2.15 g, 57%) as a white solid.  
 
Rf 0.52 (silica, 3:7 v/v ethyl acetate/hexane).  
m.p. 135–137°C. 
1H NMR (300 MHz) δ 7.59 (s, 1H), 7.58 (s, 1H), 6.84 (s, 1H), 3.90 (s, 3H), 2.69 (t, J = 
5.6 Hz, 2H), 2.62 (t, J = 5.6 Hz, 2H), 1.87 (complex m, 4H). 
13C NMR (75 MHz) δ 151.2 (C), 135.2 (C), 133.7 (C), 125.5 (C), 121.8 (CH), 109.6 
(C), 103.8 (C), 94.7 (CH), 56.6 (CH3), 23.2 (CH2), 23.1 (CH2), 23.0 (CH2), 20.7 (CH2). 
IR (NaCl, film) νmax 3357 (NH), 2920, 1682, 1464, 1306, 1162 cm-1.  
EIMS (70 eV) m/z 281 and 279 (M+•, 100%), 266 and 264 (65).  
HRMS Found: M+•, 279.0258. C13H1479BrNO requires M+•, 279.0259. 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
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5.3.2 Synthesis of “Upper” Hemisphere Analogue 
 
Methyl (E)-3-oxohex-4-enoate (190) 
 
Following a procedure developed by Zibuck et al,17 Jones’ reagent was prepared by the 
addition of H2SO4 (30.0 mL of a concentrated aqueous solution, 48.9 mmol) to a 
solution of chromium trioxide (33.5 g, 40.3 mol) in water (20 mL) followed by slow 
addition of distilled water to give 250 mL total volume. A magnetically stirred and 
chilled (ice/water bath) solution of β-hydroxyester 20418 (5.10 g, 36.0 mmol) in acetone 
(10 mL) maintained under a nitrogen atmosphere was treated, dropwise, with Jones’ 
reagent (36.0 mL. 36.0 mmol). The reaction mixture was warmed to 18°C, stirred at this 
temperature for 24 h, then quenched with methanol (10 mL) and diluted with ether (1 x 
200 mL). The separated organic phase was washed with distilled water (3 x 100 mL), 
NaHCO3 (2 x 100 mL of a saturated aqueous solution) and brine (2 x 100 mL), then 
dried (MgSO4), filtered and concentrated under reduced pressure to give a clear, yellow 
oil. Subjection of this material to flash chromatography (silica, 5 → 10% v/v ethyl 
acetate/hexane gradient elution) provided, after concentration of the appropriate 
fractions, the title compound 190 (4.90 g, 80%) as a clear, yellow oil. 
  
Rf 0.3 (silica, 1:9 v/v ethyl acetate/hexane). 
1H NMR (300 MHz) δ 6.85 (complex m, 1H), 6.08 (dd, J = 15.7 and 1.7 Hz, 1H), 4.92 
(s, 2H), 3.68 (s, 3H), 1.88 (dd, J = 7.0 and 1.4 Hz, 3H).  
13C NMR (75 MHz) δ 191.8 (C=O), 167.8 (C=O), 145.3 (CH), 131.0 (CH), 52.2 (CH3), 
46.3 (CH2), 18.3 (CH2).  
IR (NaCl, film) νmax 3323 (OH), 2955, 1745 (C=O), 1673 (C=O), 1433, 1240, 968 cm-1. 
EIMS (70 eV) m/z 142 (M+•, 100%), 127 (73), 101 (36). 
HRMS Found: M+•, 142.0636. C7H10O3 requires M+•, 142.0630. 
 
 
 
 
Jones' reagent, acetone, 
0oC to 18oC, 24 h
CO2Me
HO
CO2Me
O
(204) (190)
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1 – Allyl – 3 – (iodomethyl)piperidine (208) 
 
Following a procedure developed by Slusarchyk et al19 and Magnus et al,20 a 
magnetically stirred mixture of piperidinylmethanol 207 (1.15 g, 10.0 mmol) and 
triethylamine (14.0 mL, 100 mmol) in ethanol (20 mL) all maintained at 18°C under a 
nitrogen atmosphere was treated with allyl bromide (0.18 mL, 20.0 mmol) then heated 
to reflux and stirred at reflux for 12 h. After cooling, the reaction mixture was 
concentrated under reduced pressure, the residue dissolved in dichloromethane (200 
mL) and the resulting solution washed with K2CO3 (3 x 300 mL of a 5% aqueous 
solution). The separated organic phase was then dried (MgSO4), filtered and 
concentrated under reduced pressure to give a clear, yellow oil. A solution of this 
material in dichloromethane (50 mL) at 18°C under a nitrogen atmosphere was treated 
with triphenylphosphine (5.85 g, 22.5 mmol) and iodine (5.69 g, 22.5 mmol). The 
resulting reaction mixture was stirred for 0.25 h then imidazole (1.70 g, 25.0 mmol) was 
added in one portion and the resulting mixture heated to reflux and stirred at reflux for 3 
h. After cooling, the reaction mixture was diluted with dichloromethane (1 x 200 mL) 
and washed with sodium thiosulfate (1 x 100 mL of a 5% aqueous solution) and brine (1 
x 100 mL). The separated organic phase was then dried (MgSO4), filtered and 
concentrated under reduced pressure to give a clear, yellow oil. Subjection of this 
material to flash chromatography (silica, 10% v/v ethyl acetate/hexane 5% Et3N elution) 
provided, after concentration of the appropriate fractions, the title compound 208 (1.35 
g, 51%) as a clear, colourless, oil. 
  
Rf 0.4 (silica, 3:7 v/v ethyl acetate/hexane). 
1H NMR (300 MHz) δ 5.85 (complex m, 1H), 5.09 (complex m, 2H), 3.09 (complex m, 
2H), 2.95 (complex m, 3H), 2.74 (d, J = 11.1 Hz, 1H), 1.93–1.54 (complex m, 6H), 
1.05–0.98 (complex m, 1H). 
13C NMR (75 MHz) δ 135.1 (CH), 117.8 (CH2), 61.9 (CH2), 59.7 (CH2), 53.8 (CH2), 
38.2 (CH), 31.2 (CH2), 24.7 (CH2), 11.5 (CH2). 
IR (NaCl, film) νmax 2931, 1464, 1191, 919 cm-1. 
EIMS (70 eV) m/z 265 (M+•, 5%), 138 (100). 
HN
1. Allyl bromide, Et3N, 
    EtOH, reflux, 12 h
2. PPh3, I2, Im., CH2Cl2, 
     18 oC to reflux, 3 h
N
IHO
(207) (208)
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HRMS Found: M+•, 265.0326. C9H16127IN requires M+•, 265.0328. 
 
tert–Butyl 3–(iodomethyl)piperidine-1-carboxylate (210) 
 
Following a procedure developed by Slusarchyk et al,19 a magnetically stirred solution 
of tert-butyl-3-(hydroxymethyl)piperidine-1-carboxylate (209) (2.15 g, 10.0 mmol) in 
dichloromethane (100 mL) at 18°C under a nitrogen atmosphere was treated with 
triphenylphosphine (5.85 g, 22.5 mmol) and iodine (5.69 g, 22.5 mmol). The reaction 
mixture was stirred for 0.25 h then imidazole (1.70 g, 25.0 mmol) was added in one 
portion and the resulting solution heated to reflux and stirred at reflux for 3 h. After 
cooling, the reaction mixture was diluted with dichloromethane (1 x 200 mL) and the 
organic phase washed with sodium thiosulfate (1 x 100 mL of a 5% aqueous solution) 
and brine (1 x 100 mL). The separated organic phase was then dried (MgSO4), filtered 
and concentrated under reduced pressure to give a clear, yellow oil. Subjection of this 
material to flash chromatography (silica, 10% v/v ethyl acetate/hexane 5% Et3N elution) 
provided, after concentration of the appropriate fractions, the title compound 210 (2.67 
g, 82%) as an opaque, white solid. 
 
m.p 32–34°C.  
Rf 0.3 (silica, 1:9 v/v ethyl acetate/hexane). 
1H NMR (300 MHz) δ 4.04 (d. J = 10.6 Hz, 1H), 3.83 (dt, J = 13.3 and 3.8 Hz, 1H), 
3.07 (d, J = 6.5 Hz, 2H), 2.84 (complex m, 1H), 2.60 (t, J = 9.9 Hz, 1H), 1.94–1.89 
(complex m, 1H), 1.67–1.60 (complex m, 2H), 1.46 (s, 9H), 1.29–1.17 (complex m, 
2H). 
13C NMR (75 MHz) δ 154.7 (C=O), 79.6 (C), 49.6 (CH2), 41.1 (CH2), 38.0 (CH2), 31.4 
(CH), 28.4 (CH3), 24.3 (CH2), 9.8 (CH2).  
IR (NaCl, film) νmax 2930, 1693 (C=O), 1422, 1156 cm-1. 
EIMS (70 eV) m/z 325 (M+•, 20%), 269 (42), 199 (45), 57 (100). 
HRMS Found: M+•, 325.0536. C11H20127INO2 requires M+•, 325.0539. 
 
BocN PPh3, I2, Im., CH2Cl2,
 18oC to reflux, 3 h BocN
IHO
(209) (210)
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tert-Butyl-(2-(methoxycarbonyl)-3-oxohex-5-enyl)piperidine-1-carboxylate 
(212) 
 
A magnetically stirred solution of diisopropylamine (370 µL, 3.71 mmol) in THF (10 
mL) maintained at –20°C (NaCl/ice bath) under a nitrogen atmosphere was treated, 
dropwise, with n-butyllithium (2.30 mL of a 1.6 M solution in hexanes, 3.68 mmol). 
The reaction mixture was stirred for an additional 0.5 h at –20°C. The resulting reaction 
mixture was treated, via cannula, with a solution of β-ketoester 190 (390 mg, 3.10 
mmol) in THF (2 mL) and warmed to 0°C (ice/water bath), stirred at this temperature 
for 0.5 h then tert–butyl 3–(iodomethyl)piperidine-1-carboxylate (210) (1.00 g, 3.07 
mmol) was added. The resulting solution was warmed to 18°C and stirred at this 
temperature for 15 h, then poured into a beaker of cold distilled water (150 mL) and 
extracted with ether (2 x 50 mL). The combined organic phases were washed with 
distilled water (3 x 50 mL), then dried (MgSO4), filtered and concentrated under 
reduced pressure to give a clear, yellow oil. Subjection of this material to flash 
chromatography (silica, 5 → 20% v/v ethyl acetate/hexane gradient elution) provided, 
after concentration of the appropriate fractions, the title compound 212 (806 mg, 80%) 
as a clear, colourless oil. 
 
Rf 0.5 (silica, 3:7 v/v ethyl acetate/hexane). 
1H NMR (300 MHz) (rotomers) δ 5.60 (complex m, 1H), 5.27 (complex m, 2H), 3.85 
(complex m, 2H), 3.72 (s, 3H), 3.55 (dd, J = 4.5 and 2.1 Hz, 2H), 3.43 (complex m, 
1H), 2.78 (complex m, 2H), 2.56–2.52 (complex m, 2H), 1.76 (complex m, 2H), 1.64–
1.59 (complex m, 3H), 1.44 (s, 9H). 
13C NMR (75 MHz) (rotomers) δ 202.7 (C=O), 167.5 (C=O), 154.8 (C=O), 135.2 (CH), 
135.0 (CH), 119.9 (CH), 119.7 (CH), 79.3 (C), 55.0 (CH), 54.9 (CH3), 52.3 (CH3), 47.5 
(CH2), 47.4 (CH2), 33.6 (CH2), 33.4 (CH2), 33.2 (CH2), 32.7 (CH2), 31.3 (CH2), 30.7 
(CH3), 28.4 (CH3), 24.6 (CH2), 24.5 (CH2). 
IR (NaCl, film) νmax 2924, 1750 (C=O), 1688 (C=O), 1423, 1241, 1149 cm-1. 
ESIMS m/z 362 [(M + Na)+, 100%], 325 (33), 283 (16).  
CO2Me CO2Me
1. LDA, THF, 
   -20oC to 0oC, 1.5 h
2. (210), 0oC to 18oC, 15 h
O O
BocN
(190) (212)
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HRMS (ESI) Found: (M + Na)+, 362.1983. C18H29NO5Na requires (M + Na)+, 
362.1943. 
 
tert-Butyl-3-(2-(methoxycarbonyl)-7-tert-butyl-dimethylsiloxy-3-
oxocycloheptyl)piperidine-1-carboxylate (216) 
 
A magnetically stirred solution of β-ketoester 217 (600 mg, 2.10 mmol) in DMF (10 
mL) at 18°C maintained under a nitrogen atmosphere was treated with potassium 
carbonate (238 mg, 2.50 mmol) and tert–butyl 3–(iodomethyl)piperidine-1-carboxylate 
(210) (715 mg, 2.20 mmol). The resulting reaction mixture was heated to 90°C, stirred 
at this temperature for 15 h, then cooled and poured into a beaker of cold distilled water 
(150 mL) and then extracted with dichloromethane
 
(2 x 50 mL). The combined organic 
phases were washed with distilled water (3 x 50 mL), dried (MgSO4), filtered and 
concentrated under reduced pressure to give a clear, yellow oil. Subjection of this 
material to flash chromatography (silica, 5 → 20% v/v ethyl acetate/hexane gradient 
elution) provided, after concentration of the appropriate fractions, the title compound 
216 (765 mg, 75%) as a clear, colourless oil. 
 
Rf 0.3 (1:9 v/v ethyl acetate/hexane),  
1H NMR (300 MHz) δ 3.73 (complex m, 2H), 3.72 (s, 3H), 3.59 (t, J = 6.3 Hz, 2H), 
2.6–2.56 (complex m, 6H), 1.70 – 1.48 (complex m, 10H), 1.44 (s, 9H), 0.87 (s, 9H), 
0.03 (s, 6H).  
13C NMR (75 MHz) (rotomers) δ 204.9 (C=O), 170.3 (C=O), 170.1 (C=O), 154.74 
(C=O), 154.70 (C=O), 79.4 (C), 62.7 (CH2), 61.7 (CH2), 56.2 (CH), 56.0 (CH), 52.5 
(CH3), 52.3 (CH3), 48.9 (CH2), 42.0 (CH2), 41.6 (CH2), 33.74 (CH2), 33.70 (CH2), 32.0 
(CH2), 31.5 (CH2), 31.3 (CH2), 30.7 (CH2), 30.6 (CH), 30.3 (CH), 28.43 (CH3), 28.40 
(CH3), 25.9 (CH3), 25.0 (CH2), 24.9 (CH2), 24.4 (CH2), 24.3 (CH2), 19.92 (C), 19.90 
(C), -5.4 (CH3). 
IR (NaCl, film) νmax 2930, 1743 (C=O), 1693 (C=O), 1427, 1366, 1256 cm-1. 
EIMS (70 eV) m/z 485 (M+•, >1%), 372 (73), 282 (57), 296 (100). 
HRMS Found: M+•, 485.3172. C25H47NO6Si requires M+•, 485.3173. 
CO2Me CO2Me
O O
BocN
K2CO3, (210), DMF,
 18oC to 90oC, 15 h
OTBSOTBS
(217) (216)
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Methyl 7-tert-butyldimethylsiloxy-2-(2-methoxyphenyl)-3-oxoheptane 
carboxylate (222) 
 
Following a procedure developed by Pinhey et al,8 a magnetically stirred solution of β-
ketoester 217 (600 mg, 2.10 mmol) in chloroform (3 mL) at 18°C maintained under a 
nitrogen atmosphere was treated with pyridine (0.50 mL, 6.30 mmol) and stirred for 0.5 
h then treated with lead triacetate 96 (1.00 g, 2.11 mmol). The resulting mixture was 
heated to 40°C, stirred at this temperature for 32 h then cooled and quenched with HCl 
(drop of 1 M aqueous solution) and then diluted with ether (1 x 100 mL). The resulting 
solution was washed with HCl (1 x 100 mL of a 1 M aqueous solution) and distilled 
water (2 x 100 mL). The separated organic phase was dried (MgSO4), filtered and 
concentrated under reduced pressure to give a clear, yellow oil. Subjection of this 
material to flash chromatography (silica, 10 → 30% v/v ethyl acetate/petroleum spirit 
gradient elution) provided, after concentration of the appropriate fractions, the title 
compound 222 (640 mg, 78%) as a clear, colourless oil. 
 
Rf 0.44 (silica, 3:7 v/v ethyl acetate/hexane). 
1H NMR (300 MHz) (keto form-major isomer) δ 7.28–7.24 (complex m, 1H), 6.97–
6.92 (complex m, 3H), 3.83 (s, 3H), 3.74 (s, 3H), 3.54 (t, J = 6.3 Hz, 2H), 2.38 (t, J = 
7.8 Hz, 2H), 1.58 (complex m, 2H), 1.43 (complex m, 2H), 0.86 (s, 9H), 0.01 (s, 6H). 
(enolic form-minor isomer) 5.22 (s, 1H), 3.81 (s, 3H), 3.76 (s, 3H), 3.48 (t, J = 6.3 Hz, 
2H), 2.05 (complex m, 2H), 0.85 (s, 9H), -0.01 (s, 6H), (other signals overlapping). 
13C NMR (75 MHz) (keto form-major isomer) δ 204.4 (C=O), 169.5 (C=O), 156.7 (C), 
129.9 (CH), 129.3 (CH), 121.4 (C), 120.9 (CH), 110.7 (CH), 62.7 (CH2), 57.3 (CH), 
55.6 (CH3), 52.5 (CH3), 41.4 (CH2), 31.9 (CH2), 25.9 (CH3), 20.1 (CH2), 18.3 (C), -5.4 
(CH2). (enolic form-minor isomer) δ 176.8 (C), 173.4 (C=O). 136.1 (CH), 130.6 (CH), 
121.8 (C), 120.3 (CH), 102.1 (C), 55.4 (CH3), 51.7 (CH3), 32.3 (CH2), 32.1 (CH2), 22.7 
(CH2), (other signals overlapping). 
IR (NaCl, film) νmax 2953, 1751 (C=O), 1718 (C=O), 1464, 1248, 885 cm-1. 
EIMS (70 eV) m/z 394 (M+•, 1%), 337 (100), 305 (91). 
CO2Me CO2Me
O O
OTBSOTBS
1. py., CHCl3, 18oC, 0.5 h
2. (96), 40oC, 32 h MeO
(217) (222)
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HRMS Found: M+•, 394.2178. C21H34O5Si requires M+•, 394.2176. 
 
5.4 Procedures Associated with Work Described in Chapter Four 
 
5.4.1 Preparation of (+)-(1R,2S,5R)-5-Methyl-2-(2-(naphthalen-3-yl) 
propan-2-yl)cyclohexyl)cyclohexanol (244) 
 
(-)-(2S, 5R)-5-Methyl-2-[2-(naphthen-3-yl)propan-2-yl]cyclohexanone (248) 
 
Following a procedure developed by Yang et al,21 a three-necked round bottomed flask 
equipped with a nitrogen inlet and an addition flask containing a solution of 2-
bromonapthalene (3.45 g, 17.1 mmol) in THF (40 mL) maintained under a nitrogen 
atmosphere was treated with magnesium turnings (560 mg, 23.6 mmol), 2-
bromonaphthalene (1.00 g, 4.85 mmol) in THF (5 mL) and a few crystals of iodine. As 
soon as the Grignard reagent began to form, the 2-bromonapthalene solution was added 
slowly. The reaction vessel was then cooled to –20°C (NaCl/ice bath) and treated with 
CuI (290 mg, 1.53 mmol). After stirring for 0.5 h at this temperature, the reaction 
mixture was treated, dropwise, with a solution of (R)-pulegone (246) (2.28 g, 15.0 
mmol) in THF (20 mL). The resulting reaction mixture was warmed to 18°C, stirred at 
this temperature for 12 h then cooled to 0°C (ice/water bath) and quenched with 
ammonium chloride (1 x 20 mL of a saturated aqueous solution) and HCl (1 x 20 mL of 
a 6 M aqueous solution). The separated aqueous phase was extracted with ether (2 x 200 
mL) and the combined organic phases were washed with brine (1 x 100 mL). The 
separated organic phase was then dried (MgSO4), filtered and concentrated under 
reduced pressure to leave a clear, yellow oil.  
 
A solution of this material in EtOH (50 mL) was treated with KOH (10 mL of a 50% 
aqueous solution) and the resulting solution heated to reflux and stirred at reflux for 3 h, 
cooled and treated with distilled water (30 mL) and then extracted with ether (2 x 150 
mL). The combined organic phases were washed with HCl (1 x 100 mL of 1 M aqueous 
1. 2-bromonaphthalene, Mg, I2, THF
2. CuI, -20oC to 18oC, 12 h
3. 50% KOH, EtOH, reflux, 3 h
OO
(246) (248)
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solution), NaHCO3 (1 x 100 mL of a saturated aqueous solution), distilled water (1 x 
100 mL) and brine (1 x 100 mL), then dried (MgSO4), filtered and concentrated under 
reduced pressure to give a clear, colourless, yellow oil. Subjection of this material to 
flash chromatography provided, after concentration of the appropriate fractions, the title 
compound 248 (1.63 g, 60%) as a clear oil. 
 
Rf 0.3 (silica, 5:95 v/v ethyl acetate/hexane).  
1H NMR (300 MHz) δ 7.85–7.77 (complex m, 4H), 7.56 (complex m, 3H), 2.80 (dd, J 
= 13.0 and 4.8 Hz, 1H), 2.27 (ddd, J = 12.6, 4.2 and 1.2 Hz, 1H), 2.06 (td, J = 12.6 and 
1.2 Hz, 1H), 1.80–1.73 (complex m, 2H), 1.60 (s, 3H), 1.55 (s, 3H), 1.55–1.16 
(complex m, 3H), 0.88 (d, J = 5.0 Hz, 3H).  
13C NMR (75 MHz) δ 211.2 (C=O), 147.3 (C), 133.2 (C), 131.6 (C), 128.0 (CH), 127.5 
(CH), 127.3 (CH), 125.8 (CH), 125.3 (CH), 124.5 (CH), 124.1 (CH), 59.7 (CH), 52.3 
(CH2), 39.2 (C), 36.2 (CH2), 34.6 (CH), 29.1 (CH3), 26.7 (CH3), 23.4 (CH2), 22.2 
(CH3). 
IR (NaCl, film) νmax 2953, 1709 (C=O), 1454, 1120, 749 cm-1. 
EIMS (70 eV) m/z 280 (M+•, 91%), 170 (100).  
HRMS Found: M+•, 280.1829. C20H24O requires M+•, 280.1827.  
Specific Rotation [α]D -44.1 (c = 1.7, CHCl3). 
 
(+)-(1S,2S,5R)-5-Methyl-2-(2-(naphthalen-3-yl)propan-2-yl)cyclohexyl) 
cyclohexanol (244) and (-)-(1R,2S,5R)-5-Methyl-2-(2-(naphthalen-3-
yl)propan-2-yl)cyclohexyl)cyclohexanol (249) 
 
Following a procedure developed by Yang et al,21 a magnetically stirred and cooled 
(ice/water bath) solution of cyclohexanone 248 (800 mg, 2.86 mmol) in THF (5 mL) 
under a nitrogen atmosphere was treated with LiAlH4 (5.74 mL of a 1 M solution in 
THF, 5.74 mmol). The resulting mixture was warmed to 18°C, stirred at this 
temperature for 12 h, then quenched with ammonium chloride (1 x 5 mL of a saturated 
+
(244) (249)
O HO HO
(248)
LiAlH4, THF,
0oC to 18oC, 12 h
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aqueous solution) followed by HCl (1 x 10 mL of 2 M aqueous solution) and extracted 
with dichloromethane (2 x 100 mL). The combined organic phases were washed with 
distilled water (1 x 50 mL) and brine (1 x 50 mL). The separated organic phase was 
then dried (MgSO4), filtered and concentrated under reduced pressure to give a clear, 
colourless oil. Subjection of this material to flash chromatography (silica, 3 → 5% v/v 
ethyl acetate/hexane gradient elution) provided, after concentration of the appropriate 
fractions, the title compounds 244 (482 mg, 60%) and 249 (321 mg, 40%) as clear, 
colourless oils.  
 
Compound 244 
 
Rf 0.3 (silica, 5:95 v/v ethyl acetate/hexane).  
1H NMR (300 MHz) δ 7.85–7.78 (complex m, 4H), 7.54 (dd, J = 8.9 and 1.8 Hz, 1H), 
7.48–7.43 (complex m, 2H), 3.86 (complex m, 1H), 1.72–1.57 (complex m, 6H), 1.51 
(s, 3H), 1.47 (s, 3H), 1.09–0.99 (complex m, 2H), 0.83 (d, J = 6.2 Hz, 3H), (OH proton 
exchanges with solvent). 
13C NMR (75 MHz) δ 147.5 (C), 133.3 (C), 131.6 (C), 128.0 (CH), 127.5 (CH), 127.3 
(CH), 125.8 (CH), 125.3 (CH), 125.2 (CH), 124.3 (CH), 68.3 (CH), 51.8 (CH2), 49.3 
(CH), 40.4 (C), 35.6 (CH2), 27.7 (CH3), 26.2 (CH), 25.7 (CH3), 22.2 (CH2), 21.6 (CH3). 
IR (NaCl, film) νmax 3435 (OH), 2919, 1455, 816, 745 cm-1.  
EIMS (70 eV) m/z 282 (M+•, 58%), 264 (24), 169 (100).  
HRMS Found: M+•, 282.1984. C20H26O requires M+•, 282.1984. 
Specific Rotation [α]D +28.4 (c = 1.0, CHCl3).  
 
Compound 249 
 
Rf 0.2 (silica, 5:95 v/v ethyl acetate/hexane). 
1H NMR (300 MHz) δ 7.83–7.77 (complex m, 4H), 7.54 (dd, J = 8.9 and 1.8 Hz, 1H), 
7.49–7.43 (complex m, 2H), 3.60 (td, J = 10.1 and 4.1 Hz, 1H), 1.88–1.74 (complex m, 
3H), 1.70–1.61 (m. 3H), 1.55 (s, 3H), 1.38 (s, 3H), 1.10–0.92 (complex m, 2H), 0.88 (d, 
J = 6.3 Hz, 3H), (OH proton exchanges solvent). 
13C NMR (75 MHz) δ 149.0 (C), 133.4 (C), 131.7 (C), 128.01 (CH), 127.96 (CH), 
127.4 (CH), 126.0 (CH), 125.5 (CH), 125.2 (CH), 123.2 (CH), 73.3 (CH), 53.8 (CH2), 
45.4 (CH), 40.0 (C), 34.9 (CH3), 31.5 (CH3), 28.3 (CH), 26.6 (CH2), 24.7 (CH2), 22.0 
(CH3).  
IR (NaCl, film) νmax 3435 (OH), 2919, 1455, 816, 745 cm-1. 
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EIMS (70 eV) m/z 282 (M+•, 58%), 262 (24), 170 (100).  
HRMS Found: M+•, 282.1984. C20H26O requires M+•, 282.1984. 
Specific Rotation [α]D -28.2 (c = 1.0, CHCl3). 
 
5.4.2 General Procedure for Synthesis of Chiral Chloroformates 251 - 253 
 
Following a procedure developed by Comins et al,22 a magnetically stirred solution of 
triphosgene (126 mg, 0.43 mmol) in toluene (5 mL) maintained at –20°C (NaCl/ice 
bath) under a nitrogen atmosphere was treated with the appropriate chiral alcohol (1.00 
mmol) then, over the period of 0.1 h, a solution of pyridine (0.14 mL, 1.10 mmol) in 
toluene (5 mL). The reaction mixture was then warmed to 18°C, stirred at this 
temperature for 12 h then filtered and the filtrate washed with distilled water (2 x 20 
mL), then dried (MgSO4), filtered and concentrated under reduced pressure to give a 
clear, yellow oil. Subjection of this material to flash chromatography (silica, 0 → 5% 
v/v ethyl acetate/hexane gradient elution) provided, after concentration of the 
appropriate fractions, the relevant chiral chloroformate as either a clear, colourless oil or 
white solid.  
 
(-)-(1R,2S)-2-(2-Phenylpropan-2-yl)cyclohexyl chloroformate (251) 
 
Clear, colourless oil 
Rf 0.3 (silica, 5:95 v/v ethyl acetate/hexane). 
1H NMR (300 MHz) δ 7.35–7.18 (complex m, 5H), 4.77 (dt, J = 11.0 and 4.5 Hz, 1H), 
2.06–2.04 (complex m, 2H), 1.70–1.64 (complex m, 4H), 1.37 (s, 3H), 1.31 (s, 3H), 
1.29–1.07 (complex m, 3H). 
13C NMR (75 MHz) δ 151.8 (C=O), 149.8 (C), 128.2 (CH), 125.6 (CH), 125.4 (CH), 
84.3 (CH), 51.0 (CH), 40.0 (C), 32.7 (CH2), 27.2 (CH2), 26.7 (CH2), 26.6 (CH3), 25.5 
(CH3), 24.5 (CH2). 
IR (NaCl, film) νmax 2934, 1771 (C=O), 1170, 700 cm-1.  
EIMS (70 eV) m/z 280 (M+•, 6%), 200 (30), 119 (100).  
triphosgene, py., toluene,
 -20oC to 18oC, 12 h
HO OCl
O
(243) (251)
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HRMS Found: M+•, 280.1234. C16H2135ClO2 requires M+•, 280.1230.  
Specific Rotation [α]D -31.0 (c = 2.0, CH3OH). 
 
(+)-2-(2R)-4-Methylcyclohex-1-enyl)propan-2-yl)naphthalene (252) and (+)-
(1S,2S,5R)-(-)-5-Methyl-2-[2-(naphthyl-3-yl)propan-2-yl]cyclohexyl 
chloroformate (254) 
 
Compound 252 
 
Clear, colourless oil 
Rf 0.4 (silica, 5:95 v/v ethyl acetate/hexane).  
1H NMR (300 MHz) δ 7.83–7.72 (complex m, 4H), 7.48–7.38 (complex m, 3H), 5.74 
(t, J = 2.1 Hz, 1H), 2.20 (complex m, 1H), 1.81–1.52 (complex m, 6H), 1.50 (s, 3H), 
1.46 (s, 3H), 0.93 (d, J = 6.5 Hz, 3H). 
13C NMR (75 MHz) δ 146.9 (C), 143.9 (C), 133.4 (C), 131.7 (C), 127.8 (CH), 127.41 
(CH), 127.35 (CH), 125.75 (CH), 125.70 (CH), 125.2 (CH), 123.7 (CH), 119.6 (CH), 
43.6 (C), 34.3 (CH2), 31.5 (CH2), 28.8 (CH), 28.4 (CH3), 27.6 (CH3), 25.6 (CH2), 21.8 
(CH3). 
IR (NaCl, film) νmax 2948, 1599, 1363, 817, 744 cm-1.  
EIMS (70 eV) m/z 264 (M+•, 94%), 249 [(M – Me•)+, 100].  
HRMS Found: M+•, 264.1880. C20H24 requires M+•, 264.1878. 
Specific Rotation [α]D +21.6 (c = 1.0, CHCl3). 
 
Compound 254 
 
Clear, colourless oil 
Rf 0.3 (silica 5% v/v ethyl acetate/hexane). 
triphosgene, py., toluene, 
-20oC to 18oC, 12 h +
(252) (254)
O
O
ClHO
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1H NMR (300 MHz) δ 7.88–7.77 (complex m, 4H), 7.53–7.45 (complex m, 3H), 4.88 
(complex m, 1H), 2.01 (complex m, 1H), 1.84–1.68 (m. 4H), 1.51 (s, 3H), 1.49 (s, 3H), 
1.11–0.91 (complex m, 3H), 0.88 (d, J = 6.3 Hz, 3H) 
13C NMR (75 MHz) δ 149.3 (C=O), 146.1 (C), 133.3 (C), 131.7 (C), 128.0 (CH), 127.9 
(CH), 127.3 (CH), 126.0 (CH), 125.6 (CH), 124.3 (CH), 123.2 (CH), 81.6 (CH), 50.8 
(CH), 40.1 (C), 40.0 (CH2), 34.9 (CH2), 27.5 (CH), 26.6 (CH3), 25.0 (CH3), 22.0 (CH2), 
21.8 (CH3). 
IR (NaCl, film) νmax 2949, 1775 (C=O), 1129, 817 cm-1. 
EIMS (70 eV) m/z 344 (M+•, >1%), 264 (70), 249 (81), 169 (100).  
HRMS Found: M+•, 344.1548. C21H2535ClO2 requires M+•, 344.1543.  
Specific Rotation [α]D +28.6 (c = 1.0, CHCl3). 
 
(+)-(1R,2S,3R)-3-[N-Benzenesulfonyl-N-(3,5-dimethylphenyl)-amino]-2-
bornanyl chloroformate (253) 
 
White solid  
Rf 0.3 (silica, 1:4 v/v ethyl acetate/hexane). 
m.p. 59–61°C.  
1H NMR (300 MHz) δ 7.48–7.29 (complex m, 6H), 6.80 (s, 2H), 5.88 (s, 1H), 5.07 (d, 
J = 7.0 Hz, 1H), 3.81 (d, J = 7.0 Hz, 1H), 2.17 (s, 3H), 2.00 (s, 3H), 1.91–1.48 (complex 
m, 2H), 1.24–1.16 (complex m, 2H), 0.83 (s, 3H), 0.79 (s, 3H), 0.54 (s, 3H).  
13C NMR (75 MHz) δ 150.3 (C=O), 138.4 (C), 136.7 (C), 132.8 (C), 129.7 (CH), 128.9 
(CH), 128.8 (CH), 128.4 (CH), 128.2 (CH), 89.0 (CH), 66.7 (CH), 50.5 (C), 48.4 (CH), 
47.5 (C), 31.7 (CH2), 27.6 (CH2), 21.0 (CH3), 20.9 (CH3), 20.7 (CH3), 11.1 (CH3).  
IR (NaCl, film) νmax 2959, 1780 (C=O), 1354, 1169, 703 cm-1.  
EIMS (70 eV) m/z 475 (M+•, 1%), 413 (15), 334 (70), 254 (100).  
HRMS Found: M+•, 475.1587. C25H3035ClNO4S requires M+•, 475.1584. 
Specific Rotation [α]D +25.0 (c = 0.5, CHCl3). 
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 -20oC to 18oC, 12 h
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5.4.3 General Procedure for Synthesis of Chiral Cyanoformates 255 - 258 
 
Following a procedure developed by Childs et al,23 a magnetically stirred solution of the 
appropriate chiral chloroformate (1.00 mmol) maintained at 18°C under a nitrogen 
atmosphere was treated with potassium cyanide (71.0 mg, 1.08 mmol) and 18-crown-6 
(5.00 mg, 0.02 mmol) in dichloromethane (5 mL). The resulting reaction mixture was 
stirred at this temperature for 1 h then filtered and the filtrate was concentrated under 
reduced pressure to a give clear, yellow oil. Subjection of this material to Kugelrohr 
distillation or flash chromatography (silica, 0 → 10% v/v ethyl acetate/hexane gradient 
elution) provided, after concentration of the appropriate fractions, the relevant chiral 
cyanoformate as a either a clear, colourless oil or white solid.  
 
(-)-(1S,2R,5S)-2-isopropyl-5-methylcyclohexyl cyanoformate (255) 
 
Clear, colourless oil 
Rf 0.4 (silica, 1:9 v/v ethyl acetate/hexane). 
b.p. 60 – 63°C (20 mm/Hg)  
1H NMR (300 MHz) δ 4.88 (dt, J = 11.0 and 4.3 Hz, 1H), 2.06–2.02 (complex m, 1H), 
1.88–1.83 (complex m, 1H), 1.76–1.69 (complex m, 2H), 1.54–1.45 (complex m, 2H), 
1.19–0.96 (complex m, 2H), 0.93 (complex m, 6H), 0.76 (d, J = 6.9 Hz, 3H).  
13C NMR (75 MHz) δ 144.0 (C=O), 109.5 (CN), 80.7 (CH), 46.5 (CH), 40.1 (CH2), 
33.7 (CH2), 31.4 (CH), 26.1 (CH), 23.1 (CH2), 21.8 (CH3), 20.6 (CH3), 16.0 (CH3). 
IR (NaCl, film) νmax 2959, 2873, 2244 (CN), 1744 (C=O), 1456, 1251, 945 cm-1. 
EIMS (70 eV) m/z 138 [(M–CO2CN•)+, 56%], 123 (44), 81 (100).  
HRMS Found: (M–CO2CN•)+, 138.1409. C10H18 requires (M–CO2CN•)+, 138.1409.  
Specific Rotation [α]D -42.0 (c = 1.0, CHCl3). 
 
 
 
 
O OKCN, 18-crown-6, CH2Cl2, 18oC, 1 hCl
NC
OO
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(-)-(1R,2S)-2-(2-Phenylpropan-2-yl)cyclohexyl cyanoformate (256) 
 
 
Clear, colourless oil 
Rf 0.3 (silica, 1:99 v/v ethyl acetate/hexane) 
1H NMR (300 MHz) δ 7.37–7.19 (complex m, 5H), 4.96 (dt, J = 10.3 and 4.0 Hz, 1H), 
2.16 (td, J = 11.1 and 3.9 Hz, 1H), 1.91–1.88 (complex m, 2H), 1.74–1.72 (complex m, 
2H), 1.33 (s, 3H), 1.27 (s, 3H), 1.26–1.13 (complex m, 4H).  
13C NMR (75 MHz) δ 150.1 (C=O), 143.3 (C), 128.3 (CH), 126.1 (CH), 125.2 (CH), 
109.0 (CN), 80.4 (CH), 50.7 (CH), 39.6 (C), 32.7 (CH2), 28.7 (CH2), 26.7 (CH2), 25.4 
(CH3), 24.4 (CH3), 23.8 (CH2). 
IR (NaCl, film) νmax 2933, 2243 (CN), 1738 (C=O), 1252, 700 cm-1.  
EIMS (70 eV) m/z 271 (M+•, 21%), 200 (33), 119 (100).  
HRMS Found: M+•, 271.1569. C17H21NO2 requires M+•, 271.1572.  
Specific Rotation [α]D -31.0 (c = 1.8, CH3OH). 
 
(+)-(1S,2S,5R)-5-[2-(2-Naphthen-3-yl)propan-2-yl]cyclohexyl cyanoformate 
(257) 
 
Clear colourless oil 
Rf 0.3 (silica, 5:95 v/v ethyl acetate/hexane).  
1H NMR (300 MHz) δ 7.83–7.68 (complex m, 4H), 7.48–7.41 (complex m, 3H), 5.02 
(complex m, 1H), 1.82–1.47 (complex m, 6H), 1.45 (s, 6H), 1.08–0.89 (complex m, 
2H), 0.88 (d, J = 6.6 Hz, 3H) 
O O
KCN, 18-crown-6,
 CH2Cl2, 18oC, 1 h
Cl NC
OO
(251) (256)
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13C NMR (75 MHz) δ 145.6 (C=O), 143.4 (C), 133.2 (C), 131.8 (C), 128.0 (CH), 127.9 
(CH), 127.3 (CH), 126.2 (CH), 125.7 (CH), 124.3 (CH), 124.2 (CH), 109.4 (CN), 78.4 
(CH), 50.6 (CH), 40.1 (C), 39.2 (CH2), 34.8 (CH2), 27.9 (CH), 26.7 (CH3), 25.2 (CH3), 
22.1 (CH2), 21.7 (CH3) 
IR (NaCl, film) νmax 2925, 2241 (CN), 1743 (C=O), 1248, 1112, 745 cm-1. 
EIMS (70 eV) m/z 335 (M+•, >1%), 264 (1), 169 (100).  
HRMS Found: M+•, 335.1881. C22H25NO2 requires M+•, 335.1885.  
Specific Rotation [α]D +34.9 (c = 1.6, CHCl3). 
 
(+)-(1R,2S,3R)-[N-Benzene-sulfonyl-N-(3,5-dimethylphenyl)-amino]-2-
bornanyl cyanoformate (258) 
 
White solid 
Rf 0.4 (silica, 1:4 v/v ethyl acetate/hexane). 
m.p. 210–212°C.  
1H NMR (300 MHz) δ 7.57–7.36 (complex m, 6H), 6.90 (s, 2H), 6.00 (s, 1H), 5.28 (d, 
J = 7.0 Hz, 1H), 3.83 (d, J = 7.0 Hz, 1H), 2.26 (s, 3H), 2.09 (s, 3H), 1.75–1.69 (complex 
m, 1H), 1.60 (td, J = 13.0 and 3.4 Hz, 1H), 1.36–1.28 (complex m, 1H), 1.14–1.08 
(complex m, 1H), 0.95 (s, 3H), 0.85 (complex m, 3H), 0.66 (s, 3H). 
13C NMR (75 MHz) δ 143.7 (C=O), 138.5 (C), 138.5 (C), 132.9 (CH), 129.7 (CH), 
129.5 (C), 128.7 (C), 128.4 (CH), 128.3 (CH), 109.5 (CN), 85.3 (CH), 66.8 (CH), 50.4 
(C), 48.5 (CH), 47.5 (C), 31.8 (C), 27.4 (CH2), 21.0 (CH2), 20.9 (CH3), 20.6 (CH3), 11.2 
(CH3).  
IR (NaCl, film) νmax 2921, 2243 (CN), 1751 (C=O), 1352, 1166, 703 cm-1.  
EIMS (70 eV) m/z 466 (M+•, 12%), 325 (33), 132 (100).  
HRMS Found: M+•, 466.1922. C26H30N2O4S requires M+•, 466.1926.  
Specific Rotation [α]D +36.0 (c = 1.0, CHCl3). 
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5.4.4 General Procedure for Synthesis of Chiral β-Ketoesters 259 - 262 
 
Following a procedure developed by Mander et al,1 a magnetically stirred solution of 
diisopropylamine (0.18 mL, 1.20 mmol) in THF (10 mL) maintained at –20°C 
(NaCl/ice bath) under a nitrogen atmosphere was treated, dropwise, with n-butyllithium 
(0.70 mL of a 1.7 M solution in hexanes, 1.20 mmol). The resulting mixture was stirred 
at –20°C (NaCl/ice bath) for 0.5 h then the temperature was reduced to –78°C (dry-
ice/acetone bath) and a solution of enone 77 (98.0 mg, 1.00 mmol) in THF (5 mL) was 
added via cannula. The resulting solution was warmed to 0°C (ice/water bath), stirred at 
this temperature for 1 h, then cooled to –78°C again and HMPA (0.10 mL 1.20 mmol) 
and the appropriate chiral cyanoformate (1.10 mmol) were added. After stirring for an 
additional 0.25 h at –78°C, the reaction mixture was poured into cold water (50 mL) 
and extracted with ether (2 x 50 mL). The combined organic phases were washed with 
distilled water (3 x 50 mL). The separated organic phase was then dried (MgSO4), 
filtered and concentrated under reduced pressure to give the relevant chiral β-ketoester 
as a mixture of diastereoisomers and as either clear, yellow oils or white solids. 
 
(±)-(R/S)-(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl-2-oxo-cyclohex-3-ene 
carboxylate (259) 
 
Clear, colourless oil 
Rf 0.5 (silica, 3:7 v/v ethyl acetate/hexane).  
1H NMR (300 MHz) δ 6.97 (complex m, 1H), 6.05 (complex m, 1H), 4.72 (dt, J = 11.0 
and 4.3 Hz, 1H), 3.37 (complex m, 1H), 2.45–2.34 (complex m, 3H), 2.23–2.19 
(complex m, 1H), 2.06–2.02 (complex m, 2H), 1.68–1.64 (complex m, 2H), 1.54–1.45 
(complex m, 3H), 1.09–0.92 (complex m, 2H), 0.88 (complex m, 6H), 0.76 (complex m, 
3H).  
13C NMR (75 MHz) δ 194.0 (C=O), 169.7 (C=O), 169.5 (C=O), 150.4 (CH), 129.2 
(CH), 129.1 (CH), 75.3 (CH), 75.2 (CH), 53.7 (CH), 53.5 (CH), 46.8 (CH), 40.7 (CH2), 
40.6 (CH2), 34.2 (CH2), 31.4 (CH), 26.1 (CH), 26.0 (CH), 25.82 (CH2), 25.77 (CH2), 
1. LDA, THF, 
   -78oC to 0oC, 1 h
2.(255), HMPA, THF, 
   -78oC, 0.25 h
O
O
OO
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24.3 (CH2), 24.2 (CH2), 23.2 (CH), 23.0 (CH), 22.0 (CH3), 20.8 (CH3), 20.7 (CH3), 16.1 
(CH3), 15.9 (CH3). 
IR (NaCl, film) νmax 2955, 2871, 1733 (C=O), 1683 (C=O), 1454, 1263 cm-1.  
EIMS (70 eV) m/z 278 (M+•, 1%), 138 (96), 123 (97), 96 (100).  
HRMS Found: M+•, 278.1885. C17H26O3 requires M+•, 278.1882. 
 
(±)(R/S)-(1R,2S)-2-(2-phenylpropan-2-yl)cyclohexyl 2-oxocyclohex-3-ene 
carboxylate (260) 
 
Clear, colourless oil 
Rf 0.5 (silica, 1:9 v/v ethyl acetate/hexane).  
1H NMR (300 MHz) (major diastereoisomer) δ 7.31–7.23 (complex m, 5H), 7.13 
(complex m, 1H), 6.02 (dt, J = 10.2 and 3.7 Hz, 1H), 4.83 (sept, J = 4.8 Hz, 1H), 2.90 
(dd, J= 8.7 and 5.2 Hz, 1H), 2.43 – 1.90 (complex m, 8H), 1.70–1.60 (complex m, 3H), 
1.30 (s, 3H), 1.19 (s, 3H), 1.07 (complex m, 2H). (minor diastereoisomer) δ 6.91 
(complex m, 1H), 5.90 (ddd, J = 10.1, 2.5 and 1.6 Hz, 1H), 1.33 (s, 3H), 1.24 (s, 3H), 
0.98 (complex m, 2H), (other signals overlapping). 
13C NMR (75 MHz) (major diastereoisomer) δ 194.2 (C=O), 168.2 (C=O), 152.1 (C), 
150.0 (CH), 129.0 (CH), 127.9 (CH), 125.4 (CH), 125.0 (CH), 75.4 (CH), 53.1 (CH), 
50.5 (CH), 39.7 (C), 33.2 (CH2), 28.7 (CH3), 26.8 (CH2), 25.9 (CH2), 25.1 (CH2), 24.6 
(CH2), 24.1 (CH2), 23.9 (CH3). (minor diastereoisomer) δ 194.1 (C=O), 151.4 (C), 
150.2 (CH), 129.3 (CH), 127.8 (CH), 125.6 (CH), 124.7 (CH), 76.3 (CH), 53.5 (CH), 
50.8 (CH), 40.0 (C), 33.1 (CH2), 27.2 (CH2), 26.7 (CH2), 25.4 (CH2), (other signals 
overlapping). 
IR (NaCl, film) νmax 2935, 1731 (C=O), 1681 (C=O), 1447, 1166, 701 cm-1.  
EIMS (70 eV) m/z 340 (M+•, 5%), 200 (73), 185 (24), 119 (100).  
HRMS Found: M+•, 340.2036. C22H28O3 requires M+•, 340.2038. 
 
 
 
O
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    -78oC to 0oC, 1 h
2. (256), HMPA, THF,
     -78oC, 0.25 h
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(±)(R/S)-(1R,2S,5R)-5-methyl-2-[2-(naphthalene-3-yl)propan-2-yl] 
cyclohexyl 2-oxocyclohex-3-ene carboxylate (261) 
 
Clear, colourless oil 
Rf 0.6 (silica, 3:7 v/v ethyl acetate/hexane). 
1H NMR (300 MHz) (major diastereoisomer) δ 7.82–7.69 (complex m, 4H), 7.50–7.40 
(complex m, 3H), 7.02 (dt, J = 10.2 and 3.7 Hz, 1H), 6.12 (dt, J = 10.2 and 1.9 Hz, 1H), 
5.10 (complex m, 1H), 3.06 (complex m, 1H), 2.42–1.92 (complex m, 4H), 1.72–1.44 
(complex m, 6H), 1.42 (s, 3H), 1.40 (s, 3H), 0.92 (t, J =12.7 Hz, 2H), 0.90 (d, J = 5.4 
Hz, 3H). (minor diastereoisomer) δ 6.94 (dt, J = 10.2 and 3.7 Hz, 1H), 6.03 (dt, J = 10.2 
and 2.2 Hz, 1H), (other signals overlapping). 
13C NMR (75 MHz) δ 194.0 (C=O), 193.8 (C=O), 168.9 (C=O), 150.3 (CH), 150.2 
(CH), 147.1 (C), 146.8 (C), 133.25 (C), 131.7 (C), 131.6 (C), 129.3 (CH), 129.2 (CH), 
128.0 (CH), 127.33 (CH), 127.26 (CH), 125.8 (CH), 125.3 (CH), 125.1 (CH), 124.8 
(CH), 124.5 (CH), 124.4 (CH), 72.7 (CH), 75.4 (CH), 53.9 (CH), 53.6 (CH), 51.1 (CH), 
51.0 (CH), 40.2 (C), 40.1 (C), 39.82 (CH2), 39.78 (CH2), 35.5 (CH2), 35.3 (CH2), 31.6 
(CH2), 26.9 (CH), 26.8 (CH), 26.7 (CH3), 26.6 (CH3), 25.7 (CH2), 25.5 (CH2), 24.4 
(CH2), 24.3 (CH2), 22.4 (CH3), 22.1 (CH3).  
IR (NaCl, film) νmax 2946, 1734 (C=O), 1679 (C=O), 1454, 1237, 747 cm-1. 
EIMS (70 eV) m/z 404 (M+•, 1%), 264 (12), 249 (12), 169 (100).  
HRMS Found: M+•, 404.2359. C27H32O3 requires M+•, 404.2351. 
 
 
 
 
 
 
 
 
 
O
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(±)(R/S)-(1R,2S,3R)-(+)-[N-benzene-sulfonyl-N-(3,5-dimethylphenyl)-
amino]-2-bornanyl-2-cyclohex-3-ene carboxylate (262) 
 
White solid 
Rf 0.6 (silica, 3:7 v/v ethyl acetate/hexane).  
m.p. 223–225°C.  
1H NMR (300 MHz) (major diastereoisomer) δ 7.54–7.30 (complex m, 5H), 7.10 
(complex m, 1H), 6.98 (complex m, 1H), 6.84 (s, 1H), 6.08 (complex m, 1H), 5.68 (s, 
1H), 5.27 (d, J = 7.2 Hz, 1H), 3.83 (d, J = 7.2 Hz, 1H), 3.64 (complex m, 1H), 2.56–
2.41 (complex m, 3H), 2.39 (s, 3H), 2.03 (s, 3H), 1.88–1.24 (complex m, 4H), 1.11–
0.98 (complex m, 2H), 0.93 (s, 3H), 0.89 (s, 3H), 0.58 (s, 3H). (minor diastereoisomer) 
δ 6.20 (complex m, 1H), 3.76 (d, J = 7.2 Hz, 1H), 0.85 (s, 3H), 0.79 (s, 3H), 0.55 (s, 
3H), (other signals overlapping). 
13C NMR (75 MHz) (major diastereoisomer) δ 194.5 (C=O), 169.6 (C=O), 150.9 (CH), 
138.5 (C), 137.0 (C), 132.5 (CH), 129.3 (CH), 129.1 (CH), 128.7 (C), 128.2 (CH), 
128.1 (CH), 82.0 (CH), 67.4 (CH), 57.3 (CH), 50.4 (CH), 48.4 (CH), 47.4 (C), 32.0 
(CH2), 27.7 (CH2), 25.3 (CH2), 24.4 (CH2), 21.2 (CH3), 20.7 (CH3), 20.6 (CH3), 11.2 
(CH3). (minor diastereoisomer) δ 168.9 (C=O), 151.2 (CH), 138.4 (C), 138.0 (C), 132.6 
(CH), 129.6 (CH), 129.2 (CH), 128.4 (CH), 128.1 (CH), 81.8 (CH), 67.3 (CH), 54.2 
(CH), 50.8 (CH), 48.6 (CH), 47.2 (C), 32.1 (CH2), 27.9 (CH2), 27.6 (CH2), 26.0 (CH2), 
21.1 (CH3), 20.5 (CH3), 19.3 (CH3), 11.4 (CH3), (other signals overlapping). 
IR (NaCl, film) νmax 2925, 1740 (C=O), 1680 (C=O), 1352, 1167, 718 cm-1.  
EIMS (70 eV) m/z 535 (M+•, >1%), 395 (18), 254 (100).  
HRMS Found: M+•, 535.2391. C31H37NO5S requires M+•, 404.2392. 
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5.4.5 General Procedure for Synthesis of Chiral α-Arylated β-Ketoesters 
263 -266 
 
Following a procedure developed by Pinhey et al,8 a magnetically stirred solution of the 
appropriate chiral auxiliary-containing β-ketoester (1.00 mmol) in chloroform (5 mL) at 
18°C maintained under a nitrogen atmosphere was treated with pyridine (0.24 mL, 3.00 
mmol) and stirred for 0.5 h then treated with phenyllead triacetate (74) (506 mg, 1.10 
mmol). The resulting mixture was heated to 40°C, stirred at this temperature for 12 h, 
then cooled and quenched with HCl (drop of 1 M aqueous solution) and diluted with 
ether (20 mL). The organic phase was washed with HCl (1 x 25 mL of a 1 M aqueous 
solution) and distilled water (2 x 25 mL) then dried (MgSO4), filtered and concentrated 
under reduced pressure to give a clear, yellow oil. Subjection of this material to flash 
chromatography (silica, 5 → 20% v/v ethyl acetate/hexane gradient elution) provided, 
after concentration of the appropriate fractions, the relevant chiral α-arylated β-
ketoester as a mixture of diastereoisomers and as clear, colourless oils.  
 
(±)-(1R/S)-(1R,2S,5R)-2-Isopropyl-5-methylcyclohexyl 2-oxo-1-phenyl-
cyclohex-3-ene carboxylate (263) 
 
Rf 0.3 (silica, 1:9 v/v ethyl acetate/hexane). 
1H NMR (300 MHz) δ 7.38–7.19 (complex m, 5H), 6.87 (complex m, 1H), 6.16 (dt, J = 
10.2 and 1.9 Hz, 1H), 4.69 (complex m, 1H), 2.38–2.77 (complex m, 1H), 2.61–2.27 
(complex m, 2H), 2.06–2.01 (complex m, 1H), 1.67–1.23 (complex m, 7H), 1.07–0.90 
(complex m, 2H), 0.88 (complex m, 6H), 0.81–0.66 (complex m, 3H).  
13C NMR (75 MHz) δ 195.0 (C=O), 194.6 (C=O), 171.1 (C=O), 170.5 (C=O), 149.1 
(CH), 149.0 (CH), 136.4 (C), 136.3 (C), 129.2 (CH), 129.1 (CH), 128.0 (CH), 127.32 
(CH), 127.28 (C), 75.7 (CH), 62.6 (C), 62.4 (C), 46.42 (CH), 46.4 (CH), 40.0 (CH2), 
39.88 (CH2), 33.9 (CH2), 31.8 (CH2), 31.7 (CH2), 31.2 (CH2), 31.1 (CH2), 27.6 (CH), 
26.6 (CH), 25.4 (CH2), 25.3 (CH2), 23.8 (CH), 23.6 (CH), 22.7 (CH3), 21.8 (CH3), 
20.51 (CH3), 20.50 (CH3), 15.5 (CH3).  
IR (NaCl, film) νmax 2955, 1725 (C=O), 1683 (C=O), 1449, 1246, 1039, 696 cm-1.  
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EIMS (70 eV) m/z 354 (M+•, 4%), 216 (56), 172 (100).  
HRMS Found: M+•, 354.2199 Calcd for C23H30O3 requires M+•, 354.2195. 
 
(±)-(1R/S)-(1R,2S)–2-(2–Phenylpropan–2-yl)-cyclohexyl–2–oxo–1–phenyl–
cyclohex–3-ene carboxylate (264) 
 
Rf 0.6 (silica, 1:9 v/v ethyl acetate/hexane). 
1H NMR (300 MHz) (major diastereoisomer) δ 7.36–7.08 (complex m, 10H), 6.78 
(complex m, 1H), 6.13 (dt, J = 10.0 and 1.8 Hz, 1H), 4.81 (td, J = 10.0 and 4.2 Hz, 1H), 
2.50–2.28 (complex m, 2H), 2.10–2.07 (complex m, 2H), 1.85 (complex m, 1H), 1.64–
1.47 (complex m, 2H), 1.37–1.14 (complex m, 6H), 1.12 (s, 3H), 0.96 (s, 3H), (minor 
diastereoisomer) δ 6.82 (complex m, 1H), 4.88 (td, J = 10.0 and 4.4 Hz, 1H), 1.14 (s, 
3H), 0.95 (s, 3H), (other signals overlapping). 
13C NMR (75 MHz) (major diastereoisomer) δ 195.3 (C=O), 170.2 (C=O), 150.8 (C), 
149.0 (CH), 135.4 (C), 129.2 (CH), 128.3 (CH), 127.9 (CH), 127.8 (CH), 127.6 (CH), 
125.7 (CH), 125.0 (CH), 77.5 (CH), 62.6 (C), 50.5 (CH), 40.2 (C), 32.8 (CH2), 30.6 
(CH2), 28.6 (CH2), 27.4 (CH2), 25.6 (CH3), 24.4 (CH3), 24.3 (CH2), 23.7 (CH2). (minor 
diastereoisomer) δ 195.2 (C=O), 170.3 (C=O), 149.6 (CH), 135.6 (C), 129.2 (CH), 
128.3 125.15, 62.8 (C), 50.3 (CH), 40.25 (C), 32.6 (CH2), 29.7 (CH2), 28.8 (CH2), 27.8 
(CH2), 26.75 (CH3), 24.5 (CH3), 24.0 (CH2), 23.5 (CH2), (other signals overlapping). 
IR (NaCl, film) νmax 2931, 1720 (C=O), 1677 (C=O), 1244, 698 cm-1.  
EIMS (70 eV) m/z 416 (M+•, 1%), 269 (30), 119 (100).  
HRMS Found: M+•, 416.2365. C28H32O3 requires M+•, 416.2351. 
 
 
 
 
 
 
O
O
O
O
1.  py., CHCl3, 18oC, 0.5 h
2. (74), 40oC, 12 h
O O
(260) (264)
 193
(±)-(1R/S)-(1S,2R,5S)-5-Methyl-2-[2-(naphthalene-3-yl)propan-2-yl]-
cyclohexyl 2-oxo-1-phenyl-cyclohex-3-ene carboxylate (265) 
 
Rf 0.2 (silica, 1:9 v/v ethyl acetate/hexane). 
1H NMR (300 MHz) (major diastereoisomer) δ 7.80–7.74 (complex m, 3H), 7.55–7.26 
(complex m, 9H), 6.79 (complex m, 1H), 6.14 (d, J = 10.0 Hz, 1H), 5.00 (complex m, 
1H), 2.81 (complex m, 1H), 2.77 (complex m, 1H), 2.66–2.30 (complex m, 2H), 2.08 
(complex m, 1H), 1.73–1.35 (complex m, 2H), 1.30–1.26 (complex m, 5H), 1.02 (d, J = 
10.0 Hz, 6H), 0.84 (d, J = 6.5 Hz, 3H). (minor diastereoisomer) 6.82 (complex m, 1H), 
6.17 (d, J = 10.0 Hz, 1H), 5.05 (complex m, 1H), 1.95 (complex m, 1H), 1.01 (d, J = 10 
Hz, 6H), 0.96 (s, 3H), 0.79 (d, J = 6.5 Hz, 3H), (other signals overlapping).  
13C NMR (75 MHz) (major diastereoisomer) δ 195.6 (C=O), 170.0 (C=O), 149.1 (CH), 
147.4 (C), 135.4 (C), 133.2 (C), 131.6 (C), 129.2 (CH), 128.4 (CH), 127.9 (CH), 127.8 
(CH), 127.73 (CH), 127.5 (CH), 127.3 (CH), 125.8 (CH), 125.3 (CH), 124.7 (CH), 
124.2 (CH), 73.7 (CH), 62.7 (C), 50.9 (CH), 39.8 (C), 39.6 (CH2), 35.3 (CH2), 31.3 
(CH3), 26.7 (CH), 25.9 (CH3), 25.4 (CH3), 23.8 (CH2), 22.1 (CH3), 22.0 (CH3). (minor 
diastereoisomer) δ 195.4 (C=O), 170.3 (C=O), 149.5 (CH), 136.2 (C), 129.4 (CH), 
128.0 (CH), 127.7 (CH), 127.6 (CH), 124.9 (CH), 124.4 (CH), 73.4 (CH), 63.2 (C), 
51.2 (CH), 40.1 (CH2), 35.2 (CH2), 29.7 (CH3), 27.7 (CH), 25.7 (CH3), 23.7 (CH2), 22.6 
(CH3), 21.9 (CH3), (other signals overlapping). 
IR (NaCl, film) νmax 2924, 1723 (C=O), 1676 (C=O), 1455, 1243, 697 cm-1.  
EIMS (70 eV) m/z 480 (M+•, >1%), 264 (15), 249 (18), 169 (100).  
HRMS Found: M+•, 480.2664. C33H36O3 requires M+•, 488.2664. 
 
 
 
 
 
 
O
O
O
O
1. py., CHCl3, 18oC, 0.5 h
2. (74), 40oC, 12 h
O O
(261) (265)
 194
(±)-(1R/S)-(1R,2S,3R)-[N-Benzene-sulfonyl-N-(3,5-dimethylphenyl)-amino]-
2-bornanyl-2-oxo-1-phenyl-cyclohex-3-ene carboxylate (266) 
 
Rf 0.4 (silica, 3:7 v/v ethyl acetate/hexane). 
1H NMR (300 MHz) (major diastereoisomer) δ 7.69 (d, J = 8.0 Hz, 1H), 7.59–7.27 
(complex m, 12H), 6.80 (s, 1H), 6.10 (complex m, 1H), 5.37 (d, J = 7.0 Hz, 1H), 3.64 
(d, J = 7.0 Hz, 1H), 3.25–3.16 (complex m, 2H), 2.98 (sept, J = 4.9 Hz, 1H), 2.33 (s, 
3H), 2.04 (s, 3H), 1.88–0.97 (complex m, 6H), 0.93 (s, 3H), 0.90 (s, 3H), 0.41 (s, 3H). 
(minor diastereoisomer) δ 6.90 (s, 1H), 6.24 (dd, J = 10.0 and 2.5 Hz, 1H), 5.39 (d, J = 
7.0 Hz, 1H), 3.76 (d, J = 7.1 Hz, 1H), 0.81 (s, 3H), 0.58 (s, 3H), (other signals 
overlapping).  
13C NMR (75 MHz) (major diastereoisomer) δ 196.0 (C=O), 171.2 (C=O), 149.6 (CH), 
138.2 (C), 136.0 (C), 133.6 (C), 132.6 (CH), 129.4 (C), 129.1 (CH), 129.0 (CH), 128.7 
(CH), 128.3 (CH), 128.1 (CH), 128.0 (CH), 127.3 (CH), 82.0 (CH), 67.2 (CH), 63.3 
(C), 50.5 (CH), 48.4 (CH), 46.9 (C), 32.1 (CH2), 27.9 (CH2), 27.8 (C), 23.3 (CH2), 23.1 
(CH3), 20.9 (CH3), 20.6 (CH3), 20.4 (CH3), 11.5 (CH3). (minor diastereoisomer) δ 171.1 
(C=O), 150.8 (CH), 138.6 (C), 135.8 (C), 129.7 (C), 129.2 (CH), 128.8 (CH), 128.2 
(CH), 127.1 (CH), 82.4 (CH), 67.6 (CH), 63.9 (C), 51.0 (CH), 48.7 (CH), 47.2 (C), 32.4 
(CH2), 28.0 (CH2), 26.8 (C), 23.8 (CH2), 23.3 (CH3), 21.2 (CH3), 20.5 (CH3), 11.4 
(CH3), (other signals overlapping). 
IR (NaCl, film) νmax 2957, 1736 (C=O), 1674 (C=O), 1352, 1167, 732 cm-1.  
EIMS (70 eV) m/z 611 (M+•, >1%), 470 (1), 254 (100).  
HRMS Found: M+•, 611.2718. C37H41NO3S requires M+•, 611.2705. 
 
 
 
 
 
 
 
 
 
 
O
N
S
O
O
O
O
1. py., CHCl3, 18oC, 0.5 h
2. (74), 40oC, 12 h
O
N
S
O
O
OO
(262) (266)
 195
 5.5 References 
 
1. Mander, L. N.; Sethi, S. P., Tetrahedron Lett. 1983, 24, p. 5424. 
2. Olszewski, J. D.; Marshalla, M.; Sabat, M.; Sundburg, R. J., J. Org. Chem. 
1994, 59, p. 4291. 
3. Suginome, H.; Orito, K.; Yorita, K.; Ishikawa, M.; Shimoyama, M.; Sasaki, T., 
J. Org. Chem. 1995, 60, p. 3052. 
4. Deng, H.; Konopelski, J. P., Org. Lett. 2001, 3, p. 3001. 
5. Forbes, I. T.; Jones, G. E.; King, F. D.; Ham, P.; David, T.; Moghe, A., 
Preparation of Benzannelated Five-membered Heterocyclecarboxamides as 5-
HT Receptor Antagonists. 1996. 
6. Kozyrod, R. P.; Morgan, J.; Pinhey, J. T., Aust. J. Chem. 1985, 38, p. 1147. 
7. Combes, S.; Finet, J. P.; Siri, D., J. Chem. Soc., Perkin Trans. 1 2002, 1, p. 38. 
8. Rowe, B. A.; Pinhey, J. T., Aus. J. Chem. 1980, 33, p. 113. 
9. Ito, Y.; Hirao, T.; Saegusa, T., J. Org. Chem. 1978, 43, p. 1011. 
10. Johnson, C. R.; Adams, J. P.; Braun, M. P.; Senanayake, C. B. W.; Woykulich, 
P. M., Tetrahedron Lett. 1993, 33, p. 917. 
11. Banwell, M. G.; Kelly, B.; Kokas, O. J.; Lupton, D. W., Org. Lett. 2003, 5, p. 
2497. 
12. Iwama, T.; Birman, V. B.; Kozmin, S. A.; Rawal, V. H., Org. Lett. 1999, 1, p. 
673. 
13. Lauer, W. M.; Rondestvedt, C.; Arnold, R. T.; Drake, N. L.; Van Hook, J.; 
Tinker, J., J. Am. Chem. Soc. 1946, 68, p. 1546. 
14. Bindal, V.; Jain, K.; Handa, R. N.; Pujari, H. K., Ind. J. Chem. 1986, 25B, p. 
807. 
15. Campbell, N.; McCall, E. B., J. Chem. Soc. 1950, p. 2870. 
16. Campaigne, E.; Lake, R. D., J. Am. Chem. Soc. 1958, 24, p. 478. 
17. Zibuck, R.; Streiber, J. M., J. Org. Chem. 1989, 54, p. 4717. 
18. Van den Goorbergh, J. A. M.; Nonneman, L. E. Y.; Van der Gen, A., Rec. Trav. 
Chem. 1985, 104, p. 277. 
19. Slusarchyk, W. A.; Bolton, S. A.; Scott, A.; Hartl, K. S.; Huang, M.; Jacobs, G.; 
Meng, W.; Ogletree, M. L.; Pi, Z.; Schumacher, W. A.; Seiler, S. M.; Sutton, J. 
C.; Treurer, U.; Zahler, R.; Zhao, G.; Bisacchi, G. S., Bioorg. Med. Chem Lett. 
2002, 12, p. 3235. 
20. Magnus, P.; Thurston, L. S., J. Org. Chem. 1990, 56, p. 1166. 
21. Yang, D.; Xu, M.; Mai-Ying, B., Org. Lett. 2001, 3, p. 111. 
 196
22. Comins, D. L.; Joseph, S. P.; Goehring, R. R., J. Am. Chem. Soc. 1994, 116, p. 
4719. 
23. Childs, M. E.; Weber, W. P., J. Org. Chem. 1976, 41, p. 3486. 
 
 197
Appendix A: 
 
 
 
 
 
 
 
 
 
 
Schemes Summarising Existing Syntheses of (+)-Vinblastine 
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Reagents and conditions: (a) mCPBA, CH2Cl2, -30°C; (b) i. TFAA, CH2Cl2, -50°C; ii. NaBH4, EtOH, r.t.; (c) i. 10% 
Pd/C, H2, 1 atm., EtOH, r.t.; ii. mCPBA, CH2Cl2, -30°C;  iii. Ac2O, CH2Cl2, 0°C; (d) i. Tl(OAc)3, AcOH, 75°C; ii. 
NaBH4, EtOH, r.t. 
 
Scheme A.1: Potiers’s total synthesis of (+)-vinblastine (1) 
 
 
Reagents and conditions: (a) mCPBA, CH2Cl2, -30°C (b) i. TFAA, CH2Cl2, -60°C; ii. β-NADH, MeOH, r.t.; iii. 
FeCl3, O2, MeOH, 0°C; iv. NaBH4, MeOH, r.t. 
 
 
Scheme A.2: Kutney’s biomimetic total synthesis of (+)-vinblastine (1)  
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Reagents and conditions: (a) D-(-)-diethyl tartrate, Ti(i-PrO)4, t-BuOOH, CH2Cl2, r.t. → -20°C; (b) CuI, 
allylmagnesium chloride, THF, -30°C; (c) TsOH, (9:1 v/v) acetone/DMP, r.t.; (d) ozone, PPh3, CH2Cl2, -78°C → r.t.; 
(e) i. methyl 1,2,3,4,5,6-hexahydroazepino[4,5b]indole-5-carboxylate, THF, reflux; ii. BnBr, THF, reflux; iii. Et3N, 
MeOH, reflux; (f) 10% HCl, MeOH, reflux; (g) Ts2O, Et3N, CH2Cl2, 0°C → r.t.; (h) TMS2O, i-Pr2EtN, THF, 0°C; (i) 
i. t-BuOCl, Et3N, CH2Cl2, 0°C; ii. BF3•OEt2, AgBF4, acetone, r.t.; iii. KBH4, AcOH, r.t.; iv. reflux, MeOH; (j) i. 10% 
Pd/C, H2, MeOH, r.t.; ii. TBAF, THF, r.t.   
 
Scheme A.3: Kuehne’s total enantioselective total synthesis of (+)-vinblastine (1) 
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Reagents and conditions (a) i. thiophosgene, Na2CO3, THF, 0°C; ii. NaBH4, MeOH, 0°C; (b) i. DHP, CSA, CH2Cl2, 
r.t.; ii. benzyl methyl malonate, NaH, THF, 0°C; (c) AIBN, Bu3SnH, toluene, 110°C; (d) i. Boc2O, Et3N, DMAP, 
CH2Cl2, r.t.; ii. 10% Pd/C, H2, EtOH, r.t.; iii. Me2NH•HCl, HCHO, NaOAc, AcOH, r.t.; iv. CSA, MeOH, r.t.; (e) 
(2S)-2-[[(2,4-dinitrobenzenesulfonyl)amino]methyl]-4-ethyl-2,3-dihydrofuran, DEAD, PPh3, benzene, r.t.; (f) i. 
K2CO3, MeOH, r.t.; ii. TESCl, Im., DMF, r.t.; iii. TMSCl, DMF, r.t.; (g) PPh3, CCl4, MeCN, 70°C; (h) KOH, MeOH, 
80°C; (i) MeI, t-BuOK, THF, 0°C; (j) (PhSeO)2O, benzene, 80°C; (k) i. mCPBA, (1:9 v/v) MeOH/CH2Cl2, NaHCO3 
(aq), 0°C;  ii. HCHO, NaBH3CN, 10% HCl/MeOH, 0°C → r.t.; iii. Na2CO3, NaHSO3, r.t.; (l) NaOAc, Ac2O, r.t.        
 
Scheme A.4: Part one of Fukuyama’s stereocontrolled synthesis of (+)-vinblastine (1) 
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Reagents and conditions: (a) i. PivCl, Et3N, Et2O, 0°C; ii. n-BuLi, (R)-4-benzyl-2-oxazolidinone, THF, -78°C; (b) i. 
Ac2O, py., r.t.; ii. (i-PrO)TiCl3, i-Pr2EtN, acrylnitrile, CH2Cl2, 0°C; (c) i. NaBH4, THF, r.t.; ii. TBDPSCl, Im., DMF, 
r.t.; (d) i. DIBAL, CH2Cl2, -78°C; ii. H2NOH•HCl, NaOAc, EtOH, r.t.; iii. NaOCl (aq), CH2Cl2, r.t.; (e) Zn, AcOH, 
r.t.; (f) mCPBA, AcOH, r.t.; (g) i. K2CO3, MeOH, r.t.; ii. TESCl, Im., DMF, r.t.; iii. TMSCl, DMF, r.t. (h) LDA, 
tetrahydro-2-[(Z)-3-(2-isothiocyanatophenyl)-2-propenyl]-oxy-2H-pyran, THF, -78°C → 0°C; i. Bu3SnH, Et3B, THF, 
r.t.; (j) i. Boc2O, Et3N, DMAP, CH2Cl2, r.t.; ii. AcOH, 80°C; (k) i. TsCl, Bu2SnO, Et3N, CH2Cl2, r.t.; ii. NaHCO3, 
DMF, 80°C; iii. NsNH2, DEAD, PPh3, toluene, r.t.; (l) K2CO3, DMF, 90°C; (m) i. TFA, CH2Cl2, r.t.; ii. TsCl, 
Me2N(CH2)3NMe2, (1:1 v/v) MeCN/toluene, r.t.; iii. TFAA, py., CH2Cl2, r.t.; (n) t-BuOCl, CH2Cl2, 0°C; (o) TFA, 
CH2Cl2, 0°C → r.t.; (p) i. Et3N, MeOH, r.t.; ii. HSCH2CH2OH, DBU, MeCN, r.t.; iii. NaHCO3, i-PrOH, r.t.   
 
Scheme A.5: Part two of Fukuyama’s stereocontrolled synthesis of (+)-vinblastine (1)  
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Reagents and conditions: (a) dimethyl α-ketoglutarate, THF, reflux; (b) 10% Pd/C, H2, THF, r.t.; (c) i. i-Bu 
chloroformate, N-methylmorpholine, N-hydroxy-2-thiopyridone, Et3N, THF; ii. t-BuSH, -20°C; iii. hν 270W, 20°C; 
(d) Belleau’s reagent, THF, r.t.; (e) (i) 2-(bromomethyl)but-2-ene, MeNO2, r.t.; ii. DBU, THF, 5°C → 30°C; (f) 
mCPBA, CH2Cl2, 0°C → 25°C; (g) N-methylmorpholine N-oxide, OsO4, acetone, 25°C; (h) Lawesson’s reagent, 
toluene, 80°C → 25°C; (i) Raney nickel, THF, r.t.    
 
Scheme A.6: Part one of Magnus’s enantioselective synthesis of (+)-vinblastine (1) 
 
 
 
 
 
 
 
 
 
 
 
N
H
N
CO2Me H O
O
(-)(9R, 2S,2S') 34
N
H
CO2Bn
NH2
H
a
N
H
N b
N
H
N
H HCO2Bn CO2HO
CO2MeCO2Me
c
N
H
N
CO2Me
S
N
H
N
CO2Me H
S
f
N
H
N
CO2Me H
O
N
H
N
CO2Me H O
O
O
N
H
N
CO2Me H O
O
S
d
N
H
N
CO2Me
S
e
g
h
i
 203
 
 
 
 
 
 
 
 
 
 
Reagents and conditions: (a) 2,6-di-tert-butyl-4-methylpyridine, p-nitrobenzyl chloroformate, MeNO2, -20°C; (b) 
20% HCl (aq), THF, r.t.; (c) py•SO3, Et3N, DMSO, r.t.; (d) 10% Pd/C, H2, MeOH, r.t. 
 
Scheme A.7: Part two of Magnus’s enantioselective synthesis of (+)-vinblastine (1) 
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